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ABSTRACT
With the emerging antibiotic resistance, Staphylococcus aureus, primary causative agent
of skin and soft tissue infections (SSTIs) as well as other life-threatening conditions has
become a global health concern. While factors contributing to host defense against S.
aureus SSTIs has been well studied, impact of sex as a variable has not been reported. In
Chapter 2, we uncover the sex-specific differences in host response to S. aureus SSTIs
and the contribution of female sex hormone, estrogen (E2) in providing protection in
females. In Chapter 3, we identify mechanisms of innate differences in neutrophils
bactericidal efficacy between sexes and in Chapter 4, we report the protective role of G
protein-coupled receptor (GPER) agonist, G-1 against S. aureus SSTIs. Because no
vaccines against S. aureus has been approved yet, understanding the host defense
mechanisms is important to identify potential targets for host-directed therapeutics to
combat the ongoing antibiotic crisis.
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CHAPTER 1: INTRODUCTION

1.1. Background on S. aureus
S. aureus and antibiotic resistance
Staphylococcus aureus (S. aureus), a gram-positive bacteria, is a commensal organism
usually found in the nares and on skin surfaces of humans, its natural reservoir (1). About
thirty to fifty percent of healthy adults are colonized by S. aureus and are at higher risk of
subsequent infections because this commensal can act as an opportunistic pathogen under
immunosuppressed conditions (2). Since its discovery in 1880 in the abscess of a patient,
S. aureus has been associated with many life-threatening conditions and the emergence of
antibiotic resistant strains, such as methicillin-resistant S. aureus (MRSA) makes it a
serious health concern. Not only is S. aureus the leading cause of skin and soft tissue
infection (SSTI) (3-6), but it can also cause bacteremia, sepsis, endocarditis, and
pneumonia (7-9). Challenges in treating S. aureus infections were encountered as early as
1942 when the bacteria acquired resistance to the β-lactam antibiotic penicillin, which was
discovered in 1940 (10). Resistance was due to the acquisition of blaZ, that encodes for the
β-lactamase enzyme, which leads to the hydrolysis of the β-lactam ring of penicillin
rendering the antibiotic inactive (10). Soon after the bacteria demonstrated resistance to
methicillin, a semisynthetic penicillinase-resistant penicillin, leading to the emergence of
MRSA (10, 11). The resistance of S. aureus to methicillin is attributed to the mecA gene
that encodes for penicillin-binding protein 2a (PBP2a) (10, 11). Penicillin-binding protein
(PBP) catalyzes the crosslinking of peptidoglycan chains during bacterial cell wall
synthesis and β-lactams inhibit this activity of PBP (10, 11). PBP2a hinders this inhibitory
1

action of β-lactams by lowering the affinity of the bacteria to the antibiotic and thus confers
resistance to most available β -lactam antibiotics (10, 11). The emergence of MRSA has
resulted in a dearth of therapeutics against S aureus infections and increased mortality rates
(10, 12). In fact, the Center for Disease Control (CDC) listed MRSA, causing an estimated
80,461 invasive infections and 11,285 deaths per year, as a serious threat in its 2013
landmark report “Antibiotic Resistance Threats in the United States” (13).

Types of MRSA
MRSA causes both health care-associated (HA) and community-associated (CA)
infections (14). Hence, it has been classified into HA-MRSA and CA-MRSA depending
on the site of onset (14). MRSA infections in patients with ongoing or previous healthcare
exposure is further classified into healthcare-associated hospital onset (HAHO) or health
care-associated community onset (HACO) depending on where the infections develop
(hospital or community) (14). Both HA- and CA-MRSA cause similar infections however,
HA-MRSA is the leading cause of lower respiratory tract and surgical site infections, as
well as nosocomial pneumonia and bacteremia, whereas CA-MRSA is predominantly
isolated from skin and soft tissue infections (15, 16). The emergence of CA-MRSA poses
a serious health threat as this strain affects individuals without prior risk factors unlike HAMRSA that mainly causes infection in patients with a history of hospitalization, surgery or
long-term care patients, thus increasing disease burden among the general population (6,
17, 18).
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The genetic differences in HA- versus CA-MRSA lie in the staphylococcal chromosome
cassette mec (SCCmec) alleles that harbors genes for methicillin resistance (mecA) and the
presence of the gene encoding the Panton–Valentine leucocidin (PVL) virulence factor (15,
18). HA-MRSA usually lacks genes for PVL and contains SCCmec type I, II or III alleles,
whereas CA-MRSA has PVL genes and SCCmec type IV or V alleles (15, 18). These
strains demonstrate differences in antibiotic susceptibility as well. CA-MRSA while highly
virulent is less resistant to antibiotics compared to HA-MRSA (17). Differences in the rate
of HA- versus CA-MRSA was investigated in a 2004-2005 demographic study in San
Francisco, which found 243 cases of CA-MRSA infection/100,000 people compared to
31/100,000 for cases of infection with HA-MRSA (18). Similarly, of the 80,461 invasive
infections in 2011 reported in the antibiotic threats by CDC, 18% infection was caused by
HAHO-MRSA, 60% by HACO-MRSA and 21% by CA-MRSA (13, 14). Another study
that investigated HA-and CA-MRSA related infections reported SSTI as the most common
S. aureus infection and CA-MRSA caused about 86% of the SSTI (17). In this same study,
HA-MRSA was isolated from 11% of bloodstream infection and 32% respiratory tract
infections. Thus, both these strains can cause life-threating infections and are responsible
for the increased morbidity and mortality by S. aureus infections.

S. aureus Skin and Soft Tissue Infections (SSTIs)
SSTI accounts for approximately 90% of all S. aureus infections (19). As the name
suggests, SSTIs are a result of microbial invasion of the skin and the underlying soft tissues
(6, 20), encompassing conditions ranging from cellulitis to life-threatening necrotizing
fasciitis (21). They have been categorized into superficial, uncomplicated SSTIs (impetigo,
3

abscess, furuncle erysipelas and cellulitis) or complicated SSTIs (necrotizing infection,
infections associated with bites and animal contact, surgical site infections and infections
in the immunocompromised host) (8, 22, 23). Immunocompromised individuals include
those with diabetes mellitus, HIV patients, individuals of advanced age as well as
individuals with dysfunctional neutrophils (20, 24-26). Among SSTIs, abscesses and
cellulitis are most common with about 50-75% of patients presenting with abscesses while
25-50% of patients present with cellulitis (21).

A study conducted by Suaya et.al, investigating the incidence of S. aureus SSTI from 2001
through 2009 reported a 70% increase in all S. aureus associated hospitalization (27).
Among these, S. aureus SSTIs accounted for 51% hospitalization in 2009, a 12% increase
from 2001. This resulted in a significant increase in the total annual cost of S. aureus SSTI
hospitalizations (44% increase from 2001) (27). Another study covering SSTI incidence
from 2000 to 2012 reported a 40% increase in the overall incidence of SSTIs, resulting in
an increase in treatment costs from 4.4 billion in 2000 to $13.8 billion in 2012 (28). This
accounted for costs for ambulatory visits, emergency care as well as hospitalizations and
prescriptions (28). In August 2004, Moran et.al, enrolled patients presenting SSTIs in 11
university-affiliated emergency departments for a geographically diverse study to
determine the prevalence of MRSA with SSTIs. Of the 422 patients enrolled, 76% were S.
aureus SSTIs and 78% of these S. aureus strains were MRSA while 22% was methicillinsensitive S. aureus (MSSA) (5). Similarly, Ray et.al reported that about 50% of S. aureus
isolated from SSTIs were MRSA for the timeline they investigated (2006 to 2009) (21).
These studies collectively demonstrate that increase in incidence of S. aureus SSTI, and
4

the prevalence of MRSA has resulted in an increase in the treatment cost, hospital stay and
thus the economic burden by this pathogen.

Pathogenesis of S. aureus
The pathogenesis of S. aureus is largely associated with its virulence factors regulated by
the accessory gene regulator (agr) operon (29, 30). The agr operon regulates over 200
virulence genes responsible for invasion as well as adherence and biofilm formation (29,
30). The virulence and invasive phenotype of S. aureus infections is mainly attributed to
secretion of alpha toxin or alpha hemolysin (Hla), a 33kDa protein, known to cause pore
formation and promote inflammation (31-33). Studies on the role of Hla in skin infections
in animal models attribute the ulcer (dermonecrosis) phenotype to Hla (34, 35). Hla
activates the NLRP3 inflammasome complex leading to the production of active IL-1𝛽, a
pro-inflammatory cytokine (Figure 1.1) (33, 36). This toxin is secreted as a monomer and
assembles on the cell surface to form a heptamer leading to pore formation (37). Hla
interacts with a receptor, ADAM10 (a disintegrin and metalloproteinase 10) on the host
cell surface as well as non-specifically with the cholesterol and sphingomyelin in the lipid
bilayers to mediate this effect (38). At sub-lytic concentrations, Hla upregulates ADAM10
activity in epithelial cells and promotes the cleavage of E-cadherin, injuring the barrier
integrity of epithelial cells (39, 40). This disruption of barrier integrity and the downstream
signaling cascade leading to proinflammatory cytokine production (such as IL-1β, IL-6)
causes immune cell recruitment and infiltration resulting in tissue damage (32, 36). This
process contributes to the dermonecrotic lesions in animal models of S. aureus skin
infection (35, 37). The significance of Hla in disease is highlighted in animal models using
5

an isogenic hla mutant strain where loss or mutation in Hla leads to reduced disease
severity in SSTI as well as in a pneumonia model (34, 35, 37, 41-44).

Other pore forming toxins regulated by agr include the leukocidins: Panton-Valentine
Leukocidin (PVL), γ-hemolysin, LukDE, and LukGH (LukAB) (29). These toxins also
contribute to S. aureus pathogenicity. PVL is composed of two secreted components,
LukS-PV and LukF-PV that assemble into pore-forming octamers on the membranes (29,
45). This toxin interacts with its receptors, complement C5a anaphylatoxin chemotactic
receptor 1 (C5aR1) and C5a anaphylatoxin chemotactic receptor 2 (C5aR2) on the cell
membrane leading to cell lysis (46). Neutrophils, critical for S. aureus clearance, are lysed
by this toxin (19, 29, 45). However, their susceptibility to the toxin differs based on the
host. Human and rabbit neutrophils are more susceptible to this toxin than mouse
neutrophils (19). There are conflicting evidence on the role of PVL in disease severity in
the case of S. aureus SSTI as well as other S. aureus infections such as pneumonia, and
bone and joint infections (19, 45). Differences in outcomes are likely due to the varying
susceptibility to the toxin because of differences in receptor expression between cells and
between study subjects (human versus animals) (45, 46). LukDE and LukGH also
contribute to the pathogenesis of S. aureus through lysis of phagocytic cells (29, 45).
Specifically, LukGH, along with another peptide toxin phenol soluble modulin α (PSMα),
help S. aureus evade phagocytic clearance by lysing the cells post phagocytosis (29, 45,
47). Thus, due to their pore forming as well as lytic ability, these toxins contribute to S.
aureus pathogenesis (29, 46).

6

Figure 1.1. Hla activates NLRP3 inflammasome leading to IL-1β production.
Hla toxin binds to ADAM10 on the cell surface or to the lipid bilayers and leads to the
activation of NLRP3 inflammasome complex. This leads to the generation of Caspase-1
through the cleavage of pro-caspase -1. The active caspase-1 then cleaves pro- IL-1β to
active IL-1β. The pro-IL-1β and NLRP3 are synthesized by NF-κB, activated via binding
of PAMPs to the TLRs on the surface. Adapted from: Ezekwe et al. (2016) (48) and Shao
et al. (2015) (49).
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Current Strategies for Treatment of S. aureus Infections
With the emergence of antibiotic resistant strains, limited antibiotics are available for
treatment of S. aureus infections (4, 15, 20, 50). Infections caused by MSSA are treated
with semi-synthetic penicillins such as nafcillin, and dicloxacillin, as well as firstgeneration cephalosporins (cephalexin, cefazolin), whereas to prevent resistance
development, vancomycin is only prescribed for patients allergic to penicillin (23).
However, for treatment of MRSA, vancomycin, clindamycin, linezolid, daptomycin, and
trimethoprim/sulfamethoxazole can be used (23). While vancomycin is used for treatment
of severe MRSA infections such as pneumonia, osteomyelitis, bacteremia and complicated
SSTIs, as well as being an alternative for the corresponding MSSA infections, the
emergence of vancomycin-intermediate (VISA) and the much less prevalent vancomycinresistant S. aureus (VRSA) highlight the urgency of the current antibiotic crisis and the
need for alternative therapeutic options (23). Besides antibiotic treatment for noncomplicated SSTIs such as impetigo and cellulitis, drainage alone or drainage along with
oral or topical antibiotics administration is recommended (6, 20, 23). However, for
complicated SSTIs, hospitalization and intravenous therapy is required (6, 20, 23). Despite
the availability of some antibiotics for treatment, the rising minimum inhibitory
concentration (MIC) for these antibiotics, the treatment cost and mode of treatment
highlight the need for susceptibility testing to prevent resistance development, and the
necessity for the development of alternative therapeutic approaches, such as therapies that
interfere with virulence factor function (22, 23). In line with this, there are multiple ongoing
studies and clinical trials to develop efficacious vaccine or antibody therapies directed
towards S. aureus virulence. Importantly, therapies aimed at secreted virulence factors are
8

expected to induce less or no resistance to therapeutic targeting (7, 42, 43, 51-62).
However, these vaccines are yet to be approved. Besides identifying bacterial targets and
developing vaccines, studies have also focused on identifying host factors contributing to
defense against S. aureus (63, 64). Neutrophils are a key player in S. aureus susceptibility
because of their role in bacterial clearance (63-66). Studies have also uncovered roles for
different skin cells, such as keratinocytes and Langerhans cells, in protection against S.
aureus skin infections (67-75). With the increasing antibiotic crisis, understanding
mechanisms of host defense against S. aureus pathogenesis is especially important as
therapeutics targeted towards enhancing host defense could prove essential in combating
S. aureus infections.

1.2. Skin, the protective barrier against S. aureus SSTIs
Skin, the largest organ of a human body, is the first layer of defense against external insult
(67-69, 76-78). It is composed of layers of resident skin cells and immune cells (Figure
1.2) that provide protection against breaches (67, 68). Thus, invading bacteria has to
employ multiple mechanisms to breach this layer to cause infection (67-70, 78-80).
Commensal bacteria, secreted antimicrobial peptides and a low pH of the skin are the first
barriers against pathogenic bacteria colonizing the skin surface (67-70). The outer layer of
skin, the epidermis, is primarily composed of keratinocytes, linked by intercellular
junctions, and dead cells (mature keratinocytes) that form the hard barrier of the skin (6771, 77, 78, 81). The epidermis also consists of melanocytes that produce melanin for color
pigmentation as well as Langerhans cells and other resident immune cells (i.e.
lymphocytes) (67, 68, 72, 77, 78, 82). The middle layer of skin, the dermis, contains many
9

other immune cells such as macrophages, T cells, B cells and fibroblasts, but primarily
consists of collagen fibers (67, 68, 70, 77, 78, 83). The deepest layer of the skin is the
hypodermis, made up of fats and connective tissue (67, 68, 70, 77, 78, 84). The dermal and
hypodermal layers also house skin appendages such as hair follicles, sweat glands and
sebaceous glands, as well as blood and lymph vessels that allow for neutrophil and
monocyte recruitment during infection (67, 68, 77). The integrity of these layers and their
resident immune cells contribute to the barrier function of the skin.

Skin keratinocytes have been widely studied for their role in S. aureus infections (67, 70,
71). These cells produce antimicrobial peptides, such as β-defensins and cathelicidins,
which kill the bacteria. Keratinocytes are sensitive to alpha toxin (Hla), which can
permeabilize them leading to cell death (85). This process is concentration dependent [low
(0.1ug/mL) to high concentration (100ug/mL)] and includes cellular ATP depletion,
calcium (Ca2+)

and potassium (K+) efflux, and reduced oxygen consumption (85).

Interaction of Hla with ADAM10 on keratinocytes promotes the cleavage of E-cadherin,
an adherens junctions protein, injuring epithelial cells and skin barrier integrity (39, 40).

10

Figure 1.2. The layers of skin.
The skin consists of epidermal, dermal, and hypodermal layers that house different resident
skin cells. The outermost layer, the epidermis, consists of commensals, antimicrobial
peptides, low temperature and low pH, and dead keratinocytes (corneal layer) followed by
layers of live keratinocytes and Langerhans cells that create a protective barrier against
insult. The dermal layer contains immune cells such as macrophages, T cells, NK cells, as
well as blood vessels and skin appendages (hair follicles). Immune cells such as neutrophils
and monocytes get recruited to skin via chemoattractants secreted by the resident cells. The
hypodermis mainly consists of adipose tissues, blood and lymph vessels. Adapted from:
Miller and Cho (2011) (67) and Pasparakis et al. (2014) (69).
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Upon the breach of the epithelial cells barrier, S. aureus is recognized by the pattern
recognition receptors (PRRs) on keratinocytes and other resident immune cells (71, 73).
Recognition of pathogen-associated molecular patterns (PAMPs) such as lipopeptides and
peptidoglycan by PRRs [including toll-like receptors (TLRs) and nod-like receptors
(NOD1 and NOD2)] leads to downstream activation of transcription factors including NFkB and AP-1 that aid in the production of pro-inflammatory cytokines and chemokines
such as IL-1β, IL-6, TNFα, CXCL1, CXCL2, and numerous anti-microbial peptides
(AMPs) (71, 73). Genetic knockout mouse models have shown that these PRRs and
downstream signaling is important to limit S. aureus SSTI infection [reviewed in (73)].
Scavenger receptors (CD36) also plays a role in host-defense against S. aureus (86).
Alongside keratinocytes, resident skin macrophages act as the first responders to the insult.
Resident and perivascular macrophages phagocytose the bacteria as well as produce
chemoattractants to recruit monocytes and neutrophils to the site of infection (73). Similar
to macrophages, neutrophils clear the bacteria via phagocytosis and production of
antimicrobial agents such as reactive oxygen species (ROS) and nitric oxide (NO) (73, 79).
In addition, neutrophils undergo degranulation and form neutrophil extracellular traps
(NETs) to restrain the bacteria from spreading (73). However, because of the short life of
neutrophils, the apoptotic neutrophils must be cleared by macrophages to avoid tissue
damage, which is important for the resolution of infection (73).

In an attempt to confine the pathogen and resolve the infection, an abscess is formed which
consists of viable and necrotic neutrophils, live bacteria, tissue debris and fibrin in a fibrous
enclosed capsule surrounded by macrophages (73, 79). These abscesses either resolve
12

spontaneously after the elimination of the bacteria or require treatment (79) as described in
the section (Current Strategies for Treatment of S. aureus Infections) above.

Skin Langerhans cells (LCs) in epidermal layers also contribute to the skin defense
mechanism (72, 73, 87). These dendritic cell family members sample their surroundings
for antigen and transport them to regional lymph nodes for presentation to naïve T cells to
elicit an adaptive response (72, 73). These cells contribute to skin homeostasis by
promoting proliferation and activation of regulatory T-cells in the skin under normal
conditions. Whereas, upon infection or any other insult compromising the skin barrier, they
participate in antimicrobial response and activate the adaptive T cells response (72, 82, 88).
Release of cytokines from epidermal cells has been shown to modify LCs function and
activation. For example, TNFα activates LCs, whereas thymic stromal lymphopoietin
(TSLP) released by keratinocytes during atopic dermatitis inhibits its ability to induce
adaptive response (reviewed in (72)). During a S. aureus skin infection, these cells sense
the pathogen via their PRRs (langerin) that binds to WTA β-GlcNAc (N-acetylglucosamine
modifications on wall teichoic acid) on S. aureus and activates the T cells (Th17) response
(75).

Skin resident T cells, the alpha beta (αβ) and gamma delta (γδ) T cells, usually found in
both epidermis and the dermis layers of the skin, also contribute to the skin homeostasis
and host defense (83). In response to infection, these cells secrete cytokines and growth
factors leading to cell proliferation, cytolysis, and recruitment of other immune cells to
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infiltrate the damaged site (83). While about 20 billion T cells populate the human skin,
only about 10% or less of these cells are γδ T cells [reviewed in (83)]. However, recent
studies have demonstrated significant role of these resident γδ T cells, also called
DETC(dendritic epidermal T cells) in mice, in maintaining keratinocytes production and
proliferation as well as wound healing (83, 89). These cells produce IL-17 that plays a
crucial role in bacterial clearance during S. aureus SSTI (90). T cells also produce IFN-γ
that recruits other lymphocytes as well as activate the innate cells for bacterial clearance
(74, 83, 90). These cells are also important for cell-mediated protection against reinfections
(74, 91-93). Their importance in limiting recurrent SSTIs is evident in patients with low
CD4+ T cells counts such as in HIV patients (24, 91). A recent study by Dillen et.al,
highlights the possibility of using γδ T cells for therapeutic purposes against S. aureus
infections (74) demonstrating the crucial role these cells play in host defense against S.
aureus SSTI. Thus, the synergistic actions of the resident skin cells along with immune
cells recruited to the site provides protection against S. aureus SSTIs.

1.3. Sex bias in host response to diseases
Many factors contribute to differences in disease outcomes and one such variable that is
being widely recognized for driving this difference is sex of the species (94-101).
Biological (sex hormones and chromosomes) as well as behavioral/environmental
(habits/exposure to infectious agents) factors contribute to the sex differences in host
response (94-108). Studies on the role of sex hormones suggest their effect on immune
cells differs. Male sex hormone, testosterone, generally has an immunosuppressive effect
while the female sex hormone, estrogen, plays an immunostimulatory role (97, 98, 10014

103, 106, 107, 109, 110). Sex chromosomes X and Y also contribute to sex differences host
response. X chromosome contains genes for PRRs, cytokine receptors as well as
transcriptional factors, and Y chromosome contains regulatory genes that modulate
immune cells function affecting the susceptibility of host to various immune-related
diseases (100, 101). These factors modulate differences in host response along with the
type of pathogen for infectious diseases (94-103, 105, 106, 108, 109, 111). Multiple
epidemiological and animal model-based studies have investigated the contribution of
these stimuli on disease outcomes. The enhanced immune response due to these stimuli in
females alters the infection outcomes, such as in case of tuberculosis and aspergillosis, to
be favorable in females compared to males (100, 101). While the prevalence of infections
might be lower in females, they might experience increased disease severity and have fatal
outcomes compared to males as seen with influenza or toxoplasmosis (100, 101). Also, the
ability to mount a strong innate and adaptive response while still being protective can also
make females prone to autoimmune diseases with increased inflammation (100). In terms
of autoimmune diseases, it has been reported that about 80% of all the autoimmune cases
reported in the US are in women (100, 112). However, there are some autoimmune
conditions that are more prevalent in males such as myocarditis and idiopathic pulmonary
fibrosis (100). . Hence, based on the type of condition and the sex of the host disease
outcomes vary and this could be modulated by chromosomal, hormonal, environmental
and behavioral factors. Table 1.1 summarizes some of the epidemiological as well as
experimental findings on the type of infection, pathogen (bacteria, virus, fungi and
parasites) and differences in infection outcomes between sexes.
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Table 1.1. Sex bias in susceptibility to infections

Type of Disease

Greater
Incidence/
Susceptible
Sex

Bacteremia

Male

(109)

Campylobacteriosis

Male

(113)

Tuberculosis

Male

(114, 115)

Mice

Listerosis

Female

(116)

Human

Lyme disease

Female

(117)

Human

Herpes

Female

(118, 119)

Human

AIDS

Male

(120, 121)

Human

Hepatitis B (liver
infection)

Male

(122, 123)

Human,
Mice

MERS

Male

(124, 125)

Pathogen

Species

Staphylococcus
aureus
Campylobacter
jejuni
Mycobacterium
tuberculosis
Listeria
monocytogenes
Borrelia burgdorferi
Herpes simplex
virus type 2(HSV-2)
Human
immunodeficiency
virus (HIV)

Human,
Mice
Human,
Mice
Human,
Mice

Hepatitis B virus
Middle East
respiratory
syndrome
coronavirus (MERSCoV)
Cytomegalovirus
Aspergillus
fumigatus
Cryptococcus
neoformans
Toxoplasma gondii
Plasmodium species
Taenia solium

Human
Human
Human,
Mice
Human,
Mice
Human,
Mice
Mice

References

Female

(126)

Aspergillosis

Male

(127)

Cryptococcosis

Male

(128, 129)

Toxoplasmosis

Female

(130)

Malaria

Male

(130)

Cysticercosis

Female

(131)
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Hormonal role in the immune response
Sex hormones such as progesterone (P4), estradiol (E2) and testosterone has been shown
to be key players in modulating host immune responses, both innate and adaptive; and
therefore, infection outcomes. (95, 100, 102-106, 108, 132-142). Both males and females
express these hormones. Female hormones, estrogen and progesterone, are expressed at
high levels in females and in low levels in males while testosterone is expressed in low
levels in females compared to males (143, 144). There are three types of estrogen: estrone
(E1), 17-β estradiol (E2) and estriol (E3). E2 is the most common form, predominantly
expressed in women of childbearing age while E1 and E3 are produced after menopause
and mainly during pregnancy, respectively. These hormones modulate their effects through
different direct and indirect pathways regulated by their specific receptors (progesterone
receptor- PR, testosterone or androgen receptor (AR) and estrogen receptors (ERα, ERβ
and G-protein Coupled Receptor, GPER)) (103, 104, 110, 136, 140-152). Both male and
female cells express these receptors mediating the functionality of these hormones.

Estrogen signals through these receptors in a genomic and non-genomic action (Figure
1.3) (145-151). The genomic pathway involves E2-ER dependent gene activation regulated
by its direct interaction with the estrogen response elements (ERE) in the promoter of target
genes and through indirect interaction with transcription factors, AP-1, SP-1 (146, 148).
ERα and ERβ post E2 binding get translocated to the nucleus to mediate the genomic
pathways (146, 148). The rapid, non-genomic pathway is regulated by the membrane ER
and GPER mainly located in the endoplasmic reticulum (146, 148-150). The non-genomic
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pathway involves the activation of PI3K/AKT and MAPK pathways and the production of
cAMP, as well as intracellular calcium mobilization (146, 148-150).
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Figure 1.3. Estrogen and estrogen receptors signaling.
Estrogen binds to the estrogen receptors on the surface, cytoplasm or the endoplasmic
reticulum to initiate genomic and non-genomic signaling. Genomic actions involve gene
activation via direct binding of E2-ERs to the estrogen response element (ERE), indirect
binding to the transcription factors (TFs), or activation of TFs. The non-genomic, rapid,
action involves PI3K/MAPK signaling and activation of downstream signals. Adapted
from: Prossnitz and Barton (2014) (151).
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Progesterone is known to regulate cellular functions genomically via nuclear PR and nongenomically via membrane PR (103, 153). In case of testosterone, it binds to the androgen
receptor causing the receptors to dimerize and translocate to the nucleus to bind to the
androgen response element (ARE) in the promoter regions of the genes (103, 154). Hence,
these sex steroids bind to their respective receptors to regulate cellular function via
genomic and non-genomic pathways. For example, testosterone has been shown to
suppress the inflammatory response in macrophages and monocytes via decrease in
expression of PRR such as TLR4, whereas estrogen enhances cell-mediated immune
responses with upregulation in pro-inflammatory response and cytotoxicity as in the case
of NK cells (103, 155). Similarly, estrogen and progesterone downregulate Th17 cell
numbers as well as IL-17 production, while testosterone increases Il-17 production (100,
156). Besides regulating inflammatory responses, estrogen promotes antibody responses
and vaccine efficacy, whereas testosterone decreases the response (100, 157, 158). The
importance of estrogen in providing protection was further demonstrated in menopausal
women where reduction in estrogen production made them susceptible to infections (158).

Estrogen contributes to skin thickness. The epidermal layer of the skin is thicker in females
compared to males, however the male skin is 40% thicker in mice due to thicker dermis
(159-161). Similar role of E2 is demonstrated in females with estrogen therapy (162).
Estrogen also regulates collagen, elasticity, dryness, vascularity and pH of skin (159, 161,
162). In addition, it also plays a role in wound healing and skin pigmentation (163, 164).
E2 accelerates wound healing in an ERβ-dependent manner by decreasing neutrophil
infiltration at the site of inflammation while promoting re-epithelialization whereas
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testosterone inhibits wound healing while enhancing the inflammatory response (135, 161,
162, 164-166). Similarly, E2 via GPER regulates melanin synthesis and contributes to skin
pigmentation (161-163). Estrogen also modulates B cells and T cells activation for
protective immune response and to maintain homeostasis (167). However, stimulated
immune response by estrogen can also promote autoimmune diseases due to increased
autoantibodies and inflammatory immune cells as in the case of Systemic Lupus
Erythematosus (SLE) (168). Testosterone supplementation on the other hand improves
SLE in female mice (168). Estrogen also modulates macrophages as well as neutrophils
phagocytic and oxidative response (134, 140, 142, 169-178). Multiple studies have utilized
specific agonists/antagonists to demonstrate the effect of estrogen and their receptors as
well. Some known agonists are 4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol
(PPT) for ERα, 2,3-bis (4-hydroxyphenyl)-propionitrile (DPN) for ERβ and G-1 for GPER
that work in lieu of estrogen to mediate receptor signaling (149, 179, 180). Whereas some
known

antagonists

are

1,3-Bis

(4-hydroxyphenyl)-4-methyl-5-[4-(2-

piperidinylethoxy)phenol]-1H-pyrazoledihydrochloride (MPP) for ERα, -[2-phenyl-5,7bis (trifluoromethyl) pyrazolo [1,5-a] pyrimidin-3-yl] phenol (PHTPP) for ERβ and G-15
and G-36 for GPER that inhibit the respective receptors signaling (149, 179, 180).
However, some known ERα/β agonists and antagonists (PPT, tamoxifen, genistein, and
ICI182,780) are known to activate GPER (151). Table 1.2 summarizes some known sex
differences on immune cells response and the effects of hormones on these immune cells.
Thus, through the regulation of downstream effectors sex hormones modulates innate and
adaptive immune cells function contributing to the sex bias in host response.
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Table 1.2. Sex-differences in immune cells response and effect of hormones
Cell types

Females

Increased
phagocytic
activity and
IL-10
Macrophages
production
Increased
TLR4
expression

Effect of female
hormones

Effect of male
hormone

Males

Increased TLR4
expression

Increased
proDecreased nitric
inflammatory oxide (NO) and
cytokines
TNF
production

Neutrophils

Increased
phagocytic
activity

Increased number
and degranulation

Increased
number and
mobility

Dendritic
Cells

Increased
antigen
production
Increased
IFNγ
production

Increased
activation and
TLR7 and 9
Decreased CXC10
and IFNα

NK Cells

Increased
granule
response

Increased
Granzyme B and
IFNγ
Increased numbers
and apoptosis

Increased
counts

T Cells

Higher CD4+
T count,
CD4/CD8
Tcell ratio,
number of
activated
cells, CD8+T
cell
cytotoxicity
and TH2 bias

Increased CD8+ T
cells response, and
decreased TH17
cells numbers and
IL-17 production,
increased TH1
activity with low
E2 and TH2 with
high E2.

Decreased IFNγ,
Higher
IL-4, IL-5, and
CD8+ T
increased IL-17
cells, Treg
production,
cell numbers, Decreased CD8+
TH1 bias
T cells number
and activity

B Cells

Increased
numbers

Increased IgG and
IgM levels and
decreased CD80
and CD86

Decreased
kinases and
leukotriene
formation

No difference

Decreased
number and
proliferation

No Difference

Adapted from: Klein et al. (2016) (100) and Capone et al. (2018) (181).
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Sex-specific differences in S. aureus infections
In the case of S. aureus infections, sex specific differences in host response have been
reported with differences in nasal carriage and as well as bloodstream infection outcomes
in human (109, 182). Use of hormonal contraceptives has been shown to affect nasal S.
aureus carriage with increased colonization for its users compared to females not on
hormonal contraceptives. Also, nasal colonization is higher in males compared to females
(182). In terms of bacteremia, while males are highly susceptible, mortality is higher in
females. Moreover, exogenous estrogen administration increases disease severity.
However, estrogen has protective effect on bone loss in mouse model of S. aureus arthritis
(183). Sex differences were observed in rabbits infected with toxic shock syndrome toxin1 (TSST-1) producing strain of S. aureus in the artificial chambers implanted
subcutaneously. In this study, the authors found males to be more susceptible to infection,
and castration reduced susceptibility in males (184). Also, ovariectomy rendered females
susceptible to infection and estrogen supplementation provided protection in male rabbits,
suggesting a protective role of estrogen (184, 185). Thus, there appears to be a female bias
in S. aureus infection outcomes with increased susceptibility in males and a protective role
of estrogen. While sex differences in the host response to S. aureus and the role of estrogen
has been studied for some conditions, sex bias in host response to the most common S.
aureus infection, SSTI, has not been reported.
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1.4. Neutrophils in host defense against S. aureus
Neutrophils have been shown to be essential in clearance of S. aureus during infection (26,
63, 65, 67, 186-192). Using a mouse model for cutaneous infection, Mölne et al., reported
increased severity of skin lesions and increased risk of bacteremia in neutrophil depleted
animals (193). The importance of functional neutrophils for bacterial clearance is mainly
observed in patients with neutropenia or conditions such as chronic granulomatous disease
(CGD) that are at high risk for recurrent infections (66, 194-196). Dysfunction in
neutrophils activity due to defects in phagolysosome formation as in Chediak-Higashi
syndrome or transendothelial migration observed in leucocyte adhesion deficiency type 1
(LAD1) patients render them susceptible to life threatening infections (195, 197, 198).

During infection, these cells are the first innate responders recruited to the site via
chemokines and cytokines secreted by the resident cell types (73, 79). These phagocytic
cells internalize the bacteria and have antimicrobial mechanisms to clear them (65, 186).
Phagocytosis is initiated when the neutrophils bind to the bacteria via its pattern recognition
receptors (PRRs) such as TLRs that recognize pattern-associated molecular patterns
(PAMPs) on the bacterial surface such as peptidoglycan (PGN) or lipoteichoic acid (LTA)
(65, 186). In addition, opsonization of bacteria by serum factors such as complement
proteins or antibodies (Igs) also promote the uptake of bacteria and its clearance by
neutrophils (64, 65, 187, 191, 192, 199). Neutrophils express complement receptors such
as CR3 (CD11b/CD18) also known as Mac-1, αmβ2 integrin, that recognizes a major serum
opsonin iC3b and Fc receptors (FcRs) that recognize the Igs aiding in this process (65, 186,
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191, 200-203). These receptors allow the internalization of S. aureus limiting the bacteria
inside the neutrophil during infection. Interaction of the serum complement proteins with
these receptors is crucial for clearance of S. aureus as inactivation of these proteins by
heat-treatment of the serum leads to minimal to no killing by neutrophils (191). Internalized
bacteria are then cleared by the antimicrobial defense (oxygen-dependent and independent)
mechanisms of neutrophils (Figure 1.4) (186, 189, 204).
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Figure 1.4. Oxygen-dependent and independent killing mechanisms of neutrophils.
Neutrophils employ oxygen-dependent and -independent bactericidal mechanisms for the
clearance of S. aureus its recognition and phagocytosis by complement and Fc receptors.
Priming and activation of neutrophils leads to NADPH oxidase complex assembly for
reactive oxygen species (ROS) production. Oxidative responses include ROS derivatives
(H2O2, O2-, HOCl), and reactive nitrogen species (RNS) such as nitric oxide and its
derivatives (OONO-). Granule components (MPO, antimicrobial peptides, proteases and
enzymes) contribute to oxygen-independent killing of S. aureus. S. aureus gets exposed to
these antimicrobial agents inside the phagosome leading to its death. Adapted from: Rigby
and DeLeo (2012) (64) and Nguyen et al. (2017) (205).
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Oxygen-dependent and independent killing by neutrophils
The well-studied oxygen-dependent mechanisms involve reactive oxygen species (ROS) –
superoxide production by neutrophils as well as generation of hypochlorous acid through
interaction with myeloperoxidase (MPO) or peroxynitrite (ONOO-) by reacting with nitric
oxide (NO) (186, 189, 204). These ROS and NO are key oxidants known to aid bacterial
killing by oxidizing substrates in the medium (189). ROS is generated by NADPH oxidase
that assembles on the phagosomal membrane after the neutrophil is primed by cytokines
such as TNFα, GM-CSF or gets activated post bacterial interaction (65, 205-210). The
NADPH complex of the phagocytes consists of six different subunits assembled together
to form the NOX complex; the membrane proteins gp91phox and p22phox, and the cytosolic
proteins p40phox, p47phox and p67phox (205, 207, 211-213). Activation of neutrophils lead to
translocation of these cytosolic proteins to the membrane allowing for assembly of the
NADPH oxidase complex (205, 207, 211-214). Activated NADPH oxidase then catalyzes
the transfer of electrons from NADPH to molecular oxygen generating superoxide anions
(O2-)(205, 207, 211-213). The anion is converted to other reactive oxygen species that can
damage nucleic acids, proteins and cell membrane, leading to the lysis of the phagocytosed
bacteria (65, 205, 207, 211-213). Moreover, ROS is also released extracellularly, directly
from the plasma membrane, to kill the non-phagocytosed bacteria present outside the cells
(205). Functional NADPH complex is important in limiting infections as loss of its activity
caused by mutations in gene encoding components such as in CGD patients leads to a
defect in ROS production by phagocytes (194, 196). This failure to mount a respiratory
burst leads to increased susceptibility and recurrent infections in CGD patients to various
pathogens including S. aureus (188, 194, 196, 205, 215).
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Neutrophils oxygen-independent mechanisms involve the role of various degradative
enzymes and peptides contained in its granules and secretory vesicles (64, 65, 186, 187,
192, 216-219). Neutrophils have three granules: primary, secondary and tertiary; that can
fuse with the phagosome in the process called degranulation exposing the bacteria in the
phagosome to the granule components (216, 217, 220, 221). The primary granule, also
known as azurophilic granules consists of toxic agents such as elastase, myeloperoxidase
(MPO), cathepsins and defensins (216, 217, 219-222). The secondary and tertiary granules
are MPO negative and contain lactoferrin and matric-metalloprotease 9 (MMP9) (216, 217,
219, 221). These enzymes and proteases are toxic to the pathogen and aids in their
clearance in the phagosome (216-219, 222, 223). Importantly, the secondary and tertiary
granules also contain CR3 (CD11b/CD18) as do the secretory vesicle membranes (186,
205, 216, 217, 224-226). These complement receptors are important in bacterial
recognition and clearance as well as motility and adhesion of neutrophils (191, 200, 201,
203, 224, 227-230). Post-priming of neutrophils by TNFα, these receptors gets translocated
to the membrane via exocytosis of these granules and vesicles increasing their surface
expression in a p38MAPK-dependent manner (206, 209, 210, 231, 232). TNFα priming
also leads to activation of inside-out signaling in the neutrophils aiding in the
conformational change of these receptors on the surface from bent/closed to open/active
state (205, 233)). This active state then leads to outside-in signaling by these receptors via
ligand binding (C3-opsonized S. aureus) which is turn activates downstream signaling
events leading to ROS production and bacterial clearance (205, 233). In addition to these,
neutrophils undergoes NETosis, a process of release of DNA from neutrophils to form an
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extracellular trap that also contains histones and antimicrobial granule components to trap
and kill the pathogen, and thus contribute to bacterial clearance by neutrophils (234, 235).
Overall, after phagocytosis of S. aureus, these microbicidal granule components and ROS
derivatives creates a toxic environment for the bacteria resulting in DNA and protein
damage, ultimately leading to its death. However, S. aureus have evolved with mechanisms
to evade neutrophil killing (66, 80, 186).

S. aureus and evasion of neutrophil clearance
S. aureus as a commensal organism has mechanisms to survive and grow in the human
body (236, 237). Similarly, as a pathogen, it has evolved mechanisms to evade host defense
and adapt at harsh environments, utilizing the host machinery for its survival and growth
(25, 64, 186). S. aureus escapes neutrophil clearance through various intrinsic and extrinsic
resistance pathways ranging from scavenging of ROS, DNA damage repair to preventing
uptake by the neutrophils.(47, 64, 66, 186) S. aureus utilizes its surface proteins such as
protein A that binds to the Fc region of IgG and coats the bacteria with non-specific
antibodies to prevent recognition and phagocytosis by neutrophils (186). Similarly,
complement (C3b) mediated uptake of the bacteria is prevented by staphylococcal
complement inhibitor via its interaction with C3 convertases, interfering with C3b
generation and complement pathway activation (186, 238). Besides these defenses, S.
aureus also has machinery to prevent cell death caused by the antimicrobial agents of
neutrophils (ROS, HOCl and ONOO-). The bacteria produces enzymes such as superoxide
dismutase and catalase to neutralize the formation of these oxidative products by
converting superoxide anions (O2-) to a less potent H202, and further into H2O and O2 (63,
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64, 239, 240). Additionally, S. aureus pigment staphyloxanthin has also been shown to
have antioxidant properties (239). S. aureus also has mechanisms to evade oxygenindependent clearance by neutrophils (64). They have a three-component gene-regulatory
system that regulates downstream bacterial responses which ultimately leads to decrease
in the negative charge of the bacterial surface in the presence of antimicrobial peptides
(63). These pathogens also produce exoenzymes, nucleases, that mediates it escape from
NETs via degradation of DNA traps (241). Moreover, S. aureus produces toxins that have
lytic activity on these cells (63, 64). Overall, S. aureus uses these additional strategies to
avoid its uptake and clearance by neutrophils, allowing for persistent infection by these
pathogens.

Sex hormones and neutrophils
In case of neutrophils, sex hormones, specifically estrogen (E2), can modulate different
functionalities ranging from antimicrobial agents (ROS, NO, MPO) production to
apoptosis of these cells in a dose dependent manner (136). E2 has also been shown to
enhance neutrophil extracellular trap (NETs) formation through the G-protein coupled
receptor (GPER) in neutrophil-like HL-60 cells (242). In a study conducted using human
male and female neutrophils, significant difference in spontaneous apoptosis was observed
(136). Moreover, when male neutrophils were treated with E2, apoptotic outcomes were
delayed, suggesting a role for E2 in delayed apoptosis (136). Using human neutrophils, E2
has been shown to increase respiratory burst, degranulation and MPO activity in
neutrophils (132, 243, 244). Similarly, studies have also demonstrated E2-dependent
inhibition of superoxide (O2-) production as well as degranulation and lysosome release in
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a dose- and time-dependent manner (132, 134, 169, 171). Likewise, testosterone dependent
suppression of respiratory burst has been reported (134, 245). Estrogen stimulates nNOS
expression in a concentration dependent manner as well, with low E2 levels decreasing
nNOS expression at follicular phase compared to its expression at high E2 levels (ovulatory
phase) of the female menstrual cycle (246, 247). Moreover, E2 treatment of male cells in
vitro increases nNOS protein expression (246, 247). Thus, sex hormones modulate the
functionality of neutrophils via regulation of its bactericidal mechanisms and survival.
Table 1.3 summarizes some of these findings.
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Table 1.3. Effect of hormones on neutrophils
Dose

Effects

Male and Female

Hormone
treatment (ex
vivo)
Estrogen

Physiological

Female

Estrogen

Pharmacological

Male

Estrogen

Physiological

Male and Female
Combined

Estrogen
Testosterone

Physiological
Physiological

Sex Not Defined

Estrogen

Delay in apoptosis
Reduction in superoxide
generation, degranulation and
lysosome release
Reduction in superoxide
production
Reduction in superoxide
production
Increased superoxide production,
degranulation and MPO activity
Inhibitory effect
Increased superoxide production
Reduction in superoxide
production
Increased nitric oxide production
Enhanced nNOS protein
expression during ovulatory phase
compared to follicular phase
Increased nNOS protein expression
after E2 treatment to cells isolated
at follicular phase

Neutrophils
from:

Female mice

Estrogen

Male

Testosterone

Physiological
Pharmacological
Physiological
Physiological
Pharmacological

Female
(premenopausal)
Female
(premenopausal)
Female
(postmenopausal)
Male

Male mice

No treatment

Estrogen
In vivo
Estrogen
treatment
Estrogen
In vivo E2
treatment post
orchidectomy

Physiological

Refer
ences
(136)
(132)
(169)
(134)
(173)
(140)
(245)

(246,
247)

Increased nNOS protein expression
after E2 treatment
Physiological

Physiological
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Increased nNOS protein expression
Increased neutrophil serine
proteases, elastase expression,
MPO and iNOS protein expression

(248)

1.5. Concluding remarks and Hypotheses
S. aureus life-threatening infections and the emergence of the antibiotic resistant strains
has posed a global health concern with limited treatment options in the absence of
prophylactic or therapeutic vaccines (8, 13, 19). Similarly, multiple studies reporting
increased susceptibility in immunocompromised individuals to S. aureus infections
highlights importance of host immune response and the necessity to understand the host
defense mechanisms against S. aureus (194, 196, 249). While multiple factors contributing
to host defense against S. aureus infections have been investigated, contribution of sex
hormones in regulating these immune responses have not been fully uncovered. Thus, in
our studies detailed below, we will address the sex-specific differences in host response to
the most common S. aureus infection: SSTI. Given the protective role of estrogen in most
infections and its contribution to skin physiology and homeostasis, we hypothesized there
to be a sex bias in host response to SSTIs with estrogen-dependent differences in immune
cells response contributing to the innate resistance in females. In Chapter 2, we test this
hypothesis using a murine model of SSTI. To further investigate the sex differences in host
response to S. aureus, we determined the mechanisms driving the bias in neutrophils
bactericidal efficacy between sexes in Chapter 3 based on our findings from Chapter 2,
which suggests increased bactericidal capacity of female murine neutrophils ex vivo. As
female neutrophils are known to be highly phagocytic and estrogen regulates antimicrobial
mechanisms of neutrophils (100, 173), we postulate differences in opsonophagocytic
mechanisms (complement and complement receptors) and ROS production between male
and female neutrophils. We test this hypothesis in Chapter 3 utilizing murine neutrophils
ex vivo. Given the protective role of estrogen in females and their differential response to
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S. aureus toxin, Hla, identified in Chapter 2, we investigated the contribution of G proteincoupled estrogen receptor (GPER) in the protection observed in females using its agonist,
G-1. Since Hla disrupts epithelial barrier integrity and contributes to S. aureus
pathogenesis, we hypothesized that G-1 mediated activation of GPER provides protection
against barrier disruption and limits S. aureus SSTI. Using our murine SSTI model and
human keratinocyte cell line, HaCaT, we tested our hypothesis and the details of the
approach and findings is in explained in Chapter 4.
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Figure 1.5. Schematic of gaps addressed in Chapters 2, 3 and 4.
(A) Sex differences in host response to S. aureus SSTI is addressed in Chapter 2 using
murine model of SSTI. Based on the findings of Chapter 2, (B) Chapter 3 addresses
mechanism(s) driving differences in bactericidal capacity of murine neutrophils ex vivo
and (C) Chapter 4 investigates potential usage of estrogen receptor targeted therapeutic to
decrease infection severity in males using murine model of SSTI.
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ABSTRACT
Numerous studies have reported sex bias in infectious diseases, with bias direction
dependent on pathogen and site of infection. Staphylococcus aureus is the most common
cause of skin and soft tissue infections (SSTI), yet sex bias in susceptibility to S. aureus
SSTI has not been described. A search of electronic health records revealed an odds ratio
of 2.4 for S. aureus SSTI in males versus females. To investigate the physiological basis
of this bias, we compared outcomes between male and female mice in a model of S. aureus
dermonecrosis. Consistent with the epidemiological data, female mice were better
protected against SSTI, with reduced dermonecrosis followed later by increased bacterial
clearance. Protection in females was disrupted by ovariectomy and restored by short-term
estrogen administration. Importantly, this sex-bias was mediated by a sex-specific response
to the S. aureus-secreted virulence factor, alpha-hemolysin (Hla). Infection with wild-type
S. aureus suppressed inflammatory cytokine production in the skin of female, but not male,
mice when compared to infection with an isogenic hla deletion mutant. This differential
response was conserved following injection with Hla alone, demonstrating a direct
response to Hla independent of bacterial burden. Additionally, neutrophils, essential for
clearing S. aureus, demonstrated sex-specific S. aureus bactericidal capacity ex vivo. This
work suggests that sex-specific skin innate responsiveness to Hla and neutrophil
bactericidal capacity play important roles in limiting S. aureus SSTI in females.
Understanding the molecular mechanisms controlling this sex bias may reveal novel targets
to promote host innate defense against S. aureus skin infection.
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INTRODUCTION
Sex steroid hormones, such as estrogen and testosterone, can differentially modulate host
immune responses (102, 110, 250), yet the impact of sex and the associated steroid
hormones on mechanisms of disease susceptibility has historically been understudied (251,
252). This is especially true for skin-related research (253). Skin is the body’s largest organ
and serves as the first line of defense against exogenous insult (77, 78). Although women
have a greater incidence of dermatological disorders (253), they also demonstrate
accelerated wound healing compared to men (165, 254-256). Yet despite these differences,
very few studies have directly addressed sex-dependent effects on skin disease (253).

Between 2000 and 2012, the incidence of skin and soft tissue infections (SSTIs) in the USA
is reported to have increased 40% with treatment expenditures increasing from $4.4 billion
to $13.8 billion (in 2012 dollars) (28). Although males are often considered to be at
increased risk of infection, innate sex bias in infection susceptibility and severity varies by
pathogen and site of infection (95, 101). The dominant cause of SSTIs is Staphylococcus
aureus (5, 21, 257), and in the United States, more than half of these infections are caused
by methicillin-resistant strains (MRSA) (5, 257). Invasive S. aureus SSTI is mediated in
large part by alpha-hemolysin (Hla), a secreted pore-forming toxin that is a major virulence
factor causing dermonecrosis and inflammation (34, 35, 40, 258). However, despite the
prevalence of S. aureus in SSTI and the contribution of Hla to pathogenesis, sex bias in
innate susceptibility to S. aureus SSTI or Hla has not been reported.

38

Given the significant impact of SSTIs on human health, identifying and understanding sexdependent differences in susceptibility to S. aureus skin infections could lead to novel
treatment options. A recent literature review revealed that, compared to females, males are
more often carriers of S. aureus, which may predispose them to infection (259), and males
are at increased risk of S. aureus bacteremia (95, 259). Given the superior wound healing
capacity of females compared to males (165, 254, 255), the protection afforded by estrogen
in other models of Gram-positive infection (260, 261) and the contribution of Hla to
pathogenesis (34, 35, 40, 258), we investigated whether female sex provides innate
resistance to S. aureus SSTI in an Hla-dependent manner.

Here, we used a mouse model of S. aureus SSTI (258) to demonstrate that female sex, via
the sex hormone estrogen, provides innate resistance to S. aureus SSTI – supporting a
physiological component behind the epidemiological data showing a greater than two-fold
higher incidence of S. aureus SSTI in male versus female patients. Specifically, female
mice had an estrogen-dependent reduction in dermonecrosis and local inflammatory
cytokine levels compared to males, followed days later by significant reductions in
bacterial burden. Importantly, this bias was largely driven by a sex-specific response to
Hla. Inflammatory cytokine production at the site of S. aureus infection increased in
females infected with an isogenic hla deletion strain (LAChla) compared to infection with
wild-type S. aureus (LAC), consistent with previous studies using female mice (262).
However, when comparing the sexes, the opposite was observed in infected male mice,
with either no change or with a trend toward reduced inflammatory cytokine levels in the
absence of Hla. These differences were conserved following injection of Hla alone,
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demonstrating independence from bacterial burden. In addition, in ex vivo studies,
neutrophils from female mice demonstrated increased S. aureus bactericidal capacity
compared to neutrophils from male mice. Given that neutrophils are essential for clearing
S. aureus infections (263), this work suggests that sex-specific differences in both skin
innate responsiveness to Hla and neutrophil bactericidal capacity play important roles in
limiting S. aureus SSTI in females.

MATERIALS AND METHODS
Electric Health Records (EHR) query parameters
Incidence of S. aureus SSTI in male versus female patients was evaluated by searching the
University of New Mexico Health Sciences Center Clinical and Translational Science
Center (CTSC) Health Facts® database. The database is comprised of de-identified
electronic health records (EHR) from more than 600 participating CERNER hospitals
(UL1TR001449 NIH CTSA at UNM). We queried the database for patients of reproductive
age (postpubescent to premenopausal; 18-45 yo) receiving treatment for uncomplicated
SSTI between 2011 and 2014. Based on previous studies (3, 264), SSTIs were defined by
International Classification of Diseases, 9th Revision (ICD-9) (265) diagnosis codes 680.x
(carbuncle and furuncle) and 681.x-682.x (cellulitis and abscess). SSTIs codes were
matched with same encounter ICD-9 codes for methicillin-sensitive S. aureus (MSSA)
(41.11) or MRSA (41.12). Population statistics are based on the number of 18-45 yo (males
or females) included in the database during the same time frame.
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Bacterial strains and growth conditions
S. aureus USA300 LAC and the LAC hla deletion mutant (LAChla) were provided by
Dr. F. DeLeo (Rocky Mountain Laboratories, National Institutes of Health,/National
Institute of Allergy and Infectious Diseases, Hamilton, MT) and Dr. J. BubeckWardenburg (University of Chicago, Chicago, IL), respectively. Bacteria were cultured at
37C in trypticase soy broth (TSB) to early exponential phase as described previously
(266). CFUs were determined by plating serial dilutions on sheep blood agar (BD
Biosciences, Franklin Lakes, NJ), and stocks maintained at -80˚C in TSB with 10 %
glycerol.

Mouse model of dermonecrosis
Animal work protocols were approved by the Institutional Animal Care and Use
Committee of the University of New Mexico Health Sciences Center (UNM HSC) and
carried out in the American Association for Accreditation of Laboratory Animal Careaccredited UNM HSC Animal Research Facility. All animal work was performed in strict
accordance with recommendations in the Guide for the Care and Use of Laboratory
Animals (267) and the US Animal Welfare Act (268). C57BL/6J and BALB/c mice were
purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were acclimated for a
minimum of seven days prior to use. Ovariectomized C57BL/6J mice and sham surgery
controls were purchased from The Jackson Laboratory. These mice were allowed to
recover over several weeks ( 10 as previously described (261, 269)) prior to exogenous
administration of vehicle or 17β-estradiol (E2).
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The mouse model of dermonecrosis was performed according to previously published
protocol (258), with no attempt to target a specific phase of the estrous cycle. Twenty-four
hours before infection, 8-12 week-old male and female mice were anesthetized by
isoflurane inhalation, and NairTM (Church and Dwight, Ewing, NJ) used to remove hair
from the right flank. On the day of infection, early exponential-phase S. aureus at the
indicated inoculum was delivered in 50 µl of USP-grade saline (Braun, Irvine, CA) by
subcutaneous injection into the right flank. Mice were weighed prior to infection and daily
thereafter. Injection sites were photographed daily and area of dermonecrosis determined
by ImageJ analysis (270). At the time of sacrifice, mice were euthanized by CO2
asphyxiation and skin surrounding the injection site (2.25-cm2) excised and homogenized
prior to serial dilution and plating on sheep blood agar for CFU determination. Homogenate
was centrifuged at 12,500 x g for 10 min and supernatant (clarified homogenate) stored at
-80˚C for later cytokine analysis. Stock solutions of 17β-estradiol (E2) (Sigma-Aldrich®,
St. Louis, MO) were prepared in ethanol then diluted 10-fold in 0.9% NaCl, 0.1% BSA,
0.01% Tween 20 for injection. Where indicated, mice received intraperitoneal injections
of 10 µg/kg E2 or vehicle control on day -2 through day +2 relative to infection.
Recombinant Hla for dermonecrosis studies was prepared as previously described (86), and
1 µg of purified Hla in 50 µl USP-grade saline was injected subcutaneously into the right
flank as indicated.

Cytokine and myeloperoxidase quantification from tissue homogenate
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Cytokines and myeloperoxidase (MPO) were measured in clarified supernatant from
homogenized skin prepared as described above. Cytokines levels were determined using a
custom designed multiplex assay (Millipore, Billerica, MA), and MPO levels measured
using the ELISA Mouse Myeloperoxidase DuoSet kit (R&D Systems, Minneapolis, MN),
each according to manufacturer’s directions. For cytokine levels below the limit of
detection, one-half of the lowest standard concentration was utilized.

Histology
For histologic examination, skin samples were collected on day 3 post-infection or Hlainjection and a total of 6 lesions were evaluated for each sex and treatment group. Briefly,
a 1-cm2 sample of skin containing a lesion or an inoculation site was flattened on thin
cardboard, fixed 24-48 hours in neutral buffered formalin, then stored in 70% ethanol. The
skin sample was bisected through the center of the lesion or site of inoculation and
processed routinely for embedding in paraffin, sectioning at 5 μm thickness, and staining
with hematoxylin and eosin (H&E). H&E-stained slides were scanned by an Aperio CS2
scanner (Leica Biosystems, Buffalo Grove, IL) and morphometry was performed using the
HALO image analysis platform (Indica Labs, Albuquerque, NM) to determine the length
of necrotic epidermis and the area of dermal necrosis in each lesion. Because the necrotic
material in abscesses adhered poorly to slides and was often lost during tissue processing,
quantification of abscess size is not included.

Quantitative RT-PCR to measure inflammasome gene expression
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Infection site tissue (2.25-cm2) was collected in RNALater (Qiagen, Valencia, CA). RNA
was isolated and purified using Qiazol and RNeasy Kits (Qiagen), respectively, according
to manufacturer’s directions. High-capacity cDNA RT kits with RNAse inhibitor, random
hexamer primers (Applied Biosystems, Foster City, CA) and a PTC-200 Peltier
thermocycler (Bio-Rad, Hercules, CA) were used to generate cDNA. Quantitative PCR
(qPCR) was performed on a ViiA 7 Real-Time PCR system (Applied Biosystems) using
Taqman® Gene Expression master mix (Applied Biosystems). Gene expression was
quantified using QuantStudio software (Applied Biosystems, Foster City, CA) relative to
hprt using Prime Time Predesigned qPCR assays for nlrp3, asc, casp1 or il-1b (Integrated
DNA Technologies, Coralville, IA).

Western blot analysis of caspase-1 and IL-1β
Frozen clarified abscess homogenates were thawed rapidly at 37°C and protein
concentration measured by A280 (Nanodrop 1000 Spectrophotometer; ThermoFisher
Scientific, Wilmington, DE). Equal amounts of total protein were separated by SDS-PAGE
on a 4-12% Bis-Tris BOLT gel in MES-SDS running buffer (Life Technologies, Grand
Island, NY), prior to transfer to nitrocellulose membranes. Membranes were blocked with
3% non-fat milk (NFM) in TBS (20 mM Tris, pH 7.5 and 150 mM NaCl) for 1.5 h at 22°C,
then probed overnight at 4°C with rabbit anti-mouse anti-pro Caspase 1 + p10 + p12
antibody (Abcam, Cambridge, MA) or rabbit anti-mouse IL-1β (Abcam) in TBS plus 1%
NFM. After washing with TBST (TBS with 0.1% Tween 20), membranes were developed
using SuperSignalTM Maximum Sensitivity Substrate (ThermoFisher Scientific) following
incubation with goat anti-rabbit IgG poly-horseradish peroxide–conjugated secondary
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antibody (ThermoFisher Scientific). Imaging was performed using a Protein Simple
FluorChem R imaging system (Protein Simple, Santa Clara, CA) and band intensity
determined using Image Studio Lite software (LI-COR Biosciences, Lincoln, NE) relative
to total protein loaded based on SYPRO® Ruby staining (Lonza, Allendale, NJ).

Mouse bone-marrow neutrophil ex vivo killing of S. aureus
The indicated S. aureus isolates were prepared for ex vivo killing assays as follows: one
day prior to the assay, 2 x 107 CFU/mL of S. aureus was cultured (37˚C, 220 rpm) in TSB
along with 50 nM autoinducing peptide 1 (AIP1) (Biopeptide Co., Inc, San Diego, CA) to
stimulate quorum sensing. After 5 h, bacteria were washed twice with phenol red free
HBSS (GibcoTM, ThermoFisher Scientific, Waltham, MA) by centrifugation at 1800 x g at
4˚C for 4 min. Bacteria were briefly vortexed and sonicated, suspended in HBSS to 6 x 106
CFU/mL and stored on ice at 4˚C until use. On the day of the assay, bacteria were
opsonized in 10 % autologous mouse serum for 20 min at 37 ˚C with gentle rotation (10
rpm). Bacteria were then plated for CFU determination.

On the day of the assay, bone marrow was collected by flushing mouse femurs and tibias
with ice cold HBSS containing 2 mM EDTA using a 26-gauge needle. Red blood cells in
bone marrow were lysed in 0.2 % sodium chloride, after which neutrophils were isolated
by density gradient centrifugation using Histopaque® 1119 and 1077 (Sigma-Aldrich®).
Isolated neutrophils were suspended in Assay buffer (phenol red free HBSS with calcium/
magnesium (Lonza, Walkersville, MD), 20 mM HEPES, 1 % charcoal stripped FBS (JR
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Scientific, Woodland, CA)) and primed with 100 ng/mL mouse TNFα (BioLegend, San
Diego, CA) for 30 min at 37 ˚C with 5 % CO2.

To allow for phagocytosis, TNFα-primed neutrophils and opsonized S. aureus were
combined at an MOI of 1 and incubated for 15 min at 37 ˚C with gentle end-over-end
rotation. The mixture was then centrifuged at 200 x g (7 min) to remove non-phagocytosed
bacteria, before resuspending the pellet in room temperature Assay buffer. A sample was
sonicated in PBS containing 1 % Triton X-100 before serial dilution and plating on sheep
blood agar to determine the number of bacteria phagocytosed (t0 CFUs). Percent
phagocytosed bacteria was determined relative to the number of opsonized bacteria. The
remaining sample was incubated for 1 h at 37 ˚C with gentle end-over-end rotation, before
serial dilution and plating for CFU determination (t60). Percent killing was calculated as
follows based on CFUs at t0 and t60: (((t0–t60)/t0)*100).

S. aureus growth in the presence of E2
S. aureus USA300 LAC at 1 x 105 CFU/mL was grown overnight in TSB at 37C with
shaking in the presence of vehicle control or the indicated concentrations of E2. Growth
was measured by optical density at 600 nm (OD600) recorded at 15-min increments using a
Tecan Systems (San Jose, CA) Infinite M200 plate reader.

Statistical Analysis
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Statistical analyses were performed using Prism 7 software (Graph Pad Software, La Jolla,
CA). Variance was determined by F-test and data analyzed as appropriate by Unpaired ttest or Mann-Whitney test for non-parametric data. Necrosis data were analyzed by
Unpaired t-test with Welch’s correction for unequal variance. Multiple comparison
analyses were performed by ANOVA with post-hoc tests as indicated.
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RESULTS
Female sex confers innate resistance to S. aureus skin infections
To gain insight into potential sex bias in the incidence of S. aureus SSTI in humans, we
queried the University of New Mexico Health Sciences Center Clinical and Translational
Science Center (CTSC) Health Facts® database of electronic health records (EHR) for
patients of reproductive age (postpubescent to premenopausal; 18-45 yo) receiving
treatment for methicillin-sensitive S. aureus (MSSA) or MRSA SSTI between 2011 and
2014. We found a significantly increased incidence of infection in males compared to
females (Table 2), resulting in an odds ratio of greater than 2.3 for male infection. Given
that these findings likely result from both behavioral and biological factors (102), we
focused on the biological contribution of sex to S. aureus SSTI.

Table 2. Sex Bias in incidence of S. aureus SSTI*
Sex
Male
Female

SA SSTI
(MSSA/MRSA)
8263
(4022/4241)
6580
(2864/3716)

Population

Incidence/
100,000

11,611,077

71

21,957,204

30

Χ2

Odds
Ratio

p<0.0001

2.375
(95% CI
2.30-2.45)

*Data from the Cerner Health Facts database, 18–45 y, 2011–2014. CI, confidence
interval.

Using an established mouse model of S. aureus SSTI (258), we compared outcomes in
male and female mice on days 1 and 3 after subcutaneous infection with the wellcharacterized, highly-virulent, MRSA isolate USA300 LAC (271). While differences in
dermonecrosis did not reach significance on day 1 post-infection, by day 3, near the peak
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of pathogenesis (272), female C57BL/6J mice showed significantly reduced dermonecrosis
(>2.5-fold reduction) compared to males (Figure 2.1A-B). This effect was not restricted to
C57BL/6J mice as infected female BALB/c mice also displayed reduced day 3
dermonecrosis versus males (>1.8-fold reduction) (Figure 2.2A-B). Histologically, the
lesions in C57/BL6J males and females had a similar appearance, with a clearly delineated
central region of epidermal necrosis overlying an area of dermal necrosis which extended
into the panniculus carnosus. An intense inflammatory cell infiltrate, consisting
predominantly of neutrophils, occupied the dermis adjacent to the central area of epidermal
and dermal necrosis. An abscess consisting of degenerate neutrophils filled the subcutis at
the base of the lesion (Figure 2.1C). Although similar in character, lesions in male and
female mice varied significantly in extent, with males having greater lengths of epidermal
necrosis (9.57±0.98 vs 6.35±0.75, p=0.0277) and greater areas of dermal necrosis
(1.49±0.57 vs 0.74±0.36 mm2, p=0.0238) than females.

Differences in dermonecrosis between the sexes appeared to be largely independent of
bacterial burden at the site of infection, which differed only slightly, but significantly, on
day 1 between C57BL/6J males and females (log CFUs of 8.9 and 8.6, respectively)
(Figure 2.1D) and on day 3 between male and female BALB/c mice (8.5 vs 8.2 log CFUs,
respectively) (Figure 2.2C). Similarly, weight loss, a measure of overall morbidity, was
reduced on day 1, but not day 3, post-infection in female C57BL/6J mice versus male
controls (Figure 2.1E, for BALB/c Figure 2.2D). We next asked if there were differences
between the sexes in the cytokine response at the site of infection. Although inflammatory
cytokines can drive bacterial clearance (272, 273), inflammation at the site of S. aureus
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SSTI can also contribute to disease severity without improving bacterial clearance (274).
Here, however, as might be expected from reduced dermonecrosis, on both days 1 and 3
post-infection female C57BL/6J mice displayed reduced levels of the pro-inflammatory
cytokines IL-1 (2.6-fold, 2.9-fold, respectively), TNF (2.0-fold, 2.9 fold), IL-6 (6.9-fold,
2.5-fold) and CXCL1 (3.1-fold, 3.1-fold) at the site of infection compared to males (Figure
2.1F). However, IL-10 levels did not significantly differ between the sexes at these time
points, suggesting that the differential regulation is cytokine specific. A similar trend was
observed for BALB/c mice (Figure 2.2E). Together, these results demonstrate an innate
sex bias in the severity of S. aureus SSTI, with female sex providing a protective benefit
against pathogenesis and inflammation.
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Figure 2.1. Female mice are resistant to S. aureus skin infection compared with
males.
C57BL/6J mice were infected s.c. with 2 3 107 USA300 LAC. (A) Representative images
of infection sites (scale bar, 5 mm) and (B) area of dermonecrosis on days 1 and 3
postinfection (n = 12 mice per group from three independent experiments). (C) Histologic
appearance of normal skin and infection site lesions on day 3 postinfection (top, uninfected;
bottom, infected). Arrowheads mark the junction between viable and necrotic epidermis
and asterisks indicate areas of dermal necrosis; areas of abscessation are identified by the
letter A. Scale bar, 0.5 mm. (D) Bacterial burden (CFU) at the site of infection and (E)
percent weight change on days 1 and 3 postinfection. (F) Day 1 and day 3 inflammatory
cytokine levels in clarified infection site homogenate. Day 1, n = 4 mice per group; day 3,
n = 6–8 mice per group from two independent experiments. Histology only, n = 6 mice per
group. Data are mean 6 SEM. Mann–Whitney U test. *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001. ns, not significant.
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Figure 2.2. BALB/c female mice are better protected against S. aureus skin infection
compared to males.
BALB/c mice were infected subcutaneously with 3 x 107 LAC. (A) Representative images
of infection sites (bar=5 mm), (B) area of dermonecrosis and (C) bacterial at the site of
infection on day 3 post-infection. (D) Percent weight change on days 1 and 3 post-infection.
(E) Day 3 inflammatory cytokine levels in clarified infection site homogenate. n=8 mice
per group from two independent experiments. Data are mean ± SEM. Unpaired t-test, *
p<0.05; ** p<0.01; **** p<0.0001. ND, not detected.
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Hla contributes to sex bias in S. aureus SSTI
Sex-specific responses to S. aureus-secreted virulence factors such as Hla could account
for the pronounced differences in dermonecrosis and inflammatory cytokine production in
infected mice. To test this, we subcutaneously infected male and female C57BL/6J mice
with wild-type S. aureus (LAC) or an isogenic hla deletion mutant (LAChla) (32). Due
to the trend toward increased bacterial clearance in LAC-infected female versus male mice
on day 3 post-infection (Figure 2.1D, Figure 2.2C), we postulated there would be a
significant difference in bacterial clearance later post-infection. We compared outcomes
over the course of a 7-day infection (see Figure 2.3 for data from days 1 and 3 postinfection with LAChla). By day 7 post-infection, female mice infected with LAC again
showed significantly reduced dermonecrosis, but also significantly increased bacterial
clearance, compared to infected males (Figure 2.4A-C). During LAChla infection, male
mice showed small areas of dermonecrosis at the site of infection on day 7 (Figure 2.4A,
B), suggesting that males may be more susceptible than females to S. aureus virulence
factors other than Hla. Importantly, in contrast to LAC-infected mice, there was no
significant difference in day 7 bacterial clearance between male and female C57BL/6J mice
infected with LAChla (Figure 2.4C). These findings suggest that sex-specific differences
in innate immune control of S. aureus infection are dependent on the ability of the pathogen
to express Hla.
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Figure 2.3. Male and female mice respond similarly to skin infection with S. aureus
lacking Hla.
C57BL/6J mice were infected subcutaneously with 2 x 107 LACΔhla. (A) Representative
images of infection sites (bar=5 mm) and (B) area of dermonecrosis on days 1 and 3 postinfection (n=17-24 mice per group from at least three independent experiments). ND, not
detected. (C) Histologic appearance of day 3 post-infection lesions in male (upper panel)
and female (lower panel) mice infected with LACΔhla. Areas of abscessation are indicated
by A. In both sexes, there were mild to moderate predominantly neutrophilic infiltrates in
the dermis, hypodermis, and subcutis and extensive areas of abscessation in the hypodermis
and subcutis. Scale bar = 0.5 mm. (D) Percent weight change and (E) bacterial burden
(colony forming units, CFU) at the site of infection on days 1 and 3 post-infection. (F) Day
1 inflammatory cytokine levels in clarified infection site homogenate. (E-F) Day 1, n=4
mice per group; Day 3, n=6-8 mice per group from two independent experiments. Data are
mean ± SEM. Mann-Whitney test; ns, not significant; *p<0.05; ** p<0.01; *** p<0.001;
****p<0.0001.
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Figure 2.4. Male and female mice differentially respond to skin infection with S.
aureus lacking Hla.
C57BL/6J mice were infected s.c. with 2–3 × 107 LAC or LACΔhla. (A) Representative
images of infection sites (scale bar, 5 mm), (B) dermonecrosis (ND, not detected), and (C)
bacterial burden at the site of infection on day 7 postinfection. n = 12 mice per group (LAC)
and 7–10 mice per group (LACΔhla) from at least two independent experiments. Data are
mean ± SEM. Mann–Whitney U test. (D) Cytokine levels in infection site homogenate on
day 7 postinfection (n = 7–10 mice per group from two independent experiments). Data
are mean ± SEM. ANOVA: p = 0.0007 (IL-1β), p = 0.0008 (TNF-α), p = 0.0006 (IL-6), p
= 0.0003 (CXCL1), p = 0.0404 (IL-10). Dunn multiple comparison test: *p < 0.05, **p <
0.01, ***p < 0.001. ns, not significant.
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Interactions between sex and Hla mediate the pro-inflammatory response during
SSTI
In a previous study of S. aureus skin infection using female BALB/c mice, Hla was shown
to suppress local inflammatory cytokine production and neutrophil influx (262). However,
by comparing both sexes, our findings suggest that the local inflammatory response during
S. aureus SSTI is not only dependent on Hla, but on the sex of the host as well. To test this,
we compared inflammatory cytokine levels in the skin of male and female C57BL/6J mice
on day 7 after infection with LAC or LAChla. As expected, given the reduced
dermonecrosis and bacterial burden compared to males (Figure 2.4A-C), female mice
infected with LAC had lower local levels of IL-1, TNF, IL-6 and CXCL1 (Figure 2.4D).
Interestingly, unlike earlier time points (Figure 2.1F), day 7 post-infection females also
had reduced expression of the anti-inflammatory cytokine IL-10, suggesting that the sex
differences in cytokine production are both time and cytokine specific. In contrast to LACinfected mice, however, there was no difference in cytokine levels between male and
female mice infected with LAChla. Consistent with findings in BALB/c females (262),
local IL-1, TNF and CXCL1 levels were increased in S. aureus infected C57BL/6J
female mice in the absence of Hla (Figure 2.4D). However, this was not the case with male
mice, which showed a trend toward cytokine reduction in the absence of Hla, although this
did not reach statistical significance. Statistical analysis (2-way ANOVA) of these findings
revealed significant interactions between host sex and Hla for each cytokine (IL-1β,
p=0.0235; TNFα, p= 0.0132; IL-6, p=0.0391, CXCL1, p=0.0088 and IL-10, p=0.0258).
These findings, together with sex- and Hla-dependent differences in pathogenesis and
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bacterial clearance, demonstrate that interactions between host sex and S. aureus
expression of Hla mediate innate sex bias in murine models of S. aureus SSTI.

Females are innately resistant to Hla-mediated inflammation and pathogenesis
Hla pore formation in host cell membranes leads to NLRP3 inflammasome activation,
resulting in caspase-1 cleavage and activation, and cleavage and secretion of the mature
inflammatory cytokine IL-1 (275, 276). Notably, estrogen-mediated suppression of
inflammasome activation in another disease model has been reported (277). To gain insight
into the lower levels of IL-1 in the skin of LAC-infected female versus male mice, we
measured local transcription of inflammasome component genes nlrp3 and asc, as well as
casp1 and il-1, at different time points post-infection. Transcription of nlrp3 was
significantly reduced at the site of infection on days 1 and 3, as was il-1 on day 3 postinfection, in females relative to males (Figure 2.5A, B, Figure 2.6). In contrast, there was
no difference in transcript levels of asc and casp1 between the sexes at either time point
(Figure 2.6C). However, western blot analyses showed that although there was no
difference in infection site levels of pro-caspase 1 or pro-IL-1β between LAC-infected
males and females (Figure 2.5C-F), both active caspase-1 and mature IL-1β levels (36)
were significantly reduced in the females. Together, differences in local transcription of
nlrp3 and il-1, reduced cleavage of caspase-1 and IL-1β and reduced IL-1 secretion in
the skin of LAC-infected female versus male mice, suggests the potential for sex-dependent
regulation of NLRP3 inflammasome activation in response to S. aureus infection.
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Figure 2.5. Markers of NLRP3 inflammasome activation are reduced in female mice
during S. aureus skin infection compared with males.
C57BL/6J mice were infected as described in Fig. 1. (A) nlrp3 and (B) il-1β gene induction
at the site of infection relative to infected males. Day 1, n = 3–4; day 3, n = 7–8 mice per
group. (C–F) Immunoblotting and quantification of band intensity relative to total protein
for (C and D) pro–caspase-1 and active caspase-1 and (E and F) pro–IL-1β and mature IL1β in day 3 infection site homogenate (n = 3 mice per group). Data are mean ± SEM.
Unpaired t test. *p < 0.05, **p < 0.01. ns, not significant.
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Figure 2.6. Expression of inflammasome related genes at the site of S.aureus SSTI in
male and female mice.
C57BL/6J mice were infected as described in Figure 1. (A) nlrp3 and (B) il-1 transcription
at the site of infection relative to hprt and uninfected male controls. (C) asc and (D) casp1
(left) gene induction relative to infected males on days 1 and 3 post infection and (right)
transcription at the site of infection relative to hprt and uninfected male controls (day 1
n=3-4; day 3 n=7-8 mice per group). Data are mean ± SEM. Mann-Whitney test; ns, not
significant; *p<0.05; *** p<0.001.
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The well-characterized role of Hla in NLRP3 inflammasome activation, together with
potential differences in regulation of inflammasome activation, suggested that females
would be innately resistant to Hla-mediated pathogenesis, independent of the presence of
S. aureus. To address this, we subcutaneously injected male and female mice with purified
Hla. Compared to males, female mice displayed a greater than 4-fold reduction in
dermonecrosis on day 3 post-injection (Figure 2.7 A, B). Histologically, lesions consisted
of clearly defined regions of epidermal and dermal necrosis, with a mild granulocytic
infiltrate in the dermis; no abscessation was seen (Figure 2.7C). These lesions were
observed in all male mice treated with Hla, but in only a single female mouse. Thus, there
were marked differences between the two sexes in average length of epidermal necrosis
(14.14±1.81 vs 0.38±0.92 mm, p<0.0001) and average area of dermal necrosis (2.83±0.83
vs 0.04±0.11 mm2, p=0.0004). Compared to males, female mice also had significantly
reduced local inflammatory cytokine levels on both days 1 and 3 post-injection (Figure
2.7D), whereas IL-10 levels were below the limit of detection (data not shown). Overall,
our findings demonstrate sex-specific innate resistance to Hla-mediated pathogenesis.
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Figure 2.7. Hla-induced dermonecrosis and inflammatory cytokine production is
reduced in female mice compared with males.
C57BL/6J mice were s.c. injected with 1 μg Hla. Day 1 and 3 postinjection (A)
representative injection site images, (B) dermonecrosis, and (C) histologic appearance of
Hla-induced lesions in male (upper panel) and female (lower panel) skin on day 3
postinjection. The arrowhead marks the junction between viable and necrotic epidermis
and the asterisk indicates the area of dermal necrosis in the male skin. Black material
located above the epidermis in the female skin is a marker indicating the site of Hla
injection; marking was performed because no gross lesions developed. Note the marked
difference between the sexes in the severity of the lesions and the absence of abscessation
in either sex. Scale bar, 0.5 mm. (D) Day 1 and 3 cytokine levels in clarified injection site
homogenate. n = 10–14 mice per group from at least three independent experiments.
Histology only, n = 6 mice per group. Data are mean ± SEM. Mann–Whitney U test. *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Estrogen promotes innate resistance to S. aureus SSTI in female mice
Estrogen is known to support wound healing as well as modulate trafficking and function
of innate immune cells important for bacterial clearance (165, 171, 172, 254, 255, 278280), suggesting that ovariectomy would reduce protection during S. aureus SSTI. To test
this, female mice were ovariectomized (OVX) or given a sham operation (SO), and allowed
to recover for approximately 10 weeks (261, 269) prior to subcutaneous infection with S.
aureus. Consistent with a role for estrogen in innate resistance to S. aureus SSTI, OVX
mice displayed increased dermonecrosis (1.7-fold) compared to SO mice, as well as
slightly increased local bacterial burden (7.5 to 8.0 log CFUs) (Figure 2.8A, B).
Importantly, short-term treatment of OVX mice with exogenous estrogen in the form of
17-estradiol (E2) restored protection against S. aureus dermonecrosis and reduced weight
loss (Figure 2.8C-E), although there was no significant difference in bacterial burden with
short-term E2 administration (Figure 2.8F). Furthermore, as expected based on differences
in dermonecrosis, local inflammatory cytokine levels were increased in OVX mice and
reduced with E2 treatment (Figure 2.8G). In contrast to OVX mice, E2 treatment of SO
mice did not further improve disease outcome (Figure 2.8C-F), suggesting a threshold for
E2-mediated protection in females. Furthermore, short-term treatment of male mice with
E2 did not limit the severity of S. aureus SSTI (Figure 2.9A-C), possibly due to the
suppressive effects of testosterone on the immune response (104, 137). Therefore, together
with the absence of direct effects of E2 on S. aureus growth (Figure 2.9D), these findings
demonstrate that estrogen is an important regulator of the female innate response to S.
aureus pathogenesis.
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Figure 2.8. Ovariectomy impairs and estrogen restores female innate resistance to S.
aureus dermonecrosis.
Female C57BL/6J mice were OVX or underwent SOs. After recovery, mice were s.c.
infected with 2 × 107 CFUs USA300 LAC. Day 3 postinfection (A) dermonecrosis and (B)
bacterial burden at the site of infection in untreated mice (n = 11 mice per group from three
independent experiments). Data are mean ± SEM. Unpaired t test. (C–G) OVX and SO
mice received 10 μg/kg E2 or vehicle control (i.p.) on day −2 through day +2 relative to
infection with LAC. (C) Representative images of infection site, day 3 postinfection (D)
dermonecrosis (ANOVA, p = 0.0164), (E) percent weight change (ANOVA, p < 0.0001),
and (F) bacterial burden at the site of infection (ANOVA, not significant) (n = 3 mice per
group representative of two independent experiments). Data are mean ± SEM. Tukey
multiple comparison test. (G) Day 3 cytokine levels in clarified infection site homogenate;
ANOVA: p = 0.0284 (IL-1β), p = 0.0044 (TNF-α), p = 0.0212 (IL-6), and p = 0.0001
(CXCL1) (n = 3 mice per group). Dunn multiple comparison test. *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001.
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Figure 2.9. 17-estradiol administration to male mice does not enhance protection
against S. aureus SSTI and does not directly alter bacterial growth.
C57BL/6J male mice received 10 µg/kg 17-estradiol (E2) or vehicle (Veh) control (i.p.)
on day -2 through day +2 relative to infection with LAC. Day 1, 3 and 7 post-infection (A)
dermonecrosis, (B) percent weight change and (C) day 7 bacterial burden at the site of
infection. n=8-9 mice per group from two independent experiments. (D) Growth of LAC
in the presence of the indicated concentrations of E2 or vehicle control as measured by
OD600. Data are mean ± SEM of n=6 and representative of two independent experiments.
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Neutrophil bactericidal capacity against S. aureus is sex-dependent
Neutrophils are critical for clearance of S. aureus (263), and both sex- and hormonespecific differences in neutrophil trafficking and responses to exogenous stimulation have
been reported (133, 280-284). Excessive neutrophil accumulation, however, can contribute
to inflammation resulting in pathogenic effects (86, 285, 286). Given the differences in day
7 bacterial burden between male and female mice infected with LAC (Figure 2.4C), but
not with LAChla, we first asked whether this was associated with differences in
neutrophil presence at the site of infection. To address this, we measured myeloperoxidase
(MPO) levels at the site of infection, which is widely used as a marker for phagocyte,
frequently neutrophil, presence (272). We found that MPO levels were reduced in the skin
of LAC-infected females versus males on both days 3 and 7 post-infection (Figure 2.10A).
However, the opposite was observed in LAChla-infected mice, with MPO significantly
increased (day 7) in females compared to males. While these differences could result from
varying rates of phagocyte influx or clearance between the sexes, they suggest that
increased bacterial clearance in LAC-infected female mice is not dependent on a sustained,
elevated phagocyte presence at the site of infection.

Given the importance of neutrophils for clearance of S. aureus (263), increased S. aureus
clearance despite reduced MPO levels in LAC-infected female versus male mice could
result from differences in neutrophil bactericidal capacity. To determine whether
neutrophils from female mice are more efficient at clearing S. aureus compared to those
from male mice, we isolated bone marrow neutrophils and assessed phagocytosis and
killing of S. aureus ex vivo. Consistent with our in vivo data, female neutrophils showed
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significantly increased phagocytosis (1.5-fold) and killing (percent phagocytosed bacteria
killed) of LAC compared to males (Figure 2.10B), resulting in a 2.2-fold reduction in
CFUs. Similar to findings in male versus female mice, OVX mice also had higher local
MPO levels on day 3 post-infection compared to SO controls, and neutrophils collected
from OVX females had reduced ex vivo bactericidal efficacy compared to those from SO
mice (Figure 2.10C, D). Neutrophils from females also showed increased phagocytosis of
LAChla (1.5-fold) and total CFUs killed (1.4-fold) compared to males, although the
percent of phagocytosed bacteria killed did not vary (Figure 2.10E). However, neutrophils
from both sexes were better able to kill S. aureus ex vivo in the absence of Hla (Figure
2.10B, D). This suggests that other factors, such as increased inflammatory cytokine
production in LAChla- versus LAC-infected females, may have contributed to equivalent
bacterial clearance in male and female mice infected with LAChla (Figure 2.3 E, Figure
2.4C). Alternatively, expression of Hla and similarly regulated virulence factors following
phagocytosis of S. aureus by human neutrophils has been shown to contribute to cell lysis
(287). Whether murine neutrophil function is impacted by these factors in vivo, and
whether female neutrophils are uniquely resistant to such effects compared to male
neutrophils, is unclear. Regardless, these results indicate that sex-dependent differences in
neutrophil bactericidal capacity may also contribute to the innate sex bias in S. aureus
SSTI.
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Figure 2.10. Neutrophils from female mice have increased S. aureus bactericidal
capacity versus neutrophils from males.
(A) MPO levels in infection site homogenate on day 3 (left) and day 7 (right) postinfection
(n = 7–10 mice per group from two independent experiments). Day 3, unpaired t test; day
7, ANOVA (p < 0.0001) with Tukey multiple comparison test. (B) Phagocytosis and killing
(1 h) of LAC by bone marrow neutrophils (MOI = 1) collected from male and female
C57BL/6J mice. (C) Local MPO levels from OVX and SO C57BL/6J mice on day 3 postLAC infection. (D) LAC phagocytosis and killing (1 h) by bone marrow neutrophils (MOI
= 1) collected from OVX and SO C57BL/6J mice. (E) Phagocytosis and killing (1 h) of
LACΔhla by bone marrow neutrophils collected from male and female C57BL/6J mice.
The starting inoculum was set to 100% for phagocytosis assays (left). For percent killing,
the number of bacteria phagocytosed was set to 100% (n ≥ 3 mice per group). Data are
mean ± SEM. Unpaired t test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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DISCUSSION
Despite epidemiological evidence of sex differences in infectious diseases and the ability
of sex steroids to differentially regulate immune cells (95, 102, 110, 250), the biological
impact of sex and sex hormones on mechanisms of infection susceptibility and
pathogenesis have been largely understudied. Here we used a murine infection model to
show that female sex, via the sex hormone estrogen, provides innate resistance to SSTI
caused by the important human pathogen, Staphylococcus aureus. Remarkably, this
resistance is mediated by significant interactions between host sex and the S. aureussecreted virulence factor, Hla. We found suppressed inflammation in the skin of female vs
male mice infected with an Hla-producing isolate of S. aureus - suppression which was lost
when infected with an isogenic Hla deletion mutant. This differential response was
conserved following injection with Hla alone, demonstrating a direct, sex-specific response
to Hla, independent of bacterial burden. Together, these findings suggest that sex-specific
differences in skin innate responsiveness to Hla play an important role in limiting S. aureus
SSTI in females. In this era of growing antibiotic resistance, a detailed understanding of
the molecular mechanisms driving this sex bias may reveal novel therapeutic approaches
to promote host innate defense against infection.

Epidemiological studies have shown pathogen-specific sex bias in susceptibility and
severity of a variety of infectious diseases (95, 96, 98, 99, 101). However, such reports
outnumber research studies aimed at defining the physiological mechanisms driving these
differences in infection susceptibility. Regarding S. aureus, males, as well as females using
hormonal contraception, show increased S. aureus nasal colonization rates compared to
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females not on hormonal contraceptives (288). Given that colonization is associated with
increased risk of infection, perhaps it is not surprising that males have an increased
incidence of S. aureus bacteremia (SAB) versus females (259, 289-292). However, females
have increased risk of mortality from SAB, with reports on MRSA and communityacquired SAB showing higher 7- and 30-day mortality rates, respectively, for female versus
male patients (259, 293, 294). Consistent with this epidemiological data showing human
females are more likely to die from SAB, female mice show reduced survival following
intravenous S. aureus infection compared to males (295), and administration of exogenous
estrogen to females further increased mortality compared to vehicle-treated controls (296).
In contrast, male rabbits were more susceptible than females in a lethal subcutaneous
implant infection model using a toxic shock syndrome toxin (TSST-1) producing S. aureus
isolate (184). In this model, neutering or estrogen administration reduced lethality in male
rabbits (184, 185), whereas spaying increased infection lethality in females (184), pointing
to the powerful contributions of sex steroid hormones on infection susceptibility and
disease progression. Similarly, compared to placebo-treated OVX controls, E2
administration to OVX mice protected against S. aureus arthritis and bone loss without
affecting bacterial burden (297). More recently, Corriden et al. reported on a mouse model
of systemic S. aureus infection in which tamoxifen, a selective estrogen receptor
agonist/antagonist, increased survival and enhanced bacterial clearance (298). This
outcome was attributed to tamoxifen’s effects on neutrophil migration and function,
including enhanced formation of neutrophil extracellular traps (NETs). Interestingly, the
ability of tamoxifen to enhance neutrophil function resulted from an increase in
intracellular ceramide production and was independent of estrogen receptors. Here, we
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demonstrate male sex bias in S. aureus SSTI and show that sex-specific and estrogendependent differences in skin innate responsiveness to Hla drive this bias. It will be
important in future studies to investigate sex-specific regulation of the inflammatory
response to Hla ex vivo in murine resident skin cells, as well as validating our findings
using human neutrophils and skin from both sexes. To better characterize the role of E2 in
defense against S. aureus pathogenesis, it will also be revealing to perform more extensive
studies using SO and OVX mice, together with short-term E2 administration, at additional
time points post-infection using LAC versus LAChla or injection with Hla. Also, given
the sex difference in ex vivo killing of S. aureus by murine neutrophils and the findings of
Corriden et al. (298), it will be important to explore sex-specific and estrogen-dependent
differences in murine and human neutrophil chemotaxis and NET formation. Meanwhile,
the work reported here, focused on SSTI as the most common form of S. aureus infection
(19), expands our understanding of host-pathogen interactions in S. aureus-mediated
disease. Furthermore, the male sex bias in susceptibility to S. aureus SSTI or bacteremia,
together with the female bias towards mortality with SAB, may suggest that sex bias varies
not only by pathogen, but also by the type and severity of infection.

As the first line of defense against exogenous insult, skin plays a crucial role in the host
immune response (77, 78) and sex steroids regulate many aspects of skin physiology. These
hormones, specifically androgens such as testosterone in males and estrogens in females,
contribute to skin architecture, including differences in epidermal and dermal thickness, as
well as to immune system function (159, 299, 300). With respect to SSTI, differences in
both the resolution of infection and subsequent tissue restoration or wound healing likely
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contribute to disease severity. Interestingly, innate sex differences in the skin are perhaps
most apparent in the accelerated wound healing ability of females versus males (301).
Inhibition of cutaneous wound healing and enhanced inflammation in males has been
attributed to testosterone and the androgen receptor (AR) (135). In contrast, intact female
or ovariectomized mice treated with estrogen show accelerated wound healing and reduced
inflammation (165). Similarly, in humans, topical estrogen accelerates cutaneous wound
healing in elderly male and female patients, a finding associated with reduced neutrophil
influx and increased fibronectin levels (166). Here, we show that short-term administration
of E2 to ovariectomized mice restores protection against S. aureus dermonecrosis, further
demonstrating the protective role that estrogen plays in the skin. Notably, a recent
investigation into the female prevalence of autoimmune diseases identified an associated
female-biased transcriptomic signature in the skin that is independent of sex steroid levels
(302, 303). Whether such a transcription system independently contributes to female
protection against infectious diseases of the skin, and whether it can be exploited to
enhance host defense against SSTI, warrants further investigation.

Sex steroids are known to differentially modulate host immune responses, with estrogens
being

broadly

associated

with

immunoenhancement

and

androgens

with

immunosuppression (100, 110, 137, 304). However, a detailed understanding of the cells
and signaling pathways contributing to innate sex bias in susceptibility to a range of
infectious diseases remains lacking (95, 98, 250). Estradiol (E2), the predominant form of
estrogen produced by females, signals by binding the cytosolic/nuclear estrogen receptors
ER and ER, as well as the non-canonical membrane bound G-protein coupled estrogen
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receptor (GPER) (149, 176, 305, 306). Signaling through each receptor can result in rapid,
non-genomic effects such as calcium mobilization and cAMP production, as well as slower
transcriptional (genomic) effects mediated by ER and ER binding to gene promoters
containing estrogen response elements (ERE) or via downstream GPER activation of
transcription factors. Estrogen receptor signaling is further complicated by far ranging but
varying cell distributions, as well as differences in expression levels and the existence of
different isoforms of ER and ER (148, 149, 305-307). Similarly, androgens signal
through the AR, a ligand-inducible transcription factor that regulates gene expression by
binding to androgen response elements (ARE) (152). Given the complexity of hormone
signaling in vivo, particularly in the context of an intact immune system, it is unlikely that
protection against an invading pathogen can be attributed to a single hormone or receptor.
Rather, it is likely that the estrogen-mediated innate protection against S. aureus SSTI in
female mice reported here results from a complex interplay among these receptors and their
signaling pathways. Therefore, future studies must seek to unravel the molecular
mechanisms controlling innate protection in females.

The biological impact of sex and sex hormones on disease susceptibility and treatment has
historically been understudied. Fortunately, recent years have witnessed a growing
recognition of this gap (251, 252), culminating in the recent National Institutes of Health
call that sex be addressed as a biological variable in NIH-funded research (308). In addition
to expanding our understanding of host-pathogen interactions in S. aureus-mediated
disease, this work further highlights the significant contributions of sex and sex hormones
to infectious disease susceptibility and severity.
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ABSTRACT
We previously reported sex differences in innate susceptibility to Staphylococcus aureus
skin infection, and that bone marrow neutrophils (BMN) from female mice have an
enhanced ability to kill S. aureus ex vivo compared to those of male mice. However, the
mechanism(s) driving this sex bias in neutrophil killing have not been reported. Given the
role of opsonins such as complement, as well as their receptors, in S. aureus recognition
and clearance, we investigated their contribution to the enhanced bactericidal capacity of
female BMN. We found that levels of C3 in the serum and CR3 (CD11b/CD18) on the
surface of BMN were higher in female compared to male mice. Consistent with increased
CR3 expression following TNFα priming, production of reactive oxygen species (ROS),
an important bactericidal effector, was also increased in female versus male BMN in
response to serum-opsonized S. aureus. Furthermore, blocking CD11b reduced both ROS
levels and S. aureus killing by murine BMN from both sexes. However, at the same
concentration of CD11b blocking antibody, S. aureus killing by female BMN was greatly
reduced compared to those from male mice, suggesting CR3-dependent differences in
bacterial killing between sexes. Overall, this work highlights the contributions of CR3, C3
and ROS to innate sex bias in the neutrophil response to S. aureus. Given that neutrophils
are crucial for S. aureus clearance, understanding the mechanism(s) driving the innate sex
bias in neutrophil bactericidal capacity could identify novel host factors important for host
defense against S. aureus.
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INTRODUCTION
Neutrophils are innate immune cells essential for S. aureus clearance (64, 193, 309-311).
We recently reported a sex bias in host response to Staphylococcus aureus skin and soft
tissue infection (SSTI) and sex-specific differences in the ex vivo bactericidal capacity of
murine neutrophils against S. aureus (312). Specifically, in a mouse model of S. aureus
SSTI, female mice were better protected than males against tissue damage and showed
enhanced bacterial clearance at day 7 post-infection (312). Our findings also revealed
increased ex vivo clearance of S. aureus by murine female bone marrow neutrophils (BMN)
compared to those from their male counterparts. This finding could have important in vivo
implications to the innate sex bias in S. aureus SSTI. However, the mechanism(s) driving
this sex-specific difference in ex vivo S. aureus killing by neutrophils are yet to be
determined.

Recognition of S. aureus by neutrophil surface molecules such as toll-like receptors
(TLRs), G protein-coupled receptors (GPCRs), or opsonic receptors, such as complement
(CR) or Fc receptors (FcR), promotes phagocytosis of bacteria and exposes them to a
repertoire of antimicrobial effectors [reviewed in (64, 65)]. Known antimicrobial effectors
against S. aureus include reactive oxygen species (ROS), nitric oxide (NO),
myeloperoxidase (MPO) and neutrophil granule components released after S. aureus
phagocytosis (65). While many mechanisms for S. aureus clearance by neutrophils have
been described [reviewed in (63-66)], optimal bactericidal capacity requires cytokine
priming (191, 313, 314). For example, compared to unprimed neutrophils, TNFα priming
activates p38 MAPK, upregulates CR3 expression, and initiates production of reactive
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oxygen species (ROS), creating a toxic environment for pathogens (205, 232, 315). Given
this and that inactivation of serum complement by heat treatment results in little to no
neutrophil killing of bacteria (191, 199, 202, 316-318), in the present study we focused on
neutrophil complement receptor-mediated bacterial recognition and phagocytosis.

Specific to S. aureus, serum opsonin iC3b, generated after cleavage of complement protein
C3, is important for neutrophil-mediated recognition and clearance of S. aureus (191, 199,
202, 318). Phagocytosis is initiated when iC3b deposited on S. aureus is recognized by
complement receptor 3 (CR3), also known as Mac-1, integrin αMβ2 or CD11b/CD18, on
the neutrophil surface (200, 201, 319). Not surprisingly, in vivo C3 deficiency impairs
clearance of S. aureus in a mouse model of septic arthritis (320). However, the roles of
CR3 and C3, and how they may regulate sex-specific neutrophil bactericidal capacity
against S. aureus, have not been addressed. Given the importance of complementcomplement receptor interactions and ROS production in S. aureus clearance, we
postulated that increases in CR3 and C3 in females contributes to the sex bias in murine
neutrophil killing of S. aureus.

As expected, we found increased C3 fragments in the serum of female versus male mice
and increased CR3 expression on the surface of female murine BMN compared to those
from males, independent of priming conditions. Surprisingly, no differences were observed
in total CR3 protein levels, possibly suggesting differences in receptor trafficking to the
cell surface or in p38 MAPK activation. We also found that female murine BMN treated
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with serum-opsonized S. aureus produced increased ROS compared to male BMN.
Importantly, at the same concentrations and compared to isotype control, CR3 blocking
antibody treatment of female murine BMN reduced S. aureus killing to a much greater
extent than male BMN, whereas CR3 blocking reduced ROS production by BMN of both
sexes. This suggests that increased CR3-mediated S. aureus killing by female murine BMN
may be dependent on non-ROS effector mechanism(s). Although the exact bactericidal
effectors are yet to be identified, together, our findings support a role for CR3 and possibly
C3 in driving the ex vivo sex-bias in murine neutrophil bactericidal capacity against S.
aureus.

MATERIALS AND METHODS
Ethical Statement and animals
All animal work was conducted in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals (267) and the U.S. Animal Welfare Act (321)
and with the approval of Institutional Animal Care and Use Committee of the University
of New Mexico Health Sciences Center. Age matched, eight- to twelve-week old male and
female C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, Maine,
USA) and acclimated for a minimum of seven days prior to use. No attempt was made to
target a specific phase of the female estrous cycle. Furthermore, to avoid potential sex
differences in the adaptive immune response resulting from potential prior S. aureus
exposure, we used specific-pathogen free (SPF) mice for our studies (312) and focused on
non-FcR-mediated bacterial clearance mechanisms.
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Bacterial strains and growth conditions
MRSA USA300 isolate LAC (271) was provided by Dr. F. DeLeo (Rocky Mountain
Laboratories, National Institutes of Health, National Institute of Allergy and Infectious
Diseases, Hamilton, MT). Bacteria were cultured in Trypticase Soy Broth (TSB) at 37C
to early exponential phase as described previously (312, 322). Stocks were prepared in
TSB with 10% glycerol and maintained at -80˚C. Stock titers (colony forming units, CFUs)
were determined by plating serial dilutions on sheep blood agar (BD Biosciences, Franklin
Lakes, NJ, USA).

Isolation of murine BMN
Mice were euthanized by CO2-inhalation according to approved methods prior to collection
of bone marrow. BMN were isolated from age-matched, male and female mice as
previously described (312). Briefly, femurs and tibias of the mice were flushed with ice
cold phenol red-free Hank’s Balanced Salt Solution (HBSS) (GibcoTM, ThermoFisher
Scientific, Waltham, MA) plus 2 mM EDTA. Red blood cells (RBCs) were lysed using
Ammonium-Chloride-Potassium (ACK) lysis buffer (Lonza, Walkersville, MD) and BMN
isolated by density gradient centrifugation using Histopaque 1119 and 1077 (SigmaAldrich, St. Louis, MO).

Western blot analyses
Western blot analyses were conducted to determine levels of C3 in mouse serum as well
as CD11b and p38 versus phospho-p38 levels in BMN. For complement protein C3
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determination, murine male and female blood was collected in serum Z/1.3 microtubes
(SARSTEDT AG & Co. KG, Germany) by cardiac puncture and serum clarified by
centrifugation at 10,000 x g for 5 min. Serum samples were separated on a 4-12% Bis-Tris
BoltTM gel in MES buffer (Life Technologies, Grand Island, NY) before being transferred
to 0.45 µm nitrocellulose membranes (Bio-Rad, Hercules, CA) for staining. Five percent
non-fat milk in TBS/T buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Tween 20) was
used for antibody dilutions as well as for blocking the membrane. After blocking for 1.5 h
at 22˚C, blots were probed at 4˚C overnight using rabbit anti-mouse C3 antibody
(ab200999) (Abcam, Cambridge, MA) followed by secondary goat anti-rabbit IgG (H+L)
poly-HRP antibody (32260) (Thermo Fisher Scientific).

CD11b levels in unprimed or TNFα-primed (100 ng/mL, 30 min at 37˚C) BMN, were
determined following BMN lysis using BoltTM LDS sample buffer (Thermo Fisher
Scientific). For the quantification of phospho- and total-p38 MAPK, unprimed or TNFαprimed (10 ng/mL for 5 min at 37˚C) BMN were lysed using 1X RIPA buffer (J62524,
Alfa Aesar, Tewksbury, MA) containing protease and phosphatase inhibitors and EDTA
(Halt™ Protease and Phosphatase Inhibitor Cocktail and EDTA solution (Thermo Fisher
Scientific)) before addition to BoltTM LDS sample buffer. For CD11b and p38 MAPK,
equal amounts of protein (based on the cell number or as determined by Pierce™ BCA
Protein Assay Kit (Thermo Fisher Scientific), respectively) in BoltTM LDS buffer were
incubated at 95°C for 10 min before separation on a 4-12% Bis-Tris BoltTM gel in MES
buffer; transferred to a 0.45 µm nitrocellulose membrane and blocked using 5% non-fat
milk in 1X TBS/T. Rabbit anti-mouse CD11b antibody (ab133357) (Abcam) and Goat
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anti-rabbit IgG (H+L) poly-HRP (32260, Thermo Fisher Scientific) were used for CD11b
detection, while mouse-anti-mouse/human p38 MAPK Phospho (Thr180/Tyr182)
antibody (clone A16016A, Biolegend, San Diego, CA) and goat-anti-mouse IgG (H+L)
poly-HRP antibody (32230, Thermo Fisher Scientific) was used for the detection of
phospho-p38 MAPK. For detection of total p38 MAPK, the membrane was stripped using
WB stripping buffer (62.5 mM Tris-HCl, 2% SDS, 100 mM β-mercaptoethanol) at 50°C
for 30 min with gentle shaking. The blot was then reprobed with rabbit anti-mouse p38
MAPK antibody (Poly6224, Biolegend), followed by goat anti-rabbit IgG (H+L) polyHRP.

For membrane development, either SuperSignalTM West Femto Maximum Sensitivity
Substrate

(C3,

phospho-p38

and

p38)

or

SuperSignal™

West

Pico

PLUS

Chemiluminescent Substrate (for CD11b) (Thermo Fisher Scientific) was used and bands
imaged using a Protein Simple FluorChem R imaging system (ProteinSimple, Santa Clara,
CA). Band intensity was quantitated using Image Studio Lite (LI-COR Biosciences,
Lincoln, NE). Signal intensity for C3 was quantified relative to total protein determined
using RevertTM total protein stain (LI-COR Biosciences). For CD11b, β-actin was used as
loading control (clone AC-15, Santa Cruz Biotechnology, Dallas, TX). The ratio of
phospho-p38 to total p38 was calculated based on band intensity quantified as mentioned
above.

CR3 surface expression
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BMN (1 X 107 cells/mL) were TNFα primed (100 ng/mL for 30 min, 37˚C) or left untreated
(control group), then washed and buffer exchanged to flow buffer (PBS, 2% FBS, and 0.1%
NaN3) for staining. Cells were blocked with CD16/CD32 blocking antibody on ice for 10
min, followed by antibody staining on ice in the dark for 30 min. FITC anti-mouse Ly-6G
(Biolegend), PE-Cy7 anti-mouse CD11b (eBioscience, Thermo Fisher Scientific), APC
anti-mouse CD18 (BD Pharmingen, San Jose, CA) and their respective isotypes were used
for staining. Post-staining, cells were fixed with 1% paraformaldehyde (PFA) for 5 min at
22˚C, after which 10,000 events were recorded on an Accuri C6 flow cytometer (BD
Biosciences, San Jose, CA) for the Ly-6G positive population. For analysis, the median
fluorescence intensity (MFI) in the Ly-6G positive population was determined for CD11b
and CD18. Relative fluorescence units (FLU) was calculated by normalization to male
untreated controls.

Ex vivo killing of S. aureus by mouse BMN (bactericidal assay)
One day prior to the neutrophil bactericidal assay, 2 x 107 CFUs/mL of stock culture was
grown in TSB at 37C with constant shaking (220 rpm) for 5 h in the presence of 50 nM
autoinducing peptide 1 (AIP1) (Biopeptide Co., Inc, San Diego, CA). Following growth,
bacteria were pelleted at 1800 x g for 4 min, washed with phenol red-free HBSS, vortexed,
sonicated and resuspended in fresh HBSS at 6 x 106 CFUs/mL. Resuspended bacteria were
stored on ice at 4˚C until use. The final number of CFUs in this diluted culture was
determined as described above. The day of use, bacteria were opsonized with 10%
autologous (same sex) or heterologous (opposite sex) serum for 20 min at 37˚C with gentle
end-over-end rotation at 10 rpm.
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BMN isolated as described above were primed with 100 ng/mL mouse TNFα (BioLegend)
for 30 min (37˚C with 5% CO2) in assay buffer (phenol red-free HBSS with
calcium/magnesium (Corning Inc., Corning, NY), 20 mM HEPES, 1% charcoal stripped
FBS (JR Scientific, Woodland, CA)). To allow bacterial uptake and killing, TNFα-primed
male and female murine BMN were incubated with serum-opsonized LAC at an MOI of 1
for 15 min at 37˚C with rotation. After centrifugal removal of unbound bacteria, an aliquot
of the remaining cells was lysed by sonication in PBS containing 1% Triton X-100 (t0).
The number of bacteria present at t0 was determined by serial plating on blood agar. The
remaining cells were incubated for 1 h at 37˚C (10 rpm) after which CFUs were measured
(t60). CFUs killed and S. aureus killing were calculated based on CFUs at t0 and t60 as:
t0-t60 and (t0-t60)/t0 respectively. For relative S. aureus killing, killing for the controls
was normalized to 1 and treatment groups compared accordingly.

CR3 blocking of BMN
To determine the impact of CR3 blocking on bacterial killing, BMN were treated with
CD16/CD32 blocking antibody (BD Pharmingen Inc) 20 min after TNFα addition. Five
minutes later, anti-CD11b antibody (clone M1/70, Biolegend) or isotype control (IgG2b,
κ, Biolegend) were added in the concentrations described in the text and incubated for 5
min. Post-antibody treatment, BMN were incubated with autologous serum-opsonized
LAC and bacterial killing was determined as described above.
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ROS detection
For measurement of ROS production, TNFα-primed (10 ng/mL for 5 min, 37˚C) BMN (9
x 105 cells) were added to white 96-well tissue culture plates. Ten percent autologous
serum-opsonized LAC was centrifuged to remove unbound serum, after which 9 x 105
bacteria were added to an equal number of primed BMN. Luminol (50µM) (SigmaAldrich) and horseradish peroxidase (HRP) (1.2U/mL) (EMD Millipore, Burlington, MA)
were

used

for

detecting

BMN

production

of

hydrogen

peroxide

(H2O2).

Chemiluminescence (Relative Luminescence Units, RLU) was measured at 37˚C for 1 h
with reads taken every minute with 1000 ms integration time using a SpectraMax i3x
(Molecular Devices, LLC, San Jose, CA). The area under the curve (AUC) for ROS
production was calculated and ROS levels normalized to male BMN. For ROS production
with CR3 blocking, TNFα-primed BMN were treated with CD16/32 blocking antibody
followed by 5 min with anti-CD11b (M1/70) antibody or isotype control then incubated
with serum-opsonized LAC and luminol plus HRP. Chemiluminescence was then
measured for an hour as described above.

Statistical analysis
Statistical analyses were performed using Prism 8.2.1 software (GraphPad Software, La
Jolla, CA). Unpaired t-test or two-way ANOVA with post-hoc analyses were utilized as
indicated in the figure legends. Significance is reported as *, p<0.05; **, p<0.01; ***,
p<0.001; ****, p<0.0001; ns, not significant.
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RESULTS
Female mice have higher C3 serum levels compared to males
To begin to address the mechanism(s) of enhanced bactericidal capacity of female murine
BMN against S. aureus ex vivo, we measured the levels of complement protein C3 and its
fragments in the serum of male and female mice. Complement C3 plays an essential role
in recognition and clearance of S. aureus by phagocytes (191, 320, 323), due at least in part
to its role in opsonization and phagocytosis, as well as its ability to activate downstream
antimicrobial pathways (324). Specifically, C3 is cleaved to generate C3b and iC3b,
opsonins that both bind to the surface of S. aureus and to complement receptors on the
neutrophil surface, thus mediating phagocytosis and clearance. Western blot analyses
revealed increased levels of the C3 fragments C3b, αiC3b and C3cα2 in female compared
to male murine serum (Figure 3.1). Therefore, increased levels of serum C3 fragments in
female versus male serum may support a role for C3 in the enhanced bactericidal capacity
of female BMN.
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Figure 3.1. Female murine sera has higher C3 levels compared to males.
C3 fragment levels were measured by Western Blot in sera from age-matched male and
female mice. (A) C3 immunoblot and (B) quantification of C3 fragments relative to total
protein and normalized to males. Total C3 was calculated based on the average intensity
of the fragments. Data are mean ± SEM. Student’s t-test; *p<0.05 **p< 0.01, ***p< 0.001.
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BMNs from female mice have higher CR3 surface levels compared to those from
males
C3 fragments bind to complement receptors expressed on the surface of neutrophils (200,
201, 319, 325). In particular, complement receptor 3 (CR3 or CD11b/CD18) has high
affinity for the opsonin iC3b (200, 229, 319, 325, 326). To determine whether higher iC3b
levels in the serum of female versus male mice correlated with increased CR3 expression
on their BMN, we used immunostaining to measure expression of CD11b and CD18 on
the surface of male and female murine BMN. Flow cytometric analysis revealed
significantly higher cell surface expression of CD11b on female versus male BMN both
before and after TNFα priming (Figure 3.2A). In contrast, CD18 surface expression on
BMNs was greater for female versus male BMN only after TNFα priming (Figure 3.2B).
CR3 is typically located in neutrophil secretory vesicles and granules and translocated to
the surface post-priming and -activation by cytokines, bacteria or other neutrophil
activating agents (206, 208, 209, 225, 232, 327). This suggested that increased CR3 surface
expression on female versus male murine BMNs could result from overall higher CR3
protein expression by females. However, western blot analysis showed that overall CD11b
levels did not differ between male and female murine BMNs (Figure 3.2C, D). This
indicates that higher CD11b surface expression by female BMNs is not the result of an
overall increase in CD11b protein levels.

TNFα-mediated upregulation of CR3 is dependent upon p38 MAPK (232, 328). Therefore,
we next examined whether p38 MAPK was more readily activated, indicated by
phosphorylation, in female BMN following TNFα priming. Using Western blot analysis,
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we found no sex-specific differences in murine BMN p38 MAPK activation either pre- or
post-TNFα priming (data not shown). These findings suggest that increased CR3
expression on the surface of female versus male murine BMN is independent of both
overall CR3 expression levels and p38 MAPK-mediated translocation.
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Figure 3.2. Female murine BMN have increased CR3 surface expression compared
to males.
Flow cytometry analysis of male and female murine BMN immunostained for (A) CD11b
and (B) CD18 pre- and post-TNFα priming. Data are based on fluorescence units (FLU)
relative to male BMN pre-priming. Data are mean ± SEM from five independent
experiments, N=5. (A-B) Two-way ANOVA; Tukey’s Multiple Comparison test. (C)
Western blot analysis of male and female murine BMN showing total CD11b expression
and (D) quantification of total CD11b relative to actin by Western blot. N=2-3 mice/group.
Unpaired t-test. *p<0.05; **p< 0.01; ***p<0.001; ****p<0.0001.
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S. aureus killing by female murine BMN is enhanced by opsonization with autologous
serum
Neutrophil bactericidal capacity can depend on both serum and cellular factors that
contribute to the recognition of bacteria, as well as cellular bactericidal effectors (191, 199,
229, 232, 319, 324). Given our findings of increased C3 fragments in serum from female
versus male mice, along with increased CR3 expression on the surface of female BMNs,
we postulated that both serum and cellular components were necessary for the sex-bias in
BMN killing of S. aureus. To test this, we measured S. aureus killing ex vivo by male and
female murine BMNs using S. aureus opsonized with either same sex (here termed
autologous) or opposite sex (heterologous) mouse serum. If BMN killing of S. aureus is
solely a serum-dependent process, then we might expect an increase in killing by male
BMN with heterologous serum opsonization and a reduction in the killing by female BMN
when incubated with heterologous serum opsonized bacteria. However, if differences in
BMN killing of S. aureus are solely dependent on cellular components, then we would
expect the bactericidal capacities of BMN from mice of either sex to remain unchanged
regardless of the sex of the serum used for opsonization. As shown in Figure 3.3, S. aureus
killing by BMN from male mice did not increase regardless of the sex of serum used for
opsonization. In contrast, BMN from female mice showed increased S. aureus killing
compared to males, only when bacteria were opsonized with autologous serum. Given our
earlier findings, this may suggest that the S. aureus bactericidal capacity of BMN from
male mice is limited by their surface expression of CR3 and this cannot be overcome by
additional C3 in the serum. This suggests a cell-dependent process of S. aureus killing by
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male murine BMN, whereas, as expected, killing by female BMN is dependent upon both
the sex of the cell and the sex of the serum.

CR3 blocking reduces ex vivo S. aureus killing by murine BMNs in a sex-specific
manner
Consistent with our findings using murine BMN and serum, C3 and CR3 are important for
protection against S. aureus infection (320, 329) and C3 expression has been shown to be
regulated by estrogen (330-334). Given our finding that female murine BMN show
increased surface expression of CR3 (CD11b) compared to males, we predicted a higher
concentration of CD11b blocking antibody would be required to disrupt S. aureus killing
by female compared to male murine BMN. To test this, we performed ex vivo S. aureus
killing assays using male and female murine BMN in the presence of CD11b blocking
antibody or isotype control. As expected, the bactericidal capacity of both male and female
BMN was reduced by blocking CD11b (Figure 3.4). However, at the two highest antibody
concentrations tested, blocking of CD11b significantly reduced S. aureus killing by female
BMN compared to males, in direct contrast to predictions. This suggests that the
bactericidal capacity of female BMN is more CR3-dependent compared to males and that
primary mechanisms of male BMN bactericidal capacity are largely CR3-independent.
Whether this is the result of sex-specific differences in CR3 signaling (crosslinking/clustering), CR3-specific downstream effectors, or other CR3-dependent
mechanism(s) remains unknown. Regardless, these results clearly indicate a sex-specific,
CR3-dependent difference in the bactericidal capacity of murine BMN.
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Figure 3.3. Enhanced killing of S. aureus by female versus male murine BMNs is
both serum- and cell-dependent.
Male and female murine BMNs were incubated with S. aureus opsonized with autologous
(same sex) or heterologous (opposite sex) serum at an MOI =1 and bacterial killing
determined after 1 h. (A) Total CFUs killed and (B) relative S. aureus killing compared to
male cells with male serum opsonized bacteria. Data are mean ± SEM from three
independent experiments, N=3. Two-way ANOVA; Tukey’s Multiple Comparison test,
**p< 0.01; ***p<0.001; ****p<0.0001.
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Figure 3.4. CR3 blocking differentially reduces the bactericidal capacity of murine
neutrophils ex vivo.
BMNs from male and female mice were treated ex vivo with increasing concentrations of
CD11b blocking antibody or isotype control and S. aureus killing measured after 60 min.
(A) Total CFUs killed and (B) relative S. aureus killing by male versus female murine
BMNs with CD11b blocking compared to isotype control set to 1.0. Data are mean ± SEM
from 2-3 independent experiments each with 3 technical replicates. Unpaired t-test; ns, not
significant; *p<0.05; **p< 0.01; ***p<0.001.
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Higher ROS production in female murine BMNs is largely independent of CR3
ROS are well known effectors of phagocyte killing of S. aureus (315, 335). Notably, TNFα
priming upregulates neutrophil CR3 expression, thus potentiating NADPH oxidase
complex formation and production of ROS (232, 328, 336). Given increased expression of
CR3 on the surface of female versus male murine BMNs, we postulated that TNFα-primed
female BMN would produce enhances ROS levels when exposed to serum opsonized S.
aureus compared to male murine BMNs. Consistent with increased CR3 levels, female
murine BMN produced significantly more ROS compared to those from male mice (Figure
3.5A-B).

As described above, female BMN were better able to kill S. aureus versus male murine
BMN, and less anti-CD11b antibody was required to block S. aureus killing by female
BMN. Therefore, we predicted that blocking with anti-CD11b antibody, at concentrations
that more significantly reduced S. aureus killing by female versus male BMN, would also
result in greater reductions in ROS production by these BMN. We found that blocking
CD11b at antibody concentrations which significantly reduced the bactericidal capacity of
female murine BMN, also significantly reduced ROS production compared to isotypetreated controls (Figure 3.5C). However, with female BMN, in contrast to our prediction,
this response was not dose-dependent at the concentrations of CD11b blocking antibody
tested, and only reduced ROS production to levels seen with male BMN treated with
isotype control antibody. In contrast, reductions in ROS production by male BMN upon
CD11b blocking appeared dose-dependent, showing a greater impact of blocking at the
higher concentration. Clearly, blocking CD11b results in a more significant reduction in S.
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aureus killing by female versus male murine BMN, but with a reduced impact on ROS
production compared to male BMN. This may suggest that female murine BMN killing of
S. aureus is mediated by a mechanism involving CR3 but largely independent of ROS.
Together, these findings indicate that CR3, C3 and potentially ROS contribute to the innate
sex bias in the neutrophil response to S. aureus ex vivo.
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Figure 3.5. ROS production is increased with female murine BMNs compared to
males and partially relies on surface CR3 expression.
(A) Representative chemiluminescence assay comparing ROS production by male and
female murine BMNs primed with TNFα and incubated with serum-opsonized S. aureus.
(B) Calculated area under the curve for female BMN ROS production relative to male
BMNs. (C) Relative ROS production by male and female BMNs post-treatment with 62.5
or 125 ng of CD11b blocking antibody versus isotype control. Data are mean ± SEM from
three independent experiments, N=3 mice/group. (B) Analyzed by unpaired t-test and (C)
two-way ANOVA with Tukey’s Multiple Comparison test. ns, not significant; *p<0.05;
**p< 0.01; ***p<0.001; ****p<0.0001.
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DISCUSSION

Neutrophils are crucial early responders to S. aureus infection, as numerous studies have
shown increased susceptibility to infection and severe outcomes in neutropenic patients,
patients with dysfunctional neutrophils, or mouse models of neutropenia (64, 193-196, 337,
338). Neutrophils play a critical role in confinement and clearance of the pathogen leading
to resolution of the infection (63, 64, 79, 193). We recently reported sex-specific
differences in S. aureus killing by murine BMN ex vivo (312), with BMN from female
mice showing enhanced bacterial killing compared to those from males. However, the
factor(s) driving this sex-specific difference remained unclear. Here we show evidence that
serum C3 and cellular CR3 contribute to the sex-bias in murine BMN killing of S. aureus.
Specifically, we measured increased C3 levels in serum from female mice and increased
CR3 expression on the surface of female murine BMN, both pre- and post-TNFα priming,
compared to males. Surprisingly, differences in CR3/CD11b BMN surface expression
between the sexes did not result from overall differences in cellular CD11b expression or
TNFα-mediated activation of p38 MAPK. Consistent with increased CR3, ROS production
was greater for female BMN compared to those from male mice. However, at equal
antibody concentrations, blocking CD11b reduced S. aureus killing by female BMN to a
greater extent than male BMN, whereas it had a much-reduced effect on ROS production.
Therefore, our results point to sex-specific mechanism of S. aureus killing by murine
BMN, with female BMN killing of S. aureus largely mediated by a mechanism(s) involving
CR3, but largely independent of ROS. Given the importance of the iC3b-CR3 interaction
in the bactericidal efficacy of neutrophils, it is perhaps not surprising that their increased
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expression by female mice could be a key factor contributing to the innate sex bias in
murine BMN bactericidal capacity against S. aureus.

Serum opsonins and phagocyte (cellular) receptors each contribute to neutrophil
bactericidal capacity (191, 318-320). For example, opsonization of S. aureus with serum
heat-treated to inactive complement results in reduced to no killing of the bacteria by
human neutrophils (191, 199, 316-318). Also, the importance of pattern recognition
receptors (PRRs) and opsonic receptors (CRs or FcRs) for bacterial recognition is well
documented (63, 64). Complement receptors are crucial for neutrophil functions, such as
migration, as well as for recognition and clearance of bacteria (200, 201, 229, 319, 339).
Notably, CR3 is the predominant complement receptor for S. aureus uptake by neutrophils
(200, 201). Here we show that both serum and cellular factors contribute to the sex-specific
differences in murine neutrophil bactericidal capacity. Specifically, incubation of female
neutrophils with male serum-opsonized S. aureus significantly reduced bactericidal
capacity compared to incubation with female serum-opsonized S. aureus. However, when
male neutrophils were incubated with female serum-opsonized S. aureus, their bactericidal
capacity remained unchanged relative to bacterial opsonization with autologous serum,
suggesting a cell-dependent reduction in clearance ability of male murine BMN compared
to females. The contribution of C3 to this sex difference will be more thoroughly
investigated in future studies using C3-binding antibodies or C3-deficient serum for
bacterial opsonization.
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Blocking of CR3 hinders bacterial killing by human neutrophils, although sex of the
neutrophils was not reported (191, 201). Similarly, blocking Cd11b in male and female
murine BMN in our study resulted in a dose-dependent decrease in their bactericidal
capacity. The effect was drastic for female murine BMN relative to males, despite
increased CR3 expression on their surface. Independent of TNFα priming, we measured an
increase in CR3 surface expression on female versus male BMN, which could be in part
due to differences in receptor clustering and activation. TNFα priming of neutrophils can
activate inside-out signaling that leads to a conformational change in integrins from a
closed/bent to open/active state, thus stimulating clustering and activation resulting in
increased avidity as well as ligand affinity (205, 233, 340-342). This allows the cells to
respond to lower ligand concentrations (340, 343). Although this awaits empirical
determination, the significant blocking effect of anti-CD11b antibody on the bactericidal
capacity of female BMN could be partly explained by differences in CR3 clustering
between the sexes.

In primed and activated neutrophils, upregulated CR3 induces ROS production in a p38
MAPK-dependent manner (232, 328). While we detected no difference in p38 MAPK
activation between sexes, there were clear sex-specific differences in CR3 expression and
ROS production. Notably, ROS production was significantly higher by female versus male
BMN following activation with serum-opsonized S. aureus. Consistent with the role of
CR3 in ROS production, CD11b blocking reduced ROS production by both male and
female murine BMN. Given its involvement in the regulation of other antimicrobial
mechanisms, the differences in ROS levels observed between the sexes could have
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differential implications for the sex-specific bactericidal efficacy of neutrophils. Therefore,
the potential differential impact of ROS production by male and female murine BMN on
overall bactericidal capacity should be addressed in further studies focused on the sexspecific role of ROS in mediating these other mechanisms of bacterial killing by
phagocytes.

Together with differences in CR3 expression on the surface of BMN from female mice, we
also report an increase in C3 in their serum. As mentioned previously, estrogen (E2) can
modulate C3 expression (330-334). In addition, E2 can regulate neutrophil functions
ranging from ROS production and degranulation to NET formation (132, 134, 139, 140,
169, 171-173, 175, 244, 248, 344, 345). However, the contribution of E2 to any innate
immune function depends on the cell type, doses used (physiological or pharmacological),
as well as the specific parameters being examined (100, 102, 132, 134, 142, 171, 172, 181).
Although here we made no attempt to target a specific phase of the estrous cycle, in an
attempt to reflect the variety of estrous stages human females with S. aureus SSTI likely
face, our previous findings using BMN from ovariectomized (OVX) female mice showed
reduced bactericidal efficacy compared to BMN from sham surgery (SO) controls. This
supports a role for E2 in the increased bactericidal capacity of female murine BMN (312).
In addition to its role in ROS production, degranulation and NET formation, E2 can
regulate neutrophil number, chemotaxis and apoptosis (133, 136, 248, 346, 347). In fact,
sex differences in spontaneous apoptosis between male and female neutrophils has been
reported with female neutrophils showing delayed apoptosis compared to males (136).
TNFα, in a dose- and time-dependent manner, is also known to modulate neutrophil
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apoptosis (348-352). Similarly, interaction of MPO with CR3 can delay neutrophil
apoptosis (352, 353). In contrast, CR3-mediated phagocytosis of iC3b opsonized bacteria
induces apoptotic cell death (352, 354, 355). Therefore, both E2 and CR3 could drive
differences in neutrophil viability thus contributing to differences in bactericidal outcomes.
The exact impact of E2 and increased CR3 expression on murine BMN viability and
longevity will require empiric determination.

Even though the contribution of sex hormones in modulation of neutrophil functions has
been reported, studies on sex differences in neutrophil function are extremely limited.
Differences in the number of neutrophils between sexes have been differentially reported
for both human and mouse (356-358). Similarly, differences in ROS production by rat
neutrophils were reported, with suppressed ROS production by male neutrophils in
response to sound stress (359). Furthermore, sex differences in phagocytosis by rat
neutrophils were observed and the outcome varied based on the stimulus used (284). Our
findings with murine neutrophils add to the mechanisms contributing to the sex differences
in neutrophils.

Overall, our findings suggest that differences in serum C3, BMN expression of its receptor,
CR3, and potential differences in respiratory burst, each contributes to the sex bias in
murine neutrophil bactericidal efficacy against S. aureus. Although our observations must
be reproduced in future studies using neutrophils from human males and females, this
knowledge of potential contributors to the innate sex bias in neutrophil killing of S. aureus
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expands our knowledge of the mechanistic aspects driving the innate protection in females
against this important human pathogen.

AKNOWLEDGEMENTS
This work was supported in part by research grants from the National Institutes of Health
to PRH (AI128159, AI145324) and ERP (CA163890 and CA194496), and utilized services
and facilities provided through the NIH-funded University of New Mexico Clinical and
Translational Science Center (UL1_TR001449). Support was also provided by the UNM
Comprehensive Cancer Center (P30 CA118100) and the Flow Cytometry shared resource,
as well as the Autophagy, Inflammation and Metabolism (AIM) Center of Biomedical
Research Excellence (CoBRE) supported by NIH P20 GM121176.

102

CHAPTER 4: GPER Activation Protects against Epithelial Barrier Disruption by
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ABSTRACT
Sex bias in innate defense against Staphylococcus aureus skin and soft tissue infection
(SSTI) is dependent on both estrogen production by the host and S. aureus secretion of the
virulence factor, α-hemolysin (Hla). The impact of estrogen signaling on the immune
system is most often studied in terms of the nuclear estrogen receptors ERα and ERβ.
However, the potential contribution of the G protein-coupled estrogen receptor (GPER) to
innate defense against infectious disease, particularly with respect to skin infection, has not
been addressed. Using a murine model of SSTI, we found that GPER activation with the
highly selective agonist G-1 limits S. aureus SSTI and Hla-mediated pathogenesis, effects
that were absent in GPER knockout mice. Specifically, G-1 reduced Hla-mediated skin
lesion formation and pro-inflammatory cytokine production, while increasing bacterial
clearance. In vitro, G-1 reduced surface expression of the Hla receptor, ADAM10, in a
human keratinocyte cell line and increased resistance to Hla-mediated permeability barrier
disruption. This novel role for GPER activation in skin innate defense against infectious
disease suggests that G-1 may have clinical utility in patients with epithelial permeability
barrier dysfunction or who are otherwise at increased risk of S. aureus infection, including
those with atopic dermatitis or cancer.
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INTRODUCTION
Staphylococcus aureus is the primary cause of skin and soft tissue infection (SSTI)
worldwide (5, 12, 257). In the U.S., more than half of the isolates are methicillin-resistant
(MRSA) strains, limiting antibiotic treatment strategies (5, 257). The skin permeability
barrier serves as the first line of defense against external insults such as bacterial
pathogens(77, 78), still the cost of treating SSTI reaches billions of dollars annually (360).
To breach epithelial barriers, the majority of S. aureus isolates secrete the pore-forming
toxin, alpha-hemolysin (Hla) (361). Hla facilitates invasive infection by hijacking the host
molecule ADAM10 (a disintegrin and metalloprotease 10) to disrupt cell junctions and thus
host permeability barriers (31, 32, 34, 35, 39, 40, 258, 361-363). Since Hla-mediated
epithelial injury controls infection outcome (364), numerous prophylactic and therapeutic
strategies to directly target Hla are being pursued as treatment options (34, 51-55, 57, 59,
61). Interestingly, we recently reported a sex bias in SA SSTI in male versus female
patients (312), and showed in a murine SSTI model that sex bias in S. aureus SSTI is driven
by a sex- and estrogen-specific response to Hla (258, 312). This suggests that host-directed
therapies (HDT) might be developed to limit invasive disease by protecting barrier integrity
in the face of Hla-challenge.

Historically, estrogen has been known to exert its numerous effects on the immune
response by signaling through the classical nuclear estrogen receptors ERα and ERβ (100).
More recently, the G protein-coupled estrogen receptor (GPER) has been recognized as
mediating many of the rapid and even long-term effects of estrogen (150, 365). GPER
activation has been shown to modulate macrophage cytokine production and neutrophil
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function (244, 344, 366), as well as to reverse stroke-induced peripheral
immunosuppression in ovariectomized mice (367). Interestingly, GPER activation by the
highly selective GPER agonist G-1 (368) has also been reported to block disruption of
endothelial barrier integrity as shown by its ability to limit blood-brain barrier (BBB)
disruption following global cerebral ischemia (GCI) (369). In addition to endothelial cells,
GPER is also expressed in numerous types of skin cells including keratinocytes,
melanocytes and dermal fibroblasts (84, 370-372). However, the potential contribution of
GPER activation to skin immunity, particularly with respect to innate defense against
bacterial infection, has not been addressed. Therefore, given the role of S. aureus Hla in
SSTI and disruption of epithelial cell junctions, we hypothesized that G-1-mediated
activation of GPER would limit Hla-mediated epithelial permeability barrier disruption and
reduce S. aureus pathogenesis.

To test this hypothesis, we used a murine model of SSTI(258) to test whether G-1 limits S.
aureus SSTI and Hla-mediated pathogenesis in a GPER-dependent manner. Specifically,
G-1 treatment reduces Hla-mediated skin lesion formation and production of proinflammatory cytokines in vivo. Consistent with its ability to support BBB integrity
following GCI (369), G-1 treatment of a human keratinocyte cell line increased
intercellular junction integrity in the face of Hla-mediated permeability barrier disruption.
Furthermore, G-1 reduced keratinocyte surface expression of the Hla receptor, ADAM10,
as well as E-cadherin cleavage with Hla-challenge, a mechanism that may contribute to the
overall increase in permeability barrier integrity. Together, these studies clearly
demonstrate a novel role for GPER activation in skin innate defense against S. aureus
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infection and the important virulence factor, Hla, as well as the potential of G-1 as an HDT
to limit infectious disease.

MATERIALS AND METHODS
Reagents and cell culture
G-1 was synthesized as previously described (368). G-1 was dissolved in absolute ethanol
to make a 1 mg ml-1 stock and stored at -20˚C until use. HaCaT cells were generously
provided by Dr. Laurie Hudson (University of New Mexico Health Sciences Center,
Albuquerque, NM, USA). Prior to use as described below, HaCaT cells were cultured at
37°C, 5% CO2 in HycloneTM Dulbecco’s Modified Eagle Medium with low glucose
(DMEM low), sodium pyruvate and without phenol red (GE Healthcare, Pittsburgh, PA,
USA), plus L-glutamine, 1% HycloneTM Minimal Essential Media with Non-Essential
Amino Acids (MEM NEAA) and 10% FBS (Gibco®, ThermoFisher Scientific, Grand
Island, NY, USA).

Bacterial strains and growth conditions
The MRSA USA300 isolate LAC(271) the LAC hla deletion mutant (LAChla) were
provided by Dr. F. DeLeo (Rocky Mountain Laboratories, National Institutes of
Health,/National Institute of Allergy and Infectious Diseases, Hamilton, MT) and Dr. J.
Bubeck-Wardenburg (Washington University School of Medicine, St. Louis, MO),
respectively. For infection, bacteria were cultured in trypticase soy broth (TSB) at 37C to
early exponential phase as described previously (266). Stocks were prepared in TSB with
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10% glycerol and maintained at -80˚C for no more than two weeks prior to use. The number
of CFU per ml of frozen stock was determined by plating ten-fold serial dilutions onto
trypticase soy agar containing 5% sheep blood (Becton, Dickinson and Company; Franklin
Lakes, NJ, USA). On the day of infection, bacteria were diluted to the indicated
concentration in USP-grade saline (B. Braun Medical, Irvine, CA, USA).

Mouse skin infection model
Male and female C57BL/6J were purchased from The Jackson Laboratory (Bar Harbor,
Maine, USA). Mice were acclimated for a minimum of seven days prior to use.
Gper−/− mice (GPER KO) (Procter & Gamble, Cincinnati, OH, provided by Jan S.
Rosenbaum) were backcrossed onto the C57BL/6 background (mice originally purchased
from Harlan Laboratories, currently Envigo, Indianapolis, IN, USA) as previously
described(373). Gper−/−and corresponding wild-type (WT) mice (C57BL/6) were bred inhouse at the University of New Mexico Animal Resources Facility. The mouse model of
SSTI was utilized as previously described(258). Briefly, four to six days before infection
we used Nair™ to depilate the right flank of the mice. The day of use, G-1 stock was diluted
in absolute ethanol to 20 µg ml-1. Immediately prior to injection, 100 µl of G-1 at 20 µg
ml-1 in absolute ethanol or 100 µl absolute ethanol control was added to 900 µl diluent
(0.9% NaCl with 0.1% bovine serum albumin and 0.1% Tween-20). On days -2 through
+2 relative to infection or Hla challenge, mice were treated by intraperitoneal (IP) injection
of 100 µl of vehicle or G-1 (200 ng, ~ 10 µg kg-1). On the day of infection (d0), mice (8 to
12 weeks of age) were anesthetized by isoflurane inhalation and infected by subcutaneous
(SQ) injection of 50 µl of saline containing 2-3 x 107 CFU of LAC or LAChla. Similarly,
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mice used for Hla challenge studies were injected SQ with 1 µg recombinant Hla (86).
Mice were weighed prior to infection and every 24 hours until sacrifice, and percent weight
loss is relative to pre-infection weight at 100%. Challenge sites (infection or Hla injection)
were photographed daily and lesion areas determined by ImageJ analysis (270). Lesion
area and weight loss over the course of infection was integrated (Prism 8.0.0, GraphPad
Software, La Jolla, CA, USA) and presented as area under curve (AUC) in mm2. On day 3
post-infection, mice were sacrificed by CO2 asphyxiation and a 2.25-cm2 section of skin
surrounding the infection site was excised for mechanical disruption. As appropriate, skin
homogenate was serially diluted and plated on sheep blood agar to determine infection site
CFUs. Remaining skin homogenate was clarified by centrifugation and the clarified
fraction stored at -80°C for subsequent analysis.

Cytokine and MPO analysis
The concentration of the indicated cytokines in clarified skin homogenate was determined
using a BioPlex 200 system, BioPlex manager software (Bio-Rad, Hercules, CA, USA)
and a custom-designed mouse multiplex assay (EMD Millipore, Billerica, MA, USA)
according to manufacturer’s directions. Where cytokine levels were below the limit of
detection, one-half of the lowest standard concentration was utilized. Myeloperoxidase
(MPO) levels in clarified homogenate were measured using the ELISA Mouse
Myeloperoxidase DuoSet kit (R&D Systems, Minneapolis, MN, USA) according to
manufacturer’s directions.
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ECIS
TER of HaCaT cell monolayers was measured using an ECIS® Zθ instrument (Applied
Biophysics, Troy, NY, USA). Cells were maintained at 37°C, 5% CO2. ECIS 96W10idf
disposable electrode arrays (Applied Biophysics) were coated with 25 µl of 0.01% polyL-lysine (Millipore Sigma, Burlington, MA, USA) and incubated at least 15 min. Poly-Llysine was then removed and replaced with media A (250 µl DMEM low without phenol
red, with sodium pyruvate, L-glutamine, 1% MEM-NEAA and 10% charcoal-stripped FBS
(JR Scientific, Woodland, CA, USA)) and TER was measured every 10 min at 1000 Hz.
After resistance stabilization, media A was removed and replaced with 300 µl of HaCaT
cells (6.3 x 104) in prewarmed media A containing 100 nM G-1, 1 µM G15, 100 nM G-1
plus 1 µM G15 or vehicle control (+G-1/G15/Veh). Cells were allowed to stabilize for six
days with media replaced on day 3. On day 5, media was changed to media B (DMEM
high glucose, without phenol red, with sodium pyruvate, L-glutamine and 1 % MEMNEAA) + G-1/G15/Veh. On day 6, media was replaced with media B+ G-1/G15/Veh
containing either 1 µg Hla, HlaH35A or PBS (phosphate buffered saline) control, and TER
measures continued for 24 hours.

Quantitative RT-PCR
Infection site tissue (2.25-cm2) was collected in RNALater (Qiagen, Valencia, CA), RNA
isolated using Qiazol and purified using RNeasy Kits (Qiagen, Germantown, MD, USA)
according to manufacturer’s directions. cDNA was generated from RNA using a PTC-200
Peltier Thermocycler (Bio-Rad, Hercules, CA, USA) with High-capacity cDNA RT kits
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with RNAse inhibitor and random hexamer primers (Applied Biosystems, Foster City, CA,
USA). Quantitative PCR (qPCR) was performed on a ViiA 7 Real-Time PCR system
(Applied Biosystems) using Taqman® Gene Expression master mix (Applied Biosystems).
Gene expression was quantified using QuantStudio software (Applied Biosystems) relative
to GAPDH using a PrimeTime Predesigned qPCR assays for CDH1 and ADAM10
(Integrated DNA Technologies, Coralville, IA, USA).

Immunofluorescent staining and flow cytometry
HaCaTs were seeded in 24-well plates (4 x 105 cells in one ml in media A with G-1/Veh)
and replaced as needed until confluent. Media was changed to media B + G-1/Veh 24 hours
prior to flow analysis. HaCaTs were trypsinized (0.25% Trypsin-EDTA, Gibco) and cells
pooled from either G-1- or Veh-treated wells. Pooled cells were subsequently washed and
exchanged into flow buffer (PBS, 2% FBS, and 0.1% NaN3) then diluted to equal cell
concentrations (~3 x 106 cells ml-1). Fc inhibitor antibody (14-9161-71, ThermoFisher) was
added at 20 µl ml-1 and cells incubated at room temperature (RT) for 20 min. Cells were
then stained on ice in the dark for 30 min with either isotype control (12-4714-81,
ThermoFisher) or anti-ADAM-10 (352703, BioLegend, San Diego, CA) antibody at 10 µg
ml-1. Cells were washed three times with flow buffer and 20,000 events were recorded on
an Accuri C6 flow cytometer (BD Biosciences, San Diego, CA) with isotype corrected
mean fluorescence normalized to Veh-treated controls.

Western blot analysis of E-cadherin cleavage
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Throughout this assay, all media included either 100 nM G-1 or vehicle control (G-1/Veh)
as described above and cells were maintained at 37°C, 5% CO2. HaCaTs were seeded in
24-well plates (4 x 105 cells in one ml of media A + G-1/Veh) and media was replaced
every 48 hours until cells were confluent. Cells were then grown for 24 hours in media B
+ G-1/Veh. After 24 hours, cells were treated for eight hours with 0.5 µg ml-1 Hla (or PBS)
in media B + G-1/Veh. To collect both cleaved E-cadherin (CTF), which is released into
the media, and full-length E-cadherin (FL), which is cell-associated, an equal volume of
2X RIPA lysis buffer (374) (Triton X-100 was substituted for Nonidet P-40) was added to
each well and the plate incubated on ice for five min. Equal volumes of lysate were resolved
on 4-12% Bis-Tris Plus gels in MES buffer (ThermoFisher) and transferred to 0.45 µm
nitrocellulose membranes (Bio-Rad, Hercules, CA). Membranes were blocked with 5%
nonfat milk in TBST (20 mM Tris, pH 7.6, 150 mM NaCl, and 0.1% Tween 20) for 90 min
at RT. E-cadherin was detected using mouse anti-human E-cadherin antibodies (CL-sc8426, Santa Cruz Biotechnology, Dallas, TX; FL- 610181, BD Biosciences, San Diego,
CA) at 1:1000 followed by goat anti-mouse poly-HRP antibody (32230, ThermoFisher),
both in 1% milk in TBST. Membranes were developed using SuperSignal West Femto
Substrate (ThermoFisher), and imaged on a Protein Simple FluorChem R system
(ProteinSimple, Santa Jose, CA). Band intensity was quantitated using Image Studio Lite
(v5.2, LI-COR, Lincoln, NE) and normalized to vehicle-treated, no Hla lysates.

S. aureus growth assay
An overnight culture of LAC was diluted to 5 x 105 CFU ml-1 and treated with 1 µM or
100 nM G-1 or vehicle control. Treated bacteria were aliquoted to a 96-well plate sealed
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with a breathable membrane (USA Scientific, Ocala, FL). Plates were incubated at 37⁰C
with shaking, and the OD600 was measured every 15 min for 16 hours using a Synergy HT
plate reader (BioTek, Winooski, VT).

Hla Western blot and relative quantification
Overnight cultures of LAC and LACΔhla were diluted 1:100, treated with 100 nM G-1 or
vehicle and incubated at 37°C with shaking for 18 hours. The bacteria were pelleted and
the supernatant filtered through a 0.2 µm polyethersulfone filter (VWR, Radnor, PA).
Protein concentrations were determined by bicinchoninic acid assay (BCA)
(ThermoFisher) and equal protein volumes were resolved on a 4-12% Bis-Tris Plus gel in
MES buffer (ThermoFisher) before transfer to a 0.45 µm nitrocellulose membrane (BioRad, Hercules, CA). Membranes were blocked with 5% nonfat milk in TBS (20 mM Tris,
pH 7.6, and 150 mM NaCl) for 2 hours at RT. Hla was detected with mouse anti-HLA
antibody (6C12, IBT Bioservices, Rockville, MD) at 1:1000 and goat anti-mouse polyHRP antibody (32230, ThermoFisher) at 1:10,000, both in 1% milk in TBS. TBST (TBS
plus 0.1% Tween 20) was used for membrane washes between incubations. Membranes
were developed in SuperSignal West Femto Substrate (ThermoFisher), and imaged using
a Protein Simple FluorChem R (ProteinSimple, Santa Jose, CA). Band intensity was
quantitated using ImageStudio Lite (v5.2, LI-COR, Lincoln, NE) and normalized to
vehicle-treated, no Hla lysates.

Rabbit red blood cell lysis assays
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To assess G-1 effects on Hla production and activity, glycerol stocks of LAC were diluted
to 2 x 107 CFU ml-1 and either left untreated or treated with 1 µM and 100 nM G-1 or
vehicle then incubated at 37⁰C with shaking for 5 hours. Bacteria were pelleted by
centrifugation and the supernatant filtered through a 0.2 µm polyethersulfone filter (VWR).
To determine the effects of G-1 on Hla function, G-1 or vehicle was added to previously
untreated cultures just prior to supernatant harvest as described above. Supernatants were
diluted 2-fold in PBS and incubated statically with an equal volume of PBS-washed, 4%
rabbit red blood cells (31081, Colorado Serum Company, Denver, CO) at 37⁰C. Lysis was
measured as a decrease in turbidity at OD650 using a SpectraMax 340 plate reader
(Molecular Devices, San Jose, CA).

HaCaT cell count and viability
HaCaTs (300 µl with 6.3 x 104 total cells) were seeded into a 96-well plate in media A +
G-1/Veh and media replaced every 48 hours until the cells were confluent. Cells were then
grown for 24 hours in media B +G-1/Veh before being trypsinized (0.25% Trypsin-EDTA,
Gibco) and diluted 1:1 with 0.4% trypan blue (Gibco). Cells were counted using a TC20
automated cell counter (Bio-Rad). Viable cells were those that excluded trypan blue.

Immunofluorescence and siRNA for GPER expression
Human keratinocyte HaCaT cells were seeded on coverslips for 2-3 days, washed and fixed
in 2% paraformaldehyde. For some experiments, cells on coverslips were transfected with
human GPER siRNA (Dharmacon L-005563-00) or non-targeting control siRNA
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(Dharmacon D-001810-10-05) using Lipofectamine 3000 (Thermo Fisher Scientific) as
per manufacturer’s instructions 48 hours before fixing. For staining GPER, cells were
permeabilized and blocked with 3% BSA in PBST (PBS containing 0.1% Triton X-100)
for 1 h and then incubated with rabbit anti-human GPER antibody (SAB 2700363, Sigma
at 1:250), using 3% normal goat serum (NGS) in PBS as blocker for 3 h. Cells were washed
with PBS and incubated with goat anti-rabbit IgG conjugated to Alexa Fluor 568 in PBS
containing 3% NGS for 1 h. Subsequently, cells were washed, mounted in Vectashield, and
imaged by confocal microscopy using a Zeiss LSM800 Airyscan confocal microscope
(Zeiss, Oberkochen, Germany).

Statistical analysis
GraphPad Prism version 7.03 (GraphPad Software, San Diego California) was used for all
statistical evaluations. Statistical analyses of two groups was performed using an Unpaired
Students t-test or Mann Whitney U test for non-parametrics as appropriate based on
variance (F test). For comparisons between more than two groups, one-way ANOVA was
used with parameters based on D’Agostino & Pearson omnibus or Shapiro-Wilk normality
tests, and with Tukey’s or Bonferroni’s (ANOVA) or Dunn’s (Kruskal-Wallis test, nonparametrics) post-hoc multiple comparison analyses as indicated. Results were considered
statistically significant at p<0.05.

Ethics approval
All animal studies were conducted in adherence with the recommendations in the Guide
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for the Care and Use of Laboratory Animals (267) and the Animal Welfare Act, and were
approved by the Institutional Animal Care and Use Committee (IACUC) of the University
of New Mexico Health Sciences Center (Animal Welfare Assurance number D16-00228).
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RESULTS
GPER activation reduces pathogenesis in a mouse model of S. aureus SSTI
GPER activation has a variety of effects on innate immune function, including modulation
of macrophage cytokine production and neutrophil function (244, 344, 366), as well as
reversing stroke-induced immunosuppression (367). To determine whether GPER
activation would support innate immune defense against infectious disease, we evaluated
the effects of GPER activation on the outcomes of S. aureus infection using a well
characterized murine model of SSTI (258). Male mice were treated with the GPERselective agonist G-1 (368, 375) or vehicle control prior to subcutaneous (SQ) infection
with the community-acquired MRSA isolate LAC (271) (Figure 4.1a). Over the course of
a three-day infection, G-1-treated mice showed significantly reduced lesion area
(neutrophil-filled abscesses with subsequent dermonecrosis) (p<0.001) and weight loss
(p<0.05) (a general measure of morbidity) compared to vehicle-treated controls (Figure
4.1b-c). On day 3 post-infection (typically the peak of lesion formation (272)), G-1-treated
males also had reduced bacterial burden compared to control-treated mice (Figure 4.1d).
Consistent with reduced lesion area, bacterial burden, and the demonstrated antiinflammatory effects of G-1 (366), G-1-treated mice also had lower local levels of the
inflammatory cytokines IL-1β, TNFα, IL-6 and CXCL1 (Figure 4.1e). As expected, given
lower levels of the neutrophil-recruiting chemokine CXCL1, local levels of
myeloperoxidase (MPO), often used as a surrogate marker for neutrophil presence (376),
were reduced in G-1-treated mice (Figure 4.1f) suggesting a potential association between
reduced lesion size with G-1-treatment and reduced neutrophil accumulation. In contrast
to reduced levels of pro-inflammatory cytokines, levels of the anti-inflammatory cytokine
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IL-10 did not significantly differ between groups (p=0.0884). This indicates that while G1 reduces inflammation, it is not a general suppressor of cytokine production (Figure 4.1e).

Female mice are innately better protected than males against S. aureus SSTI (312), so we
asked whether G-1 would further limit pathogenesis in female mice. At the male infectious
dose of 2 x 107 LAC CFU, females develop much smaller lesions than males. Therefore,
to assess additional G-1 protection in females, the infectious dose was increased to ~3 x
107 CFU. Compared to vehicle-treated controls, G-1-treated female mice showed
significant reductions in lesion area (p<0.01), whereas differences in weight loss and
bacterial burden did not reach statistical significance (Figure 4.2). G-1-treated female mice
also had reduced levels of the inflammatory cytokine TNFα at the site of infection, with no
significant reduction in levels of the other cytokines tested or MPO compared to vehicletreated mice (Figure 4.2). Given that G-1 does not directly inhibit bacterial growth
(Figure 4.3), these results suggest that GPER activation limits the severity of S. aureus
SSTI by a host-dependent mechanism.
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Figure 4.1. G-1 promotes protection against S. aureus SSTI in male mice.
WT (C57BL/6J) male mice were treated IP with vehicle (Veh) or 200 ng G-1 on days −2,
−1, 0, + 1 and + 2 relative to SQ infection with 2 × 107 CFU of USA300 MRSA isolate
LAC. Mice were weighed and lesion size measured daily before mice were sacrificed on
day 3 post-infection. (a) Illustration of the G-1 treatment and infection timeline. (b)
Representative day 3 post-infection images and area under the curve (AUC) for lesion size
(mm2) and (c) percent weight change (relative to pre-infection weight) over the 3-day
infection. (d) Day 3 post-infection bacterial burden. (e) IL-1β, TNFα, IL-6, CXCL1 and
IL-10 levels and (f) myeloperoxidase levels in clarified injection site homogenate collected
on day 3 from the site of infection. Data are mean ± SEM, n = 6–7 mice per group from
two independent experiments. Unpaired t-test: ns, not significant; *p < 0.05;
**p < 0.01;***p < 0.001.
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Figure 4.2. G-1 promotes protection against S. aureus SSTI in female mice.
WT (C57BL/6J) female mice were treated IP with vehicle (Veh) or 200 ng G-1 on days 2, -1, 0, +1 and +2 relative to SQ infection with 3 x 107 CFU of USA300 MRSA isolate
LAC. Mice were weighed and lesion size measured daily before mice were sacrificed on
day 3 post-infection. (a) AUC for lesion size (mm2) and (b) percent weight change over the
3-day infection. (c) Day 3 post-infection bacterial burden. (d) IL-1, TNF, IL-6, CXCL1
and IL-10 levels in clarified injection site homogenate collected on day 3 from the site of
infection. (e) Day 3 post-infection myeloperoxidase levels in clarified infection site
homogenate. n=7-8 mice per group from two independent experiments. Data are mean ±
SEM Unpaired t-test: ns, not significant; *, p<0.05; **, p<0.01.
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Figure 4.3. G-1 does not inhibit S. aureus growth.
Growth of LAC in the presence of 100 nM and 1 µM G-1 or vehicle control as measured
by OD600. Data are mean ±SEM.
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G-1 limits the severity of S. aureus SSTI in a GPER-dependent manner
G-1 is a highly selective GPER ligand with respect to both classical estrogen receptors and
other GPCRs (366, 368), suggesting that the benefits of G-1-treatment against S. aureus
SSTI should depend on host expression of GPER. To test this, we compared outcomes
between male GPER knockout (GPER KO) mice and corresponding wild-type (WT)
C57BL/6 controls treated with G-1 or vehicle and infected with LAC. Compared to
vehicle-treated controls, G-1-treatment significantly reduced lesion size (p<0.001) and
increased bacterial clearance (p<0.01) without affecting weight loss in infected WT mice,
but had no effect on lesion size or bacterial clearance in GPER KO mice (Figure 4.4a-c).
Notably, infection outcomes in the absence of G-1 did not significantly differ between WT
and GPER KO male (Figure 4.4a-c) or female (Figure 4.4d-f) mice. This indicates that
innate defense in this model is normally GPER-independent and suggests that increased
estrogen-dependent, innate protection in female mice (312) is mediated through classical
estrogen receptors. However, our findings clearly show that G-1 limits pathogenesis in both
males and females and that GPER could be a promising target for HDT. Most importantly,
these results demonstrate that the efficacy of G-1 in limiting S. aureus SSTI is host- and
GPER-dependent.
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Figure 4.4. G-1-mediated protection against SSTI is GPER-dependent.
(a–c) WT (C57BL/6) and GPER KO male mice were treated IP with vehicle or 200 ng G1 on days −2, −1, 0, + 1 and + 2 relative to SQ infection with ~3 × 107 CFU of USA300
MRSA isolate LAC. Shown are (a) lesion area (AUC in mm2) over the course of a 3-day
infection, (b) day 3 post-infection bacterial burden at the site of infection and (c) percent
weight change (AUC) post-infection. n = 6–9 mice per group from two independent
experiments. (d–f) Female WT and GPER KO mice were infected as described above.
Shown are (d) lesion AUC (mm2) over the course of a 3-day infection, (e) day 3 postinfection bacterial burden at the site of infection and (f) percent weight change (AUC) postinfection. n = 14–21 mice per group from three independent experiments. Data are
mean ± SEM. ANOVA (a) p = 0.0002, (b) p = 0.0024 and (c) not significant. Tukey’s
multiple comparison test (a–c) or Unpaired t-test (d-f): ns, not significant; *p < 0.05;
**p < 0.01; ***p < 0.001.
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G-1 limits Hla-mediated pathogenesis in a murine dermonecrosis model
In animal models of S. aureus SSTI, the secreted virulence factor alpha-hemolysin (Hla)
drives lesion formation at the site of infection (34, 35, 40). Given the host-dependent
protective effects of G-1 against S. aureus SSTI, we postulated that G-1-treatment would
limit pathogenesis in male mice directly challenged with Hla. Consistent with results in
mice infected with S. aureus, G-1 treatment significantly reduced lesion formation,
inflammatory cytokine production (IL-1β, TNFα, IL-6 and CXCL1) and MPO levels at the
site of subcutaneous Hla-injection compared to vehicle-treated controls (Figure 4.5). To
corroborate the role of Hla in G-1-mediated protection in the skin, we infected male mice
with an isogenic Hla deletion mutant of S. aureus (LACΔhla). In the absence of Hla
expression, skin lesion formation is minimal or absent, so outcomes are based largely on
bacterial burden and weight loss. Importantly, G-1-treatment did not significantly alter
LACΔhla infection outcomes based on day three post-infection bacterial clearance and
overall weight loss (Figure 4.6). Given that G-1 does not impact bacterial Hla expression
or Hla activity (Figure 4.6), these results provide support for a mechanism in which G-1
protects against Hla-mediated pathogenesis by altering the host response.
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Figure 4.5. G-1 reduces Hla-mediated lesion formation and inflammation.
WT (C57BL/6 J) male mice were treated IP with vehicle or 200 ng G-1 on days −2
through + 2 relative to SQ injection of 1 µg Hla. (a) Representative day 3 post-injection
images (scale bar = 5 mm) and lesion size (AUC in mm2) over the 3 days post-injection.
(b) IL-1β, TNFα, IL-6, CXCL1 and (c) myeloperoxidase levels measured in clarified
injection site homogenate collected on day 3 post-injection. Data are mean ± SEM, n = 8
mice per group from two independent experiments. Mann –Whitney U test: *p < 0.05;
**p < 0.01; ***p < 0.001.
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Figure 4.6. G-1 does not alter SSTI outcomes in the absence of Hla and does not
inhibit Hla production or activity.
(a-b) WT (C57BL/6J) male mice were treated IP with vehicle or 200 ng G-1 on days -2, 1, 0, +1 and +2 relative to SQ infection with 3 x 107 CFUs LACΔhla. (a) Day 3 postinfection bacterial burden and (b) percent weight change (AUC) over the 3 day infection.
Data are mean ± SEM, n=13 mice per group from two independent experiments. (c)
Western blot (left) and quantification (right) of Hla in sterile supernatant from LAC and
LACΔhla grown for 18 h in the presence of vehicle control or 100 nM G-1. Three samples
per group are shown (left). ND, not detected. (d-e) Analysis of Hla-mediated rabbit red
blood cell (rRBC) lysis using sterile LAC supernatant collected after 5 h growth in the
presence of the indicated concentrations of G-1 or vehicle control (d) or sterile 5 h LAC
supernatant with the indicated concentrations of G-1 or vehicle control added at the time
of the assay (e). Percent protection against rRBC lysis relative to PBS at 100%. Triton
control shows total lysis. Data are mean ± SD. Unpaired t-test; ns, not significant.
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G-1 limits keratinocyte permeability barrier disruption by Hla
Hla is a major contributor to the pathogenesis of S. aureus infections involving epithelial
cells, including SSTI and pneumonia (PNA) (31, 32, 34, 35, 40, 42-44). During these
infections, Hla disrupts host permeability barriers to facilitate invasive infection (31, 32,
34, 35, 39, 40, 258). Recently, GPER activation was reported to limit disruption of BBB
integrity in a rodent model of GCI (369). Furthermore, GPER is expressed in numerous
types of skin cells including melanocytes, dermal fibroblasts and the most prominent skin
cell type, keratinocytes (84, 370-372). Given our in vivo data showing that G-1 limits skin
damage caused by Hla, and the role of S. aureus Hla in disrupting epithelial cell junctions,
we hypothesized that activation of GPER with G-1 would limit Hla-mediated epithelial
permeability barrier disruption. One measure of permeability barrier integrity is resistance
of cell monolayers to passage of an electric current (electrical cell-substrate impedance
sensing (ECIS)) (377). As keratinocytes are the major skin cell type, we used the HaCaT
human keratinocyte cell line (378) to determine whether G-1 limits Hla-mediated
disruption of epithelial barrier integrity. GPER expression in HaCaT cells was first verified
by immunofluorescent staining with and without siRNA knockdown of GPER, after which
we demonstrated that G-1 did not affect cell growth or viability during culture (Figure
4.7).
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Figure 4.7. GPER is expressed in HaCaT cells and G-1 does not alter HaCaT cell
growth or viability.
(a) Immunofluorescence microscopy showing GPER staining in siControl-treated HaCaT
cells, but not in siGPER-treated cells. (b) Cell count and viability of HaCaT cells grown to
confluence in the presence of 100 nM G-1 or vehicle. Data are mean ± SEM. Unpaired ttest. ns, not significant.
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Next, HaCaT cells were grown to confluence in the presence of vehicle or G-1 and changes
in transepithelial electrical resistance (TER) were measured by ECIS. After reaching stable
resistance, monolayers were exposed to Hla or the inactivate Hla mutant, HlaH35A (41, 379).
As previously reported, there was no significant reduction in TER between control cells
and those challenged with HlaH35A (40) regardless of G-1-treatment (Figure 4.8a and data
not shown). In contrast, whereas Hla rapidly reduced keratinocyte barrier integrity
(decreased TER) in vehicle-treated cells, cells grown in the presence of G-1 were
significantly more resistant (p<0.01) to permeability barrier disruption, with an average
33% increase (p=0.0079) in TER compared to vehicle control (Figure 4.8a-b). The G-1
mediated reduction in permeability barrier disruption was reversed in the presence of the
GPER-antagonist, G15 (375) (Figure 4.8c), consistent with the requirement for GPER for
G-1 efficacy in vivo (Figure 4.4a-c). Notably, G-1 did not alter HaCaT cell numbers
(Figure 4.7), suggesting that increased barrier integrity is independent of potential G-1mediated effects on cell growth or viability.

Hla disrupts epithelial barriers by binding its cell surface receptor, ADAM10 (39, 40, 380),
which in turn cleaves E-cadherin. Given that E-cadherin is a component of the adherens
junctions responsible for epithelial permeability barrier integrity (40, 380), and that G-1
limited keratinocyte permeability barrier disruption by Hla (Figure 4.8a-b) and reduced
skin damage (lesion area) in Hla-injected mice (Figure 4.5a), we predicted that G-1 would
reduce E-cadherin cleavage following Hla challenge. To test this, we used immunoblotting
to measure full-length E-cadherin (FL) and the cleaved C-terminal fragment (CTF) from
HaCaT cell monolayers grown in the presence of vehicle or G-1 and exposed to Hla
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(Figure 4.8d-e). In the absence of Hla, G-1 significantly increased expression of FL Ecadherin (Figure 4.8e, left) while decreasing baseline cleavage (CTF) (Figure 4.4e, right).
As expected, following an eight-hour culture with Hla, FL E-cadherin was significantly
decreased (Figure 4.8e, left) and cleavage (CTF) was increased independent of treatment
(Figure 4.8e, right). However, whereas FL E-cadherin levels were equivalent between
vehicle- and G-1-treated cells in the presence of Hla (Figure 4.8e, left), G-1-treatment
reduced E-cadherin cleavage (CTF) (Figure 4.8e, right). Given reduced Hla-mediated Ecadherin cleavage with G-1, we asked whether G-1 altered expression of E-cadherin or the
Hla receptor ADAM10. Although transcription of CDH1, which encodes E-cadherin, was
not altered by G-1 alone, CDH1 transcription was increased in G-1-treated keratinocytes
exposed to Hla (Figure 4.8f). Also, whereas G-1 alone increased ADAM10 transcription
approximately 15% (p<0.05) (Figure 4.8g), HaCaT cells treated with G-1 displayed 23%
less ADAM10 (p<0.0001) on the cell surface compared to control-treated cells (Figure
4.8h). Together, these findings suggest that G-1 may contribute to transcriptional
regulation of CDH1 when Hla is present, as well as post-transcriptional regulation of
ADAM10 expression or trafficking to the keratinocyte cell surface. This in turn may
contribute to maintenance of epithelial permeability integrity in the face of Hla-challenge
(Figure 4.8a-b).
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Figure 4.8. G-1 reduces Hla-mediated keratinocyte permeability barrier disruption.
HaCaTs were grown to confluence in the presence of vehicle or 100 nM G-1 prior to
challenge (t = 0) with 1 µg/mL Hla or HlaH35A (indicated by arrow in (a)). Changes in
permeability barrier resistance at 1000 Hz were measured by ECIS. (a) Representative
ECIS recording of HaCaT monolayer treated as described above. (b) Change in HaCaT
permeability barrier resistance at 12 h after Hla exposure. Data are mean ± SEM from two
(HlaH35A) to six (Control and Hla) independent experiments each with 6–8 technical
replicates per condition. Mann-Whitney U test. (c) HaCaT cells were grown in G-1, G15,
G-1 + G15 or vehicle control. Shown is the change in permeability barrier resistance at 12 h
after Hla exposure. Data are mean ± SEM of a representative experiment of two
independent experiments each with a minimum of 8 technical replicates.
ANOVA < 0.0001. (d) Western blot analysis of full-length (FL) E-cadherin and the cleaved
C-terminal fragment (CTF) in vehicle- and G-1-treated (100 nM) HaCaT cell monolayers
after eight hours incubation with 0 or 0.5 µg/mL Hla. MW, molecular weight markers. Four
replicates for each group are shown. Image Studio Lite was used to invert luminescent
image to that shown to uniformly enhance contrast for quantification of CTF. (e) Relative
quantification of E-cadherin FL (left) and CTF (right) of samples in (c) and based on band
intensity relative to vehicle-treated cells in the absence of Hla. (f) Quantitative PCR
analysis of CDH1 and (g) ADAM10 transcription by vehicle- and G-1-treated (100 nM)
HaCaT cells. Expression is shown relative to GAPDH and normalized to vehicle-treated
control cells. (h) Surface expression of ADAM10 on vehicle- and G-1-treated (100 nM)
HaCaT cells measured by immunofluorescent staining and flow cytometry. Shown is
percent expression relative to vehicle-treated controls. Data are mean ± SEM from two
independent experiments each with three technical replicates per condition. Unpaired ttest: ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
131

DISUSSION
The skin permeability barrier provides protection against transcutaneous water loss,
invasion by microbial pathogens and access of environmental toxins to underlying sensitive
tissues (77, 78). However, bacteria have had countless generations to evolve powerful tools
to disrupt this barrier and cause SSTIs resulting in annual treatment costs of billions of
dollars (360). As the most common cause of SSTI, S. aureus secretes Hla to disrupt
epithelial barriers and facilitate invasive infection. Specifically, Hla binds ADAM10 on
host cells, resulting in cleavage of the cell junction protein E-cadherin and loss of
permeability barrier integrity (31, 32, 34, 35, 39, 40, 258, 362, 363). Here we show that G1, the highly selective ligand of the non-classical estrogen receptor GPER, limits the
severity of S. aureus SSTI and production of pro-inflammatory cytokines in a murine
challenge model. The effects of G-1 are dependent on S. aureus expression of Hla, a finding
supported by reduced skin pathogenesis (lesion formation) in G-1-treated mice compared
to controls following direct Hla challenge. Not surprisingly, G-1 efficacy is dependent
upon host expression of GPER, as protection against S. aureus SSTI is lost in GPER KO
mice. Furthermore, G-1 reduces keratinocyte surface expression of the Hla receptor
ADAM10 and limits Hla-mediated disruption of epithelial barrier integrity in vitro.
Therefore, along with supporting endothelial permeability barrier integrity following
ischemic injury (369), our findings show that G-1 promotes epithelial barrier integrity and
host innate defense against a major bacterial toxin. Given that Hla-mediated epithelial
injury controls infection outcome (364), and that G-1 lacks the feminizing effects seen with
estrogen treatment (373), this work demonstrates the potential efficacy of G-1 as an HDT
to promote skin innate defense and reduce the burden of S. aureus SSTI.
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The role of estrogen signaling in immune regulation has historically been studied in terms
of the classical estrogen receptors ERα and ERβ (100). In contrast, although GPER is
expressed by a variety of immune cells, including monocytes, macrophages, neutrophils
and lymphocytes (147, 167, 244, 344, 381-386), the impact of GPER signaling on immune
function is in the early stages of investigation. Interestingly, GPER activation can result in
both pro- and anti-inflammatory responses. For example, GPER signaling can modulate
neutrophil function (244, 344), regulate both pro- and anti-inflammatory cytokine
production (366, 384) and promote regulatory T-cell responses (383). GPER has also been
shown to provide protection in a mouse model of multiple sclerosis (366), to contribute to
monocyte-dependent skin inflammation in response to serum from lupus patients, and to
reverse peripheral immunosuppression in an ovariectomized mouse model of stroke (367).
GPER is also expressed in skin cells (84, 370-372), where it contributes to cytoskeletal
organization

(371, 387) and melanin synthesis (370). Here we demonstrate the

contribution of GPER activation to host innate defense against S. aureus skin infection and
to increasing epithelial barrier integrity in the face of Hla challenge. These findings not
only significantly expand our understanding of GPER signaling in innate immune defense,
but also demonstrate a novel role for G-1 in the maintenance of barrier integrity in human
keratinocytes.

Hla plays a major role in the pathogenesis of S. aureus infection in numerous animal
models, particularly models of SSTI and PNA (34, 35, 39, 40, 362, 363). Its importance is
further evidenced by ongoing efforts to develop prophylactic and therapeutic strategies
targeting Hla expression or function (34, 51-55, 57, 59, 61). For example, recombinant Hla
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toxoid was recently shown to be a safe and immunogenic candidate vaccine antigen in
healthy adults in Phase 1-2 clinical trials (NCT01011335) (57). In addition, Suvratoxumab
(formerly known as MEDI4893), an anti-Hla monoclonal antibody, has successfully
completed Phase 1 safety trials (NCT01769417) (388) and is currently in a Phase 2 safety
and efficacy trial (NCT02296320) (389) to prevent or limit S. aureus pneumonia in
mechanically ventilated adults. Along with these approaches, the use of G-1, which also
protects against Hla-mediated pathogenesis, could provide an additional therapeutic benefit
to patients. Interestingly, combination treatment with the Hla neutralizing antibody
MEDI4893, and either vancomycin or linezolid, two clinically important antibiotics,
improved outcomes in mouse models of S. aureus SSTI (59) and PNA (60, 61). Whether
G-1 will have similar adjunctive efficacy with antibiotic therapy against S. aureus infection
is an important point for future investigation. Further studies are also required to determine
the mechanism by which G-1 increases keratinocyte transcription of the gene encoding the
Hla receptor ADAM10 while also reducing its surface expression (Figure 4.8f-g).
Although speculative, this mechanism may involve G-1-mediated effects on posttranslational regulation of ADAM10, including suppression of ADAM10 trafficking to the
cell surface. In any case, the use of G-1 as an HDT to promote skin innate defense may
prove a valuable component of a multifaceted approach to reduce the burden of S. aureus
infection.

The ability of G-1 to promote epithelial barrier integrity and to limit S. aureus infection
supports its potential clinical utility in patient populations at increased risk for infection.
For example, S. aureus colonization is frequently associated with atopic dermatitis and
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psoriasis, skin diseases that feature epidermal barrier dysfunction (390-393), and S. aureus
may actually contribute to skin inflammation in these patients (394). Recurrent S. aureus
SSTI is also a hallmark of autosomal dominant hyper IgE syndrome (AD-HIES) (91) and
it has recently been shown that the impaired epithelial response to infection in these
patients results from overproduction of the pro-inflammatory cytokine TNFα (395). TNFα
also contributes to the severity of atopic dermatitis, though TNF blockade by anti-TNF
biologicals has thus far failed to improve outcomes in these patients (62). Here we show
that whereas G-1 provides greater overall improvement in S. aureus skin infection
outcomes in the more susceptible male (312) versus relatively resistant female mouse
population, G-1-treatment significantly reduces lesion size as well as TNFα production in
S. aureus infected mice of both sexes. This suggests that G-1, which reduces but does not
completely prevent TNFα production and signaling, may be efficacious in limiting the
severity of S. aureus skin infection in highly susceptible AD-HIES and atopic dermatitis
patients.

Here we used a short-term skin infection model to capture the innate immune response to
S. aureus infection in advance of the development of any adaptive immunity. Therefore,
our findings indicate that G-1 enhances innate immune defense against infection. This
suggests the potential of G-1-treatment for limiting infection in groups with increased risk
of S. aureus infection due to impaired innate immunity such as cancer patients undergoing
chemotherapy or surgery (396-399). Given that what begins as an SSTI can lead to S.
aureus pneumonia, sepsis or other life threatening infection (400), it will be essential to
experimentally determine the efficacy of G-1 in limiting S. aureus skin infection in disease
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models of patients with increased susceptibility to S. aureus. Furthermore, since a single
dosing regimen was utilized for the current studies, additional investigations will be needed
to determine the optimal dosing strategy for efficacy against S. aureus SSTI in
immunocompetent mice as well as disease models of susceptible patient populations.
Overall, developing an HDT that limits infection in diverse patient populations could
positively influence clinical practice and improve human health.

Although our findings suggest the potential utility of G-1 to limit pathogenesis during S.
aureus skin infection, it could have much broader clinical utility. For example, since many
innate defense mechanisms are effective against a variety of bacterial pathogens, therapies
aimed at GPER activation may also prove efficacious for treating a variety of infections.
In addition, given that a monoclonal antibody targeting Hla has shown synergy with
antibiotic therapy in animal models of S. aureus infection (59-61), G-1 may likewise have
adjunctive efficacy. Furthermore, the ability of G-1 to promote endothelial (369) and
epithelial barrier integrity may prove useful in treating AD, psoriasis, or other diseases
involving dysfunctional permeability barriers. Finally, regardless of its therapeutic
potential, G-1 may provide a powerful tool for identifying other GPER-dependent host
targets to improve epithelial barrier integrity and promote host innate immune defense.
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CHAPTER 5: DISCUSSION
SUMMARY
Staphylococcus aureus, the primary cause of SSTI, is a global health concern possessing
mild to life threatening risks (5, 8, 21, 257, 264). The incidence of S. aureus SSTI has
increased over the years with a 40% increase in the SSTIs incidence in the US between
2000 to 2012 (28, 50). Another study conducted by Miller and colleagues have reported
increased frequency of SSTIs than other conditions such as urinary tract infections or
pneumonia from 2005 to 2010 in ambulatory and inpatient settings (50, 264). This has
increased the number of hospital visits and treatment costs significantly (28, 50). With
about 50% of the SSTI cases reported caused by MRSA (5, 50, 257), the rising antibiotic
crisis points towards a need for an alternative therapeutic approach (9, 13).

Numerous studies have identified bacterial factors responsible for S. aureus pathogenesis
and multiple antibodies and vaccines developed against these targets are being tested for
their ability to limit S. aureus infections (34, 52, 54, 55, 59-61, 262). However, with the
ever-evolving survival mechanisms of the bacteria and multiple systems regulating their
virulence, developing a vaccine that encompasses all these targets is challenging (401,
402). Hence, the necessity to utilize multiple approaches to combat S. aureus infection.
One such approach would be to boost the host immunity against the pathogen. For the
identification of host targets for therapeutic purposes, understanding the mechanism of host
defense against S. aureus is important. Multiple studies have highlighted the importance of
innate immune cells, neutrophils and macrophages as well as resident skin cells in
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combating S. aureus skin infections (20, 68). Also, research focused on the roles of
hormones on regulating skin physiology as well as immune cells function have been
conducted (403, 404). However, S. aureus SSTI outcomes have not been examined from a
sex-bias perspective. Sex-specific differences in infectious diseases has been reported with
variation in outcomes depending on the type of the pathogen, infection, and the host factors
(behavioral, biological or physiological) (94-107). Importance of including both sexes in
research studies was demonstrated by the differences in clinical trials outcomes based on
findings from one sex (405, 406) and thus, NIH has mandated the inclusion of both sexes
in the research funded by the institute and that the data be reported including sex as a
biological variable (308). Our findings relative to this mandate that are reported here are
outlined in Figure 5.1 and briefly highlighted below.

Sex differences in S. aureus nasal colonization as well as susceptibility to S. aureus
bacteremia has been reported for humans (109). However, sex-specific differences in host
response to S. aureus SSTI that accounts for about 90% of all S. aureus infections (19) has
not been reported. Hence, in Chapter 2 we investigated the sex bias in host response to S.
aureus SSTI using a murine infection model. Based on the increased nasal carriage and
susceptibility to S. aureus bacteremia in males (109) and the effect of female hormone
estrogen in wound healing (164), we hypothesized there to be a female bias in S. aureus
SSTI outcomes with estrogen contributing to the protection in females. Using a murine
SSTI model, we were the first to report sex-specific differences in innate response to S.
aureus SSTI. Our findings show female mice to be innately resistant to S. aureus SSTI and
that the resistance is E2-dependent. Our animal study results were in line with the UNM
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CTSC database search results that showed increased incidence of S. aureus SSTI in males
compared to females for the age group (18-45 years) and the timeline (2011-2014) queried
with an odds ratio of greater than 2 for male infection. While the database search results
could vary due to differences in hospital visits, as well as biological and behavioral
differences between sexes, the animal study suggests physiological differences in host
response to infection. The work presented in Chapter 2 also uncovers a key role for host
cell, neutrophils and bacterial toxin, Hla in driving the differences in infection outcomes,
suggesting that multiple variables contribute to the sex bias. We found differences in
neutrophils bactericidal capacity ex vivo with increased S aureus clearance by female
murine neutrophils compared to males. Also, males and females respond differentially to
Hla, a key contributor to dermonecrosis and invasive S. aureus infection (31-33). These
findings highlight the importance of investigating both sexes for infection outcomes.
Taking this work further, we investigated the mechanisms driving the sex-specific
differences in bactericidal capacity of murine neutrophils in Chapter 3. We examined the
contribution of complement system (C3 and CR3) and antimicrobial agents (ROS) in
driving the enhanced bactericidal capacity of female neutrophils. In Chapter 3, we report
increased complement protein C3 levels in the female serum, CR3 expression on
neutrophils surface and ROS production by female murine neutrophils. Based on our
findings on Chapter 2 where we saw E2-dependent protection in females we explored the
role of estrogen receptor, GPER and its agonist G-1 in driving the sex bias and in providing
protection against S. aureus SSTI in Chapter 4. We show GPER activation limits S. aureus
pathogenesis, uncovering a novel role for this receptor in skin innate defense mechanism.
Importantly, G-1 treatment reduced disease severity in males. Mechanistically, we show
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reduction in ADAM10 expression and barrier permeability with G-1 administration to the
human keratinocyte cell line HaCaTs. This effect of G-1 on S. aureus pathogenesis and
infection outcome suggests a potential therapeutic role for G-1 in limiting S. aureus SSTI
as well as other conditions involving barrier dysfunctions.

Overall, we have identified: (A) sex bias in host innate response to S. aureus SSTI,
differences in murine neutrophils bactericidal capacity ex vivo and differential response to
Hla between sexes in Chapter 2, (B) factors contributing to enhanced S. aureus clearance
ability of female murine neutrophils ex vivo in Chapter 3 and (C) protective role of G-1
and GPER in barrier integrity and against S. aureus pathogenesis in Chapter 4
(summarized in Figure 5.1). Thus, our findings were the first to show that sex bias exists
in host innate response to S. aureus SSTI and that female mice are innately resistant to it
compared to males. We also found differences in bactericidal capacity of murine
neutrophils between sexes ex vivo and demonstrated that differences are potentially due to
differences in serum complement protein C3, cellular CR3 expression and ROS production
with their levels being higher in females compared to males. In addition, we demonstrated
a protective role for estrogen in providing protection in female mice against S. aureus SSTI,
and found a novel role for GPER agonist, G-1, in reducing disease severity, especially in
male mice. Mechanistically, we found a protective role of G-1 in barrier integrity in vitro
with G-1 treatment reducing epithelial cells (HaCaTs) barrier disruption by S. aureus toxin,
Hla. Our work highlights the importance of investigating sex differences in host response
and provides insight into mechanisms driving sex bias in host response to S. aureus SSTI.
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These findings could be useful for the identification and development of potential host
targets to combat the antibiotics crisis.

142

Figure 5.1. Summary of the findings of Chapters 2, 3 and 4.
See text for details.
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FUTURE CONSIDERATIONS
Although we reported differences in host response to S. aureus SSTI and a role for host
neutrophils and differential response to the bacterial toxin, Hla, in driving the difference,
several questions remain. One of the first gaps that needs to be addressed is the mechanistic
differences in skin resident cells function between sexes. Also, it must be determined how
these cells respond differentially to Hla and contribute to the sex bias. We reported a role
for E2 in providing protection in females against SSTI. Estrogen’s role in skin thickness as
well as regulation of skin immune cells function is known (403, 404). Thus, understanding
the mechanism of E2 mediated protection against S. aureus pathogenesis and the
contribution of its receptors (ERα, ERβ and GPER) in driving the sex bias is important to
identify their potential as therapeutic targets. We have already shown a role for GPER and
its agonist G-1 in providing protection against S. aureus SSTI. Taking this further,
identifying the role for other ERs (ERα, ERβ) will be important in devising strategies to
enhance host response.

In terms of sex bias in immune cells response, we have demonstrated enhanced S. aureus
bactericidal capacity of female murine neutrophils ex vivo with serum complement protein
C3, its receptor CR3, and ROS levels contributing to this increased clearance ability of
female neutrophils. Differences in neutrophils function between sexes might be a result of
developmental differences, thus a gene expression analysis using RNA sequencing will
help uncover innate differences between sexes. We know ROS is crucial for bacterial
clearance by neutrophils, however, neutrophils employ other oxygen-independent
mechanisms for bacterial clearance as well (63, 64). Thus, determining their role in
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enhanced bactericidal capacity of female neutrophils is important to identify other factors
driving the differences in neutrophils clearance ability besides ROS. In our study presented
in Chapter 2, we also show estrogen dependent differences in clearance ability of female
neutrophils, with decreased bactericidal efficacy of OVX neutrophils compared to sham
controls. E2 is known to modulate neutrophils function (antimicrobial agents production,
degranulation) as well as chemotaxis, hence the role of E2 and ERs in driving the
differences in bactericidal efficacy between sexes needs to be determined. In addition,
since G-1 via GPER contributes to host defense against S. aureus SSTI and barrier
integrity, we will investigate its role in other S. aureus infections, such as pneumonia to
expand the therapeutic potential of G-1 against other S. aureus infection.

The gaps that will be addressed are: (A) differences in resident skin cells composition
between sexes, their response against S. aureus insult, and the role of E2 and ERs in
regulating these functions and sex bias in S. aureus SSTI, (B) innate differences in
neutrophils between sexes, contribution of oxygen-independent mechanisms to increased
bactericidal capacity of female murine neutrophils and the role of E2 and ERs, and (C)
efficacy of G-1 in protection against S. aureus pneumonia through regulation of barrier
permeability. A summary of these gaps and experimental schematics are depicted in
Figures 5.2. to 5.6. The discussion below will elaborate on these gaps and approaches to
address them.
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Figure 5.2. Summary of gaps to be addressed based on the findings of Chapter 2, 3
and 4.
See text for details.
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5.1.1. Sex bias in skin cells composition and function against S. aureus
The skin is composed of multiple layers of cells as described in Chapter 1. These resident
cells contribute to protection against external insult. Specifically, keratinocytes, fibroblasts
Langerhans cells, resident T cells, neutrophils and macrophages have been studied for their
role in protection against S. aureus pathogenicity (20, 68). However, the difference in their
functionality against S. aureus has not been assessed from a sex bias perspective. Male and
female skin differ in thickness with male skin being thicker than females. However, the
female epidermis is known to be thicker than males, likewise, the male dermis is known to
be thicker than females (160, 407). In addition, a study by Koyama et al. have reported sex
specific differences in Langerhans cells density in mice where they quantitively
demonstrated increased LCs in females compared to males (408). Their findings suggest
the suppressive effect of testosterone in LCs count as castration increased the LC numbers
in male mice. Hence, we expect to find differences in the number of epidermal and dermal
cells between the sexes. To determine this, first we will isolate the single cell populations
from male and female skin following the protocols from Kashem et al. (409) and Benck et
al. (410). Differences in the baseline number of these cells between the sexes will be
assessed by utilizing cell specific markers [described in (409, 410)] and their analysis by
flow cytometry.

To determine their role in protection against S. aureus pathogenesis between sexes, these
single cells isolated as mentioned above will be treated ex vivo with S. aureus culture
supernatants from wild-type (WT, containing all secreted toxins and PAMPs), as well
isogenic Hla mutant, Δhla strain (lacking secreted Hla toxin) and recombinant purified Hla
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given the significance of Hla in dermonecrosis. These cells will then be examined for
NLRP3 inflammasome activation as well as production of pro-inflammatory cytokine
using western blot analysis for active caspase-1 and IL-1β (Figure 5.3). We will also
determine differences in other pro- (TNFα, IL-6) and anti-(IL-10) inflammatory cytokines
produced as a result of NF-κB activation. Differences in the cytokines profile might
provide insight into some key factors providing tolerance against Hla in females. These
findings will shed some light onto whether it is the composition and absolute number of
the cells or the difference in their response to S. aureus pathogenesis or both that dictates
the sex bias in host response to S. aureus SSTI.
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Figure 5.3. Sex bias in skin cells composition and function, role of E2 and ERs.
Male and female skin differs in epidermal, dermal and overall thickness. E2 contributes to
reduced skin thickness in females. Estrogen also modulates NF-κB activation that regulates
NLRP3 inflammasome activation. Gaps to be addressed are: [I] Differences in skin layers
composition between sexes and [IIa] their function (NLRP3 inflammasome activation) in
response to S. aureus toxin, Hla and PAMPs. [IIb] effect of E2/ER on skin cells function
and their contribution to S. aureus SSTI. Adapted from: Miller and Cho (2011) (67) and
Pasparakis et al. (2014) (69); Ezekwe et al. (2016) (48) and Shao et al. (2015) (49).
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Based on the outcomes, we will also determine their specific roles in the infection outcomes
using the murine S. aureus SSTI model. We will specifically focus on Langerhans cells
and the tissue resident γδ T cells as these cells are known to contribute to host defense
against S. aureus infections (73, 82, 83, 87, 89). Langerhans cells are known to regulate
proliferation as well as antigen presentation to T cells ((72, 82, 87)). T cells have also been
shown to enhance recruitment of phagocytes, contribute to host defense via production of
IL-17 as well as maintain keratinocyte production and proliferation (74, 83, 89-91).
However, their contribution in S. aureus SSTI outcomes has not been investigated from a
sex bias perspective. Hence, we will determine the contribution of these cells to females’
resistance to S. aureus SSTI. We will determine differences in lesion size and bacterial
clearance. Based on Koyama Y, et.al (408) findings, we know LCs number differs in the
skin of male and female mice. Given its role in host defense, we expect to see a significant
loss of protection with LCs after depletion in the skin of female mice using a LangerinDTR mouse model. These mice lack all Langerin+ cells after diphtheria toxin injection
(411, 412). Similarly, with the depletion of resident γδ T cells using commerciallyavailable anti–TCR γδ antibody as in (413), we expect to see exacerbated infection
outcomes in γδ T cells-depleted female mice compared to isotype treated controls. With
the males, we expect the infection condition to worsen given the protective roles of these
cells. The schematic of infection is outlined in Figure 5.4. The outcomes of these infection
studies will help determine whether these cells are the key players contributing to innate
resistance to females. This information will further the therapeutic research by providing
host targets to enhance immune response against S. aureus SSTI. This would be extremely
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useful for the treatment of immunocompromised patients that are highly susceptible to S.
aureus skin primary and recurring infections.
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Figure 5.4. Contribution of Langerhans cells (LCs) and γδ T cells to sex bias in host
defense to S. aureus SSTI.
LCs and γδ T cells, resident skin cells, are known to contribute to host defense against S.
aureus infections. However, their contribution to sex bias in host response to S. aureus
SSTI is not yet known. Using the murine dermonecrosis model, gaps to be addressed are:
[1] Contribution of LCs and [2] γδ T cells to the female innate resistance to S. aureus SSTI
and effect of loss of these cells on male SSTI outcomes using LC depleted mice and
antibody depletion of γδ T cells.
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5.1.2. Role of E2 and ERs in skin cells function and sex bias in S. aureus SSTI
Our findings in Chapter 2 suggests a role for E2 in the protection against S. aureus SSTI
in females. Similarly, in Chapter 4 we see protective effect of G-1 against S. aureus SSTI
in both sexes. Hence, to determine the mechanisms behind this protection we will take two
approaches. First, we will determine the expression of ERs in all the skin cell types
mentioned above and treat both the male and female cells ex vivo with physiological
concentrations of E2 prior to and during their exposure to S. aureus WT and Δhla
supernatants as well as purified Hla toxin. Then we will assess the difference in outcomes
(as mentioned as above) between E2 and vehicle treated male and female cells to determine
the effect of E2 treatment on their response (Figure 5.3). E2 via ERs is known to promote
NF-κB activation as an early response to infection yet inhibit the activation of NF-κB or
increase the expression of anti-inflammatory genes during later response to prevent damage
(108, 414, 415). Because NF-κB regulates NLRP3 inflammasome activation as well as
inflammatory responses, we expect to see a time-dependent decrease in inflammasome
activation as well as production of pro-inflammatory markers with E2 treatment, in line
with our findings with decreased inflammasome activation in females. The second
approach will be to use ER genetic knock out animal models to determine their role in S.
aureus infection outcomes between sexes. We have already reported no difference in
infection outcomes between wild-type (WT) and GPER-/- mice. This suggests a role for
classical ERs (ERα and ERβ) in E2 mediated protection in females. ERα and ERβ are well
studied for their role in prevention of skin flap necrosis as well as wound healing,
respectively (164, 404, 416). Our preliminary findings as well as a published report (417)
also suggests increased skin thickness in the absence of ERα. Thus, loss of these receptors
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might exacerbate the infection outcomes. In the case of GPER, use of its agonist G-1
reduced S. aureus pathogenesis even though loss of GPER did not affect disease severity
of S. aureus SSTI. This suggests activation of GPER-dependent pathways could confer
protection in mice. Similar outcomes could be expected with the classical ER knockouts as
well where loss of the receptor might not cause any difference in outcomes, but activation
of their downstream pathways could enhance protection. This might explain the
mechanism of E2-dependent protection in females. It is likely that more than one ER
contributes to the protective role of E2 and therefore multiple agonists of these receptors
need to be investigated for therapeutic purposes.

5.2.1. Innate differences in neutrophils between sexes
Neutrophils originate in the bone marrow and undergo a series of processes to become a
mature and functional phagocyte (192, 418). These cells are then recruited to the site of
infection via chemoattractants secreted by resident cells post-insult by a foreign substance,
where these cells contribute to host defense via its phagocytic and bactericidal function
(192, 418). Studies have focused on the role of sex hormones in regulation of neutrophil
chemotaxis as well as antimicrobial functions (242, 244, 346, 419); however, the innate
differences in murine neutrophils between sexes have not been examined. Dysfunctional
neutrophil conditions such as Chédiak–Higashi syndrome (CHS), myeloperoxidase (MPO)
deficiency, Leukocyte adhesion deficiency type 1 (LAD1) are linked to mutations in genes
at specific chromosomal locations (215). Thus, we predict RNA sequencing for the gene
expression analysis of male and female neutrophils could uncover factors that contribute
to innate differences in neutrophils between sexes. The genes with greater than 2-fold
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differences in their expression profiles between sexes can be further investigated to
determine their role in neutrophils bactericidal function. The findings from this will help
uncover innate versus induced differences in neutrophils between sexes.
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Figure 5.5. E2 and ERs in enhanced bactericidal capacity of female murine
neutrophils.
E2 is known to regulate oxygen-dependent and independent killing mechanisms of
neutrophils as well as its apoptosis. Gaps to be addressed are: Innate differences in
neutrophils between sexes and role of E2 and ERs (ERα, ERβ, and GPER) in: [1] enhanced
oxygen-dependent clearance of S. aureus by female neutrophils, [2] degranulation and
oxygen-independent clearance of S. aureus by female neutrophils, and [3] regulation of
neutrophil apoptosis. Adapted from: Rigby and DeLeo (2012) (64) and Nguyen et al.
(2017) (205).
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5.2.2. E2 and ERs in enhanced bactericidal capacity of female neutrophils
In Chapter 2, we reported E2-dependent enhancement in the bactericidal capacity of
female neutrophils using neutrophils from the ovariectomized (OVX) mice. However, the
mechanism by which E2 regulates this is not yet known (Figure 5.5). The effect could be
mediated by differences in ER-dependent functions that affect their bactericidal capacity.
The effect of ERs could be genomic, due to the regulation of transcription factors, likely
by classical ERs or rapid and transient via GPER. Rodenas et al. have highlighted GPER’s
role in enhancing neutrophil function with increased superoxide production post activation
with pharmacological concentrations of G-1 (244). Also, E2 has been shown to modulate
neutrophil oxygen-dependent killing mechanisms (136, 172, 346). Thus, to determine the
role of specific ERs in mediating E2’s function, we will isolate neutrophils from ER
knockout mice and determine the bactericidal efficacy as well as ROS production by these
cells. It is likely that more than one ER contributes to the enhanced clearance ability of
female neutrophils, thus we might see reduction but not complete abolishment of the effect
in these knockout cells. However, with the identification of receptors function and their
downstream signals we could supplement estrogen or ER agonists to OVX female
neutrophils or male neutrophils and determine their application to enhance murine
neutrophils bactericidal capacity against S. aureus.

E2 is also known to regulate neutrophil apoptosis (136, 244, 420). In terms of E2’s role in
neutrophil apoptosis, studies have reported dose-dependent differences with conflicting
evidence on pro- versus anti-apoptotic effect of E2 on neutrophils (136, 244, 420). Using
GPER-specific agonist G-1, Rodenas et al. have demonstrated increased viability and
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functionality of neutrophils post-activation (244). The delayed apoptosis as well as
decreased chemotaxis of neutrophils by E2 could compliment our findings that show
enhanced bactericidal capacity of female neutrophils ex vivo as well as lower levels of
MPO, a neutrophil surrogate marker, as early as 24 hours post-S. aureus subcutaneous
administration at the site of infection. This suggests E2-dependent increase in bactericidal
capacity and delayed apoptosis contributes to enhanced clearance of bacteria by female
neutrophils despite fewer cells being recruited to the site of infection. However, recent
studies have suggested a role for Annexin 1, an endogenous glucocorticoid protein in
reducing neutrophil infiltration and activating apoptosis of these cells (192, 421). This
protein is also known to promote clearance of apoptotic neutrophils by macrophages for
resolution of inflammation (192, 421). A recent study by Nadkarni et al. reported increased
Annexin 1 expression in female neutrophils compared to males and increased mobilization
of this protein to the surface post E2 treatment of male human neutrophils (422). Based on
E2’s role in Annexin 1 expression and the role of this protein in promoting apoptosis, the
contribution of E2 in neutrophil apoptosis is unclear. This is likely due to differences in E2
dosage used in these studies as well as differences in E2 levels at different phases of
menstrual cycle as well as pregnancy. Thus, the viability of male and female neutrophils
in our studies need to be determined (Figure 5.5). The increased Annexin 1 expression in
the study by Nadkarni et al. was shown to be mediated by the classical ERs via a nongenomic mechanism. Since G-1 via GPER has been shown to delay apoptosis of
neutrophils, there is likely an ER-dependent balance on how E2 regulates the survival of
neutrophils.
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5.2.3. Oxygen-independent clearance of S. aureus by female neutrophils
In Chapter 3, we focused on the differences in ROS production by neutrophils and the
increased ROS contributing to the bactericidal capacity of female neutrophils. Considering
the role of E2 in regulating degranulation of neutrophils, we will investigate the
contribution of this mechanism to enhanced bactericidal capacity of female neutrophils
(Figure 5.5). Neutrophil antimicrobial peptides (AMPs), antimicrobial proteins such as αdefensins, elastase, cathelicidins, cathepsins, azurocidin, lactoferrin, lysozyme and
proteinase-3 are the oxygen-dependent antimicrobial agents (63, 204, 216, 217). All these
microbicidal agents are found in neutrophils granules and vesicles. Exocytosis and
degranulation lead to the release of these oxygen-independent antimicrobial agents to the
plasma membrane or the phagosomal membranes (64, 209, 423). As a marker of granule
release, we will specifically determine differences in elastase (primary), lactoferrin
(secondary) and MMP-9 or gelatinase (tertiary) by ELISA in male and female murine
neutrophils using commercially-available kits. Another way of testing this would be to
determine intracellular calcium level between sexes as Ca2+ signaling is known to
contribute to granule release with increased intracellular Ca2+ promoting release of the
granules (217, 424). Thus, post-TNFα priming and activation with serum-opsonized LAC,
we will determine the differences in intracellular Ca2+ levels in male and female
neutrophils. Activation of GPER by E2 is known to rapidly increase Ca2+ intracellular
levels in cells (150, 365) . Thus, we expect to find increased Ca2+ levels as well as increased
release of the granule components in females compared to male neutrophils. As reviewed
in Rigby and Deleo (2012) (64), there is likely a synergistic action between oxygen-
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dependent and independent antimicrobial agents in enhancing the bactericidal capacity of
female neutrophils.

5.3. Protective role of G-1 in male mice against S. aureus pneumonia
Pneumonia is a life-threating infection caused by S. aureus, with an estimated 50,000 cases
per year in the US alone (56). S. aureus has been a leading cause of ventilator-associated
pneumonia (VAP) and is now being recognized as a cause of community-acquired
pneumonia (CAP) as well (56). As with SSTIs, more than 50% of the isolates are
methicillin-resistant, resulting in increased mortality from MRSA pneumonia (56).
Similarly, Hla regulates the virulence of S. aureus in pneumonia (32, 56). Hence, multiple
Hla directed therapeutics are being tested for efficacy against S. aureus pneumonia, both
alone and in conjunction with antibiotics (vancomycin and linezolid) (43, 56, 58, 425).
Sexual dimorphism in bacterial pneumonia has been reported, with males having higher
susceptibility than females. In terms of sex-specific differences in S. aureus pneumonia,
the incidence was higher in males compared to females, with a 1.84 M/F ratio (111, 426).
The protective role of E2 has also been demonstrated, with resistance to pneumococcal
pneumonia reported in females and E2 treated male mice compared to male controls (261).
This study highlighted the role of alveolar macrophages in bacterial killing of
Streptococcus pneumoniae as well as S. aureus. Furthermore, this enhanced killing of S.
pneumoniae by female macrophages was attributed to E2-dependent activation of
endothelial NOS, NOS3 (261). Both G-1 and E2 are known to induce phosphorylation of
eNOS and NO formation via GPER (427). Based on these and our findings on role of G-1
in protection against Hla pathogenesis, we hypothesize that G-1 could be used as a potential
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therapeutic for protection against S. aureus pneumonia in males. To test the hypothesis, we
will use a well-established mouse model of S. aureus pneumonia (274, 428), and administer
G-1 following the same 5 day regimen as in Chapter 4, 2 days prior to intranasal
inoculation of S aureus to male mice to 2 days after the infection (outlined in Figure 5.6).
Disease progression and severity will be assessed by monitoring for hunched posture,
piloerection, labored breathing, immobility, and loss of resistance to handling (428). We
expect to see differences in infection outcomes with increased survival, or less severe
symptoms, in G-1 treated mice compared to controls. We will also examine differences in
male alveolar macrophage response ex vivo after in vivo G-1 treatment (5-day regimen)
and in vitro short-term treatment with S. aureus killing assay. The macrophages will be
isolated from bronchoalveolar lavage (BAL) fluid following the protocol from Nayak et
al. (429). Similar to the findings of Yang et al., we expect to see increased bacterial
clearance and increased NOS3 expression in G-1 treated macrophages post-incubation with
S. aureus and its culture supernatants, respectively. Also, we will examine for differences
in ADAM10 expression and protein levels in G-1 treated or control macrophages after
treatment with S. aureus culture supernatants. In addition, their levels will also be
examined in G-1 treated lung epithelial cells, isolated following the protocol in Nakano et
al. (430), based on our findings on skin epithelial cells (human keratinocytes cell line,
HaCaT). We will perform these experiments using female mice as well to determine G-1’s
role in enhancing protection in females. Since, pathogenicity of S. aureus pneumonia is
associated with Hla, decrease in ADAM10 protein with G-1 would suggest dual role for
G-1 in protection in S. aureus pneumonia along with NOS3 expression. The findings of
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these experiments will provide insight into the broad role of G-1 as a therapeutic against S.
aureus infections in males with no feministic effect.
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Figure 5.6. Role of G-1 in protection against S. aureus pneumonia.
Males are more susceptible to S. aureus pneumonia. Female macrophages demonstrate
enhanced clearance of S. aureus through E2 dependent increase in NOS3 expression. Gaps
to be addressed are: [1] Protective effect of G-1 in S. aureus pneumonia model, and [2]
Effect of G-1 treatment (short and long term) on alveolar macrophages S. aureus killing
ability, NOS3 expression and ADAM10 expression and protein levels in macrophages and
epithelial cells post incubation with S. aureus culture supernatants.
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CONCLUSIONS
Despite the global health threat posed by S. aureus infections, no vaccines nor monoclonal
antibodies have yet proven efficacious in clinical trials (58). However, there are multiple
ongoing studies at different phases of clinical trials assessing the efficacy and safety of
these vaccines and monoclonal antibodies (58). To add to this, the emergence of antibioticresistant strains and their increased association with infections makes treatment more
challenging; hence the need for alternate therapeutic approaches (6, 13, 15, 18, 431). While
there are ongoing studies to identify bacterial targets and clinical trials for antibacterial
therapies, our studies highlight the importance of understanding the mechanism of host
response to the pathogen. With differences observed in S. aureus SSTI outcomes between
sexes, with females being innately resistant to infection, our findings demonstrate the
necessity for inclusion of both sexes in future S. aureus research. The increased resistance
of females to S. aureus SSTI was in part due to female sex hormone, estrogen as well as
innate immune cells, neutrophils role in providing protection and differential response to
Hla toxin. In Chapter 4, we demonstrated a novel, protective effect of GPER agonist, G1 suggesting the potential therapeutic use of G-1 against S. aureus SSTI. Further studies
need to be conducted to investigate the role of other estrogen receptors and their agonists
for protection. Our findings in Chapter 3 reveal the differences between male and female
murine neutrophils S. aureus clearance mechanisms. The work in these chapters
demonstrate the importance of considering the sex-specific differences in host response
and the contribution of sex hormones in driving the infection outcomes. In addition, it
highlights the importance of understanding how the host responds to an infection. This will
be useful to identify targets in the host to promote host defense. Our findings on sex bias
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in host response and potential therapeutic usage of G-1 could be expanded to other S.
aureus infections to identify other host targets and to broaden the therapeutic potential of
G-1. Based on these findings, G-1 in conjunction with anti-bacterial therapeutics could be
used to enhance the host defense while inhibiting bacterial growth and virulence. Overall,
differences in host immune response needs to be considered while designing therapeutic
approaches to maximize their efficacy in disease prevention.
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APPENDICES
APPENDIX A: ABBREVIATIONS
α: Alpha
β: Beta
β-GlcNAc: β N-acetylglucosamine
AD-HIES: Autosomal Dominant Hyper IgE Syndrome
ADAM10: A Disintegrin and Metalloproteinase 10
Agr: accessory gene regulator
AIDS: Acquired Immunodeficiency Syndrome
AIP: Auto Inducing Peptide
AKT: Protein Kinase B
AMP: Anti-microbial Peptides
AR: Androgen Receptor
ARE: Androgen Response Element
AUC: Area Under the Curve
ASC: Apoptosis-associated speck-like protein containing a CARD
BMNs: Bone marrow neutrophils
C3: Complement 3
CA-MRSA: Community-acquired Methicillin Resistant S. aureus
CFU: Colony Forming Unit
CGD: Chronic Granulomatous Disease
CHS: Chediak-Higashi Syndrome
CR3: Complement receptor 3
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DETC: Dendritic Epidermal T Cells
DNA: Deoxyribonucleic acid
DPN: 2,3-bis (4-hydroxyphenyl)-propionitrile
E2: Estrogen/17β -estradiol
ECIS: Electrical Cell-substrate Impedance Sensing
EDTA: Ethylenediaminetetraacetic acid
ER: Estrogen Receptor
ERE: Estrogen Response Elements
fMLP: N-formyl-L-methionyl-L-leucyl-phenylalanine
GM-CSF: Granulocyte-Macrophage Colony-Stimulating Factor
GPCR: G Protein-Coupled Receptor
GPER: G Protein-coupled Estrogen Receptor
HaCaT: Human keratinocyte cell line
HA-MRSA: Hospital-acquired Methicillin Resistant S. aureus
HBSS: Hanks’ Balanced Salt solution
HDT: Host-Directed Therapeutics
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HIV: Human Immunodeficiency Virus
HRP: Horseradish Peroxidase
HSV: Herpes Simplex Virus
LAC: Los Angeles County
LAD-1: Leucocyte Adhesion Deficiency-1
LCs: Langerhans Cells
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LTA: Lipoteichoic Acid
Mac-1: Macrophage-1 antigen
MAPK: Mitogen-activated Protein Kinase
MERS: Middle East Respiratory Syndrome
MIC: Minimum Inhibitory Concentration
MOI: Multiplicity of Infection
MPO: Myeloperoxidase
MPP: 1,3-Bis (4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1Hpyrazoledihydrochloride
MRSA: Methicillin Resistant S. aureus
MSSA: Methicillin Sensitive S. aureus
NADPH: Nicotinamide Adenine Dinucleotide Phosphate
NET: Neutrophil Extracellular Trap
NLRP3: NOD-, LRR- and pyrin domain-containing protein 3
NO: Nitric Oxide
NOD: Nucleotide-binding and oligomerization domain
NOS: Nitric Oxide Synthase
NOX: NADPH Oxidase
OVX: Ovariectomized
PAMPs: Pathogen-Associated Molecular Patterns
PBP: Penicillin Binding Protein
PBS: Phosphate-Buffered Saline
PGN: Peptidoglycan
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PHTPP: [2-phenyl-5,7-bis (trifluoromethyl) pyrazolo [1,5-a] pyrimidin-3-yl] phenol
PI3K: Phosphoinositide 3-kinase
PPT: 4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol
PR: Progesterone Receptor
PRR: Pattern-Recognition Receptors
PSMα: Phenol Soluble Modulin alpha
PVL: Panton-Valentine Leukocidin
RIPA buffer: Radioimmunoprecipitation assay buffer
RNA: Ribonucleic acid
RNS: Reactive Nitrogen Species
ROS: Reactive Oxygen Species
SAB: S. aureus bacteremia
SDS-PAGE: Sodium Dodecyl Sulfate–Polyacrylamide Gel Electrophoresis
SLE: Systemic Lupus Erythematosus
SO: Sham
SSTI: Skin and Soft Tissue Infection
TER: Transepithelial Electrical Resistance
TF: Transcription Factor
TNF: Tumor-Necrosis Factor
TLR: Toll-like Receptor
TSB: Trypticase soy broth
TSLP: Thymic Stromal Lymphopoietin
TSST-1: Toxic Shock Syndrome Toxin-1
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VISA: Vancomycin-Intermediate S. aureus
VRSA: Vancomycin-Resistant S. aureus
WTA: Wall Teichoic Acid
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